



CASE
COMPREHENSIVE
CANCER CENTER



**American Society of Hematology (ASH) Annual Meeting
December 5-8, 2020**

<http://www.hematology.org/Annual-Meeting/Program/>

****Case CCC Members in BOLD; Presenter UNDERLINED****
Events listed in Eastern Standard Time (EST)

PRESENTATIONS/SESSION CHAIRS/MODERATORS

Amar Desai, PhD

Case Comprehensive Cancer Center

Speaker, [Regulation of the Hematopoietic Niche By 15-PGDH](#) and Live Q&A

Wednesday, Dec 2, 2020, 10:05 AM-10:45 AM; Scientific Workshops @ ASH, Stem Cells

Hetty E. Carraway, MD, MBA

Case Comprehensive Cancer Center, Cleveland Clinic

Moderator, Blood Drop: Health Disparities

Thursday, Dec 3, 2020, 10:15 AM-10:55 AM; ASH-a-Palooza

Chair, [Myelodysplastic Syndromes: What We Have And What We Want](#)

Speaker, [Therapy For Lower Risk MDS](#)

Saturday, Dec 5, 2020, 12:30 PM-1:15 PM; Education Program

[ASH-a-Palooza Thank You Video](#) (Available On-Demand beginning Dec 2)

Keith R. McCrae, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [MicroRNA and Role in Cancer Associated Thrombosis](#) and Live Q&A

Thursday, Dec 3, 2020, 10:05 AM-10:29 AM; Scientific Workshops @ ASH

Speaker, [Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies](#)

Friday, Dec 4, 2020, 2:00 PM-5:00 PM; Satellite Symposia

Lalitha V. Nayak, MD

Case Comprehensive Cancer Center, University Hospitals

Speaker, [NLF-2, Cancer, and Thrombosis](#) and Live Q&A

Thursday, Dec 3, 2020, 10:29 AM-11:17 AM; Scientific Workshops @ ASH, Interplay Between the Hematologic System and Solid Tumor Progression

Shadi Swaidani, MD, PhD

Cleveland Clinic

Speaker, [Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors](#) and Live Q&A

Thursday, Dec 3, 2020, 11:55 AM-12:56 PM; Scientific Workshops @ ASH, Late-Breaking Research Presentations

Peng Zeng, MD

Case Western Reserve University

Speaker, [Ponatinib Induction of Vascular Inflammation](#) and Live Q&A

Thursday, Dec 3, 2020, 10:29 AM-11:17 AM; Scientific Workshops @ ASH, Interplay Between the Hematologic System and Solid Tumor Progression

Deepa Jagadeesh, MD, MPH

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Blood Buddy Forum: Adult and Pediatric BMT](#)

Thursday, Dec 3, 2020, 1:00-3:00 PM; ASH-a-Palooza

Speaker, [Blood Buddies: Pediatric and Adult BMT](#)

Friday, Dec 4, 2020, 1:00-3:00 PM; ASH-a-Palooza

Sanjay Ahuja, MD

University Hospitals Rainbow Babies & Children's

Speaker, [Blood Buddy Forum: Pediatric Clinical Non-Malignant Hematology](#)

Thursday, Dec 3, 2020, 1:00-3:00 PM; ASH-a-Palooza

Marvin T. Nieman, PhD

Case Comprehensive Cancer Center

Speaker, [Blood Buddy Forum: PhD Careers](#)

Thursday, Dec 3, 2020, 1:00-3:00 PM; ASH-a-Palooza

Speaker, [Leading Yourself](#)

Monday, Dec 7, 2020, 2:20 PM-2:30 PM; Education Program, Junior Faculty Career Development Education Session

Brian T. Hill, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy](#)

Friday, Dec 4, 2020, 10:00 AM-1:00 PM; [Friday Sattelite Symposia](#) – [Register Here](#)

Bhumika J. Patel, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine](#)

Friday, Dec 4, 2020, 10:00 AM-1:00 PM; [Friday Sattelite Symposia](#) – [Register Here](#)

Betty K. Hamilton, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine](#)

Friday, Dec 4, 2020, 10:00 AM-1:00 PM; [Friday Sattelite Symposia](#) – [Register Here](#)

Jaroslav P. Maciejewski, MD, PhD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine](#)

Friday, Dec 4, 2020, 10:00 AM-1:00 PM; [Friday Sattelite Symposia](#) – [Register Here](#)

Eric D. Hsi, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Co-Chair, [Joint Session: Scientific Committee On Hematopathology And Clinical Laboratory Hematology & Scientific Committee On Lymphoid Neoplasia](#)

Sunday, Dec 6, 2020, 5:00-5:45 PM; Scientific Program

Weifei Zhu, PhD

Cleveland Clinic

Speaker, [Microbiome-Derived Metabolites Affecting Vascular Function](#)

Monday, Dec 7, 2020, 12:00 PM-12:45 PM; Scientific Program, Gut Microbiome and the Endothelium

ORAL ABSTRACTS – CASE CCC PRESENTER

[284 Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies

Hematology Disease Topics & Pathways: Diseases, MDS, Biological Processes, Myeloid Malignancies, genomics, pathogenesis

Saturday, Dec 5, 2020: 5:00 PM

Jakob Woerner^{1}, Yidi Huang, MS^{2*}, Yimin Huang^{3*}, Janet Wang, BS^{4*}, Jesus M Hernández-Sánchez, PhD^{5*}, Jaroslaw P. Maciejewski, MD, PhD⁶, Mehmet Koyuturk, PhD^{1*}, Stephan Hutter, PhD^{7*}, Torsten Haferlach, MD⁷ and Thomas Laframboise, PhD^{4*}*

¹Case Western Reserve University, Cleveland

²Case Western Reserve University, Cleveland, OH

³Case Western Reserve University, Cleveland, OH

⁴Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁵Universidad de Salamanca, IBSAL, Salamanca, Spain

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷MLL Munich Leukemia Laboratory, Munich, Germany

[653 Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes \(MDS\) from Study P-2001 \(NCT02610777\)](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes

Hematology Disease Topics & Pathways Follicular Lymphoma, ALL, multiple myeloma, Biological, Marginal Zone Lymphoma, Diseases, smoldering myeloma, CLL, Mantle Cell Lymphoma, LGLL, Therapies, CNS Lymphoma, MDS, DLBCL, enzyme inhibitors, Technology and Procedures, cytogenetics, Myeloid Malignancies

Monday, Dec 7, 2020: 2:30 PM

Mikhael A. Sekeres¹, Justin M. Watts, MD², Atanas Radinoff^{3}, Montserrat Arnan Sangerman, MD, PhD^{4*}, Marco Cerrano^{5*}, Patricia Font Lopez^{6*}, Joshua F. Zeidner, MD⁷, Maria Diez-Campelo, PhD, MD^{8*}, Carlos Graux^{9*}, Jane L. Liesveld, MD¹⁰, Dominik Selleslag, MD¹¹, Nikolay Tzvetkov, MD^{12*}, Robert J. Fram^{13*}, Dan Zhao^{13*}, Sharon Friedlander^{13*}, Kevin Galinsky^{13*}, Douglas V. Faller^{13*} and Ades Lionel^{14*}*

¹Leukemia Program, Cleveland Clinic, Cleveland, OH

²University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

³University Hospital Sveti Ivan Rilski, Sofia, Bulgaria

⁴Institut Català d'Oncologia-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet, Barcelona, Spain

⁵Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Turin, Italy

⁶Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain

⁷University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC

⁸University Hospital of Salamanca, IBSAL Institute for Biomedical Research of Salamanca, Salamanca, Spain

⁹Université Catholique de Louvain, Centre Hospitalier Universitaire, Namur, Yvoir, Belgium

¹⁰The James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY

¹¹AZ Sint Jan Brugge-Oostende, Brugge, Belgium

¹²MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria

¹³Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

¹⁴Hôpital Saint-Louis Hématologie Clinique, Paris, France

738 CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Program: Oral and Poster Abstracts

Type: Oral

Session: 704. Immunotherapies: Therapeutic T cell Manipulation

Hematology Disease Topics & Pathways: Biological, CRS, Diseases, neurotoxicity, Mantle Cell Lymphoma, CAR-Ts, Therapies, Non-Hodgkin Lymphoma, Adverse Events, B-Cell Lymphoma, DLBCL, Lymphoid Malignancies, Clinically relevant

Monday, Dec 7, 2020: 5:00 PM

Paolo F Caimi, MD¹, Ashish Sharma^{2*}, Patricio Rojas, MD^{3*}, Seema Patel, PharmD^{4*}, **Jane Reese^{1,2*}**, **Folashade Otegbeye, MBBChir, MPH¹**, Andrew Worden^{5*}, Michael Kadan^{5*}, Michael Maschan, MD, PhD⁶, Rimas J Orentas, PhD⁷, Boro Dropulic, PhD, MBA^{5*}, **Rafick Sekaly^{8*}** and **Marcos de Lima, MD¹**

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

²Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

³Pontificia Universidad Catolica de Chile, Santiago, CHL

⁴Adult Hematologic Malignancies & Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, MD

⁶Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

⁷Pediatrics, University of Washington School of Medicine, Seattle, WA

⁸Case Western Reserve University, Cleveland, OH

ORAL ABSTRACTS – NON-CASE CCC PRESENTER (with CASE CCC/CLEVELAND CO-AUTHORS)

24 A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel combination therapies in treatment of newly diagnosed AML

Hematology Disease Topics & Pathways: Adult, Diseases, Therapies, Combinations, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, Dec 5, 2020: 10:30 AM

Keith W. Pratz, MD¹, Mohamad Cherry, MD, MS², Jessica K. Altman, MD³, **Brenda W. Cooper, MD⁴**, Jose Carlos Cruz, MD⁵, Joseph G. Jurcic, MD⁶, Mark Levis, MD, PhD¹, Tara Lin, MD⁷, Alexander E. Perl, MD⁸, Nikolai A. Podoltsev, MD, PhD⁹, Gary J. Schiller, MD¹⁰, Jason E. Hill, PhD^{11*}, Angela James, PhD^{11*}, **Qiaoyang Lu, MS^{11*}** and **Ramon V. Tiu, MD^{12*}**

¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

²Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK

³Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

⁴University Hospitals, Cleveland Medical Center, Cleveland, OH

⁵Methodist Physician Practices, San Antonio, TX

⁶Columbia University Medical Center, New York, NY

⁷University of Kansas Medical Center, Kansas City, KS

⁸Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA

⁹Yale School of Medicine, New Haven, CT

¹⁰David Geffen School of Medicine at UCLA, Los Angeles, CA

¹¹Astellas Pharma Global Development, Northbrook, IL

¹²Astellas Pharma, Inc., Northbrook, IL

34 The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Type: Oral

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Single Cell Profiling and Novel molecular Markers

Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Saturday, Dec 5, 2020: 11:30 AM

Hassan Awada, MD¹, Arda Durmaz^{2*}, Carmel Gurnari, MD^{3*}, Ashwin Kishtagari, MBBS¹, Manja Meggendorfer, PhD⁴, Cassandra M. Kerr, MS^{5*}, Teodora Kuzmanovic^{5*}, Jibril Durrani, MD^{1*}, Yasunobu Nagata, MD, PhD^{5*}, Tomas Radivoyevitch, PhD^{5,6*}, **Anjali S Advani, MD⁷, Farhad Ravandi, MBBS⁸, **Hetty E. Carraway, MD, MBA⁹**, **Aziz Nazha, MD¹⁰**, Claudia Haferlach, MD¹¹, **Yogenthiran Sauntharajah, MD¹²**, **Jacob Scott, MD^{5*}**, Valeria Visconte, PhD¹, Hagop M. Kantarjian, MD¹³, Tapan M. Kadia, MD⁸, **Mikael A. Sekeres¹⁰**, **Torsten Haferlach, MD¹⁴** and **Jaroslav P. Maciejewski, MD, PhD⁵****

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Translational hematology and Oncology research, Taussig Cancer Center, Cleveland Clinic, Cleveland

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁴MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁷Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

⁸Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

⁹Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

¹¹MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany

¹²Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹³University of Texas MD Anderson Cancer Center, Houston, TX

¹⁴MLL Munich Leukemia Laboratory, Munich, Germany

51 A Phase 2 Study of the LSD1 Inhibitor IMG7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Program: Oral and Poster Abstracts

Type: Oral

Session: 634. Myeloproliferative Syndromes: Clinical: New Therapies and JAKi-based Combinations for Myelofibrosis

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, MPN, Study Population, Myeloid Malignancies, Clinically relevant

Saturday, Dec 5, 2020: 10:30 AM

Abdulraheem Yacoub, MD¹, Kristen M. Pettit, MD², Terrence J Bradley, MD³, Aaron T. Gerds, MD, MS⁴, Maciej Tartaczuch, MD^{5*}, Jake Shortt, FRACP, FRCPA, PhD⁶, Natasha Joan Curtin, MD, FRACP, FRCPA^{7*}, James M. Rossetti, DO⁸, Kate Burbury, MBBS, FRACP, FRCPA, DPhil^{9*}, Adam J. Mead, MD, PhD¹⁰, Joachim R Göthert, MD¹¹, Steffen Koschmieder, MD¹², Amber Jones, MA^{13*}, Jennifer Peppe, BS^{14*}, Georges Natsoulis, Ph.D.^{13*}, William S. Stevenson, MBBS, PhD¹⁵, Joanne Ewing, MD, PhD^{16*}, Claire Harrison, DM, FRCP, FRCPATH¹⁷, Alessandro M. Vannucchi, MD¹⁸, Justin M Watts, MD¹⁹, David M Ross, MBBS, PhD, FRACP, FRCPA^{20*}, Moshe Talpaz, MD²¹ and Hugh Young Rienhoff Jr., MD²²

¹The University of Kansas Cancer Center, Leawood, KS

²Rogel Cancer Center, University of Michigan, Ann Arbor, MI

³University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵School of Clinical Sciences, Monash University, Melbourne, Australia

⁶Department of Haematology, Monash Health, Clayton, Australia

⁷Monash Health, Monash University, Melbourne, Australia

⁸UPMC Hillman Cancer Center, Pittsburgh, PA

⁹Peter MacCallum Cancer Centre, Melbourne, Australia

¹⁰MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

¹¹Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany

¹²Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany

¹³Imago Biosciences, Inc., San Carlos, CA

¹⁴Imago BioSciences, Inc., San Carlos, CA

¹⁵Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia

¹⁶University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

¹⁷Department of Clinical Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom

¹⁸CRIMM; Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy

¹⁹University of Miami, Coral Gables, FL

²⁰Department of Haematology, Flinders Medical Centre and University, Adelaide, SA, Australia

²¹University of Michigan Medical Center, Ann Arbor, MI

²²Imago Biosciences, San Francisco

75 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transp

Program: Press Program Presentations

Session: Press Briefing on What's on the Horizon: Practice-Changing Clinical Trials

Hematology Disease Topics & Pathways: Biological, Adult, bone marrow, Diseases, Therapies, Elderly, MDS, Study Population, Clinically relevant, Myeloid Malignancies, transplantation, stem cells

Friday, Dec 4, 2020, 12:30 PM-1:00 PM

Ryotaro Nakamura, M.D.¹, Wael Saber, MD, MS², Michael J Martens, PhD^{3*}, Alyssa Ramirez^{3*}, Bart L. Scott, MD⁴, Betul Oran, MD, MS⁵, Eric Leifer, Ph.D.^{6*}, Roni Tamari, MD⁷, Asmita Mishra, MD^{8*}, Richard T. Maziarz, MD⁹, Joseph P. McGuirk, DO¹⁰, Peter Westervelt, MD, PhD¹¹, Sumithra Vasu, MD, MBBS¹², Mrinal M. Patnaik, MD, MBBS¹³, Rammurti Kamble, MD¹⁴, Stephen J. Forman, MD¹, **Mikhael A. Sekeres¹⁵, Frederick R. Appelbaum, MD⁴, Adam M. Mendizabal, MS^{3*}, Brent Logan, PhD^{16*}, Mary M. Horowitz, MD, MS¹⁶ and **Corey Cutler, MD, MPH, FRCPC¹⁷****

¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

²CIBMTR, Medical College of Wisconsin, Milwaukee, WI

³The Emmes Company, Rockville, MD

⁴Fred Hutchinson Cancer Research Center, Seattle, WA

⁵Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX

⁶Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

⁷Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

⁸Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁹Knight Cancer Institute, Oregon Health and Science University, Portland, OR

¹⁰Department of Blood and Bone Marrow Transplant, The University of Kansas Medical Center, Kansas City, KS

¹¹Washington University School of Medicine, Saint Louis, MO

¹²Ohio State University Wexner Medical Center, Columbus, OH

¹³Division of Hematology, Mayo Clinic, Rochester, MN

¹⁴Baylor College of Medicine Methodist Hospital, Houston, TX

¹⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁶Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

¹⁷Division of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Inst., Boston, MA

135 High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractor

Program: Oral and Poster Abstracts

Type: Oral

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities I

Hematology Disease Topics & Pathways: Biological, antibodies, HSCs, Adult, Therapies, Elderly, Cell Lineage, Study Population, Clinically relevant, stem cells

Saturday, Dec 5, 2020: 12:30 PM

Boglarka Gyurkocza, MD¹, Rajneesh Nath, MD², Hannah Choe, MD³, Stuart Seropian, MD⁴, Patrick J. Stiff, MD⁵, Sunil Abhyankar, MD⁶, Edward Agura, MD⁷, Mark Litzow, MD⁸, Benjamin K. Tomlinson, MD⁹, George L. Chen, MD¹⁰, Parameswaran Hari, MD, MRCP¹¹, Johnnie Orozco, MD^{12*}, Zaid S. Al-Kadhim, MD^{13*}, Camille Abboud, MD¹⁴, Koen Van Besien, MD, PhD¹⁵, Mitchell Sabloff, MSc, MD, FRCPC¹⁶, Margarida Magalhaes Magalhaes-Silverman¹⁷, James M. Foran, MD¹⁸, Michael W. Schuster, MD¹⁹, Partow Kebriaei, MD²⁰, Moshe Levy, MD^{21*}, Hillard M Lazarus, MD²², Sergio A. Giral, MD²³, Qing Liang, PhD^{24*}, Mark S. Berger, MD²⁴, Vijay Reddy, MD, PhD²⁴ and John M. Pagel, MD PhD²⁵

¹Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

²Banner MD Anderson Cancer Center, Gilbert, AZ

³Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

⁴Hematology, Yale University School of Medicine, New Haven, CT

⁵Loyola University Chicago Stritch School of Medicine, Maywood, IL

⁶University of Kansas Cancer Center, Kansas City, KS

⁷Baylor University Medical Center at Dallas, Dallas, TX

⁸Division of Hematology, Mayo Clinic, Rochester, MN

⁹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁰Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹¹Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

¹²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹³Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

¹⁴Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

¹⁵Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY

¹⁶Hematology, The Ottawa Hospital General Campus, Ottawa, ON, Canada

¹⁷Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

¹⁸Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

¹⁹Stony Brook University Hospital Cancer Center, Stony Brook, NY

²⁰Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

²¹Baylor University Medical Center, Dallas, TX

²²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Shaker Heights, OH

²³Memorial Sloan Kettering Cancer Center, New York, NY

²⁴Actinium Pharmaceuticals, Inc., New York, NY

²⁵Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

170 Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML

Hematology Disease Topics & Pathways: AML, Biological, Adult, Diseases, Therapies, checkpoint inhibitors, MDS, Study Population, Myeloid Malignancies

Saturday, Dec 5, 2020: 4:15 PM

Jacqueline S. Garcia, MD¹, Yael Flamand, MS^{2*}, Benjamin K. Tomlinson, MD³, Michael Keng, MD^{4*}, Lourdes M. Mendez, MD, PhD⁵, Samer Khaled, MD⁶, Asad Bashey, MD, PhD⁷, Andrew M. Brunner, MD⁸, Alexandra Savell, BS^{1*}, Donna Neuberg^{9*}, Ilene Galinsky^{10*}, Marlise R. Lusk, MD¹¹, David P. Steensma, MD¹, Martha Wadleigh, MD^{10*}, Eric S. Winer, MD¹⁰, David E. Avigan, MD¹², Nicole Cullen^{11*}, Scott Rodig, MD, PhD^{13,14}, Livius Penter^{1*}, R. Coleman Lindsley, MD, PhD¹, Stephanie Andrews^{11*}, Matthew S. Davids, MD¹, Catherine J. Wu, MD¹, Richard M. Stone, MD¹⁰, Daniel J. DeAngelo, MD, PhD¹⁵ and Robert J. Soiffer, MD¹⁶

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

³Case Western Reserve University, Cleveland, OH

⁴UVA, Charlottesville, VA

⁵Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA, Boston, MA

⁶Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

⁷BMT Group of Georgia, Atlanta, GA

⁸Massachusetts General Hospital, Boston, MA

⁹DFCI, Los Angeles, CA

¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston

¹¹Dana-Farber Cancer Institute, Boston, MA

¹²Beth Israel Deaconess Medical Center, Boston, MA

¹³Dana-Farber Cancer Institute, Center for Immuno-Oncology, Boston, MA

¹⁴Department of Pathology, Brigham & Women's Hospital, Boston, MA

¹⁵Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA

¹⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

186 Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)

Program: Oral and Poster Abstracts

Type: Oral

Session: 711. Cell Collection and Processing

Hematology Disease Topics & Pathways: Fanconi Anemia, iron deficiency, PNH

Saturday, Dec 5, 2020: 3:45 PM

Jack W. Hsu, MD¹, Nosha Farhadfar, MD², Hemant S. Murthy, MD³, Brent Logan, PhD^{4*}, Stephanie Bo-Subait, MPH^{5*}, Noelle V. Frey, MD, MS⁶, Steven C. Goldstein, MD⁷, Mary M. Horowitz, MD, MS⁸, Hillard M Lazarus, MD⁹, Joshua Schwanke^{10*}, Nirali N. Shah, MD¹¹, Stephen R. Spellman, MS^{12*}, Galen E. Switzer, PhD^{13*}, Steven M Devine, MD¹⁴, Bronwen E. Shaw, PhD, MRCP, FRCPath¹⁵ and John R. Wingard, MD^{16*}

¹Department of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL

²Shands HealthCare & University of Florida, Gainesville, FL

³Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL

⁴Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁵CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN

⁶Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA

⁷Florida Hospital Cancer Institute, Orlando, FL

⁸Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

⁹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Shaker Heights, OH

¹⁰NMDP, Minneapolis, MN

¹¹Pediatric Oncology Branch, National Cancer Institute/Nih, Bethesda, MD

¹²CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI

¹³University of Pittsburgh, Pittsburgh, PA

¹⁴National Marrow Donor Program (NMDP)/Be The Match, Minneapolis, MN

¹⁵CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

¹⁶Division of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, FL

188 Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Program: Oral and Poster Abstracts

Type: Oral

Session: 711. Cell Collection and Processing

Hematology Disease Topics & Pathways: Biological, antibodies, Therapies, transplantation, stem cells

Saturday, Dec 5, 2020: 4:15 PM

Shivaprasad Manjappa, MD, MBBS¹, Robert Fox^{2*}, Jane Reese^{2*}, Amin Firoozamand, MD^{3*}, Hannah Schmikli, RN^{4*}, Savannah Nall, RN^{5*}, Merle Kolk^{2*}, Paolo F Caimi, MD², James J. Driscoll, MD, PhD^{6,7}, Marcos de Lima, MD² and Ehsan Malek, MD⁸

¹Case Western Reserve University, BEACHWOOD, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³University Hospital Cleveland Medical Center/ Seidman Cancer Center, Cleveland, OH

⁴University Hospitals Cleveland Medical Center, Cleveland, OH

⁵University Hospital Cleveland Medical Center, Cleveland, OH

⁶Case Western Reserve University, Cleveland, OH

⁷Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁸Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

193 Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment

Program: Oral and Poster Abstracts

Type: Oral

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities II

Saturday, Dec 5, 2020: 4:00 PM

Boglarka Gyurkocza, MD¹, Rajneesh Nath, MD², Hannah Choe, MD³, Stuart Seropian, MD⁴, Patrick J. Stiff, MD⁵, Sunil Abhyankar, MD⁶, Edward Agura, MD⁷, Mark Litzow, MD⁸, Benjamin K. Tomlinson, MD⁹, George L. Chen, MD¹⁰, Parameswaran Hari, MD, MRCP¹¹, Johnnie Orozco, MD^{12*}, Zaid S. Al-Kadhim, MD^{13*}, Camille Abboud, MD¹⁴, Koen Van Besien, MD, PhD¹⁵, Mitchell Sabloff, MSc, MD, FRCPC¹⁶, Margarida Magalhaes Magalhaes-Silverman¹⁷, James M. Foran, MD¹⁸, Michael W. Schuster, MD¹⁹, Partow Kebriaei, MD²⁰, Moshe Y. Levy, MD²¹, Hillard M Lazarus, MD²², Sergio A. Giral, MD²³, Qing Liang, PhD^{24*}, Mark S. Berger, MD²⁴, Vijay Reddy, MD, PhD²⁴ and John M. Pagel, MD PhD²⁵

¹Memorial Sloan-Kettering Cancer Center, New York, NY

²Banner MD Anderson Cancer Center, Gilbert, AZ

³Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

⁴Hematology, Yale University School of Medicine, New Haven, CT

⁵Loyola University Chicago Stritch School of Medicine, Maywood, IL

⁶Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

⁷Baylor University Medical Center at Dallas, Dallas, TX

⁸Division of Hematology, Mayo Clinic, Rochester, MN

⁹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁰Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹¹Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

¹²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹³Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

¹⁴Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

¹⁵Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY

¹⁶Hematology, The Ottawa Hospital General Campus, Ottawa, ON, Canada

¹⁷Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

¹⁸Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

¹⁹Stony Brook University Hospital Cancer Center, Stony Brook, NY

²⁰Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

²¹Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

²²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Shaker Heights, OH

²³Memorial Sloan Kettering Cancer Center, New York, NY

²⁴Actinium Pharmaceuticals, Inc., New York, NY

²⁵Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

196 Computer Vision and Deep Learning Assisted Microchip Electrophoresis for Integrated Anemia and Sickle Cell Disease Screening

Program: Oral and Poster Abstracts

Type: Oral

Session: 803. Emerging Diagnostic Tools and Techniques II

Hematology Disease Topics & Pathways: Anemias, sickle cell disease, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures, Clinically relevant, newborn screening

Saturday, Dec 5, 2020: 3:15 PM

Ran An, PhD¹, Yuncheng Man^{1*}, Shamreen Iram^{1*}, Erdem Kucukal, PhD^{1*}, Muhammad Noman Hasan, PhD^{1*}, Ambar Solis-Fuentes^{1*}, Allison Bode^{1*}, Ailis Hill^{1*}, Kevin Cheng^{1*}, Yuning Huang^{1*}, Sanjay Ahuja, MD^{1,2}, Jane A. Little, MD³, Michael Hinczewski, PhD^{1*} and Umut A. Gurkan, PhD¹

¹Case Western Reserve University, Cleveland, OH

²University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

³University of North Carolina at Chapel Hill, Chapel Hill, NC

202 Performance of Khorana Score to Predict One-Year Risk of Venous Thromboembolism in over Two Million Patients with Cancer

Program: Oral and Poster Abstracts

Type: Oral

Session: 904. Outcomes Research - Non-Malignant Conditions: Venous Thromboembolism Associated with Cancer and/or COVID-19

Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting, Non-Biological, Thrombosis, Clinically relevant, VTE

Saturday, Dec 5, 2020: 3:15 PM

Yasmin Arafah, MD¹, Taha Al-Juhaishi, MD², Ghaith Abu Zeinah, MD³, Lalitha V. Nayak, MD⁴ and Sadeer Al-Kindi, M.D.^{5*}

¹Department of Medicine, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

²Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

³Richard T. Silver Myeloproliferative Neoplasms Center, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY

⁴Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

⁵Division of Cardiology, Harrington Heart and Vascular Institute, Case Western Reserve University and University Hospitals, Cleveland, OH

204 Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry

Program: Oral and Poster Abstracts

Type: Oral

Session: 904. Outcomes Research - Non-Malignant Conditions: Venous Thromboembolism Associated with Cancer and/or COVID-19

Saturday, Dec 5, 2020: 3:45 PM

Ang Li, MD, MS¹, Nicole M. Kuderer, MD, MSc², Jeremy L. Warner, MD, MS³, Aakash Desai, MD⁴, Dimpy P. Shah, MD, PhD^{5*}, Julie Fu, MD, MA⁶, Monica Li^{7*}, Rebecca Zon^{8*}, Surbhi Shah, MD⁹, Shuchi Gulati, MD¹⁰, Ali Raza Khaki, MD¹¹, Amit Kulkarni, MD¹², Amro Elshoury, MBBChir¹³, Michael A. Thompson, MD, PhD¹⁴, Petros Grivas, MD, PhD^{15*}, Gilberto de Lima Lopes, MD, MBA^{16*}, Yu Shyr, PhD^{17*}, Nathan A Pennell, MD, PhD^{18*}, Andrew Schmidt, MD^{19*}, Christopher R Friese^{20*}, Daniel Stover^{21*}, Jaymin Patel^{22*}, Balazs Halmos^{23*}, Toni K. Choueiri, MD^{24*}, Solange Peters, MD^{25*}, Donna R. Rivera, PharmD^{26*}, Corrie Painter, PhD^{27*}, Brian Rini, MD^{28*}, Gary H. Lyman, MD²⁹, Jean M. Connors, MD³⁰ and Rachel P. Rosovsky, MD, MPH³¹

¹Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX

²Advanced Cancer Research Group, Seattle, WA

³Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

⁴Division of Hematology, Department of Medicine, MayoClinic, Rochester, MN

⁵Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

⁶Tufts Medical Center, Watertown, MA

⁷Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston

⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA

⁹University of Minnesota, Minneapolis, MN

¹⁰University of Cincinnati/Barrett Cancer Center, Cincinnati, OH

¹¹Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

¹²Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN

¹³Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹⁴Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Delafield, WI

¹⁵Fred Hutchinson Cancer Research Center/University of Washington/Seattle Cancer Care Alliance, Seattle

¹⁶Sylvester Comprehensive Cancer Center at the University of Miami, Miami

¹⁷Biostatistics, Vanderbilt University School of Medicine, Nashville, TN

¹⁸Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁹Dana-Farber Cancer Institute, Boston, MA

²⁰University of Michigan, Ann Arbor, MI

²¹Ohio State University Medical Center, Columbus, OH

²²Breast Oncology Program, Beth Israel Deaconess Medical Center, Boston, MA

²³Montefiore Medical Center, Bronx, NY

²⁴Dana Farber Cancer Institute, Boston

²⁵Lausanne University, Lausanne, Switzerland

²⁶National Cancer Institute, Bethesda

²⁷Cancer Program, Broad Institute, Cambridge, MA

²⁸Vanderbilt Ingram Cancer Center at Vanderbilt University Medical Center, Nashville, TN

²⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

³⁰Brigham & Women's Hosp./Dana Farber Cancer Inst., Boston, MA

³¹Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA

207 Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Healthcare Disparities

Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant, Quality Improvement

Saturday, Dec 5, 2020: 3:00 PM

Augusta Eduafo, DO^{1*}, Leland Metheny III, MD², James Driscoll^{3*}, Benjamin K. Tomlinson, MD², Kirsten M Boughan, DO², Molly M Gallogly, MD, PhD², Marcos de Lima, MD² and Ehsan Malek, MD⁴

¹Internal Medicine Department, St. John Medical Center, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Case Western Reserve University, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

215 Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

Program: Press Program Presentations

Session: Press Briefing on Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19

Hematology Disease Topics & Pathways: SARS-CoV-2/COVID-19, Coronaviruses, ALL, Lymphoma (any), CLL, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Clinically relevant

Saturday, Dec 5, 2020, 11:00 AM-11:30 AM

William A. Wood, MD, MPH¹, Donna S. Neuberg, ScD², John Colton Thompson^{3*}, Martin S. Tallman, MD⁴, Mikkael A. Sekeres, MD, MS⁵, Laurie H. Sehn, MD, MPH⁶, Kenneth Anderson, MD⁷, Aaron D Goldberg, MD, PhD⁸, Nathan A Pennell, MD, PhD^{9*}, Charlotte M. Niemeyer, MD¹⁰, Emily Tucker, MS^{11*}, Kathleen Hewitt, DNP, CPHQ, AACC, RN^{12*}, Robert M Plovnick, MD, MS¹² and Lisa K. Hicks, MD, MSc¹³

¹Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC

²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

³ASH Research Collaborative, Washington, DC

⁴Memorial Sloan-Kettering Cancer Center, New York, NY

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada

⁷Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁸Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

⁹Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰University Children's Hospital, Freiburg, Germany

¹¹ASH Research Collaborative, Washington DC, DC

¹²American Society of Hematology, Washington DC, DC

¹³Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada

257 Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders

Hematology Disease Topics & Pathways: AML, Diseases, Bone Marrow Failure, MDS, MPN, Myeloid Malignancies

Saturday, Dec 5, 2020: 5:45 PM

Misam Zawit, MBBS^{1*}, Jibril Durrani, MD^{1*}, Wenyi Shen, MD^{2*}, Vera Adema, PhD^{3*}, Cassandra M Kerr, MS^{1*}, Hassan Awada, MD¹, Sunisa Kongkiatkamon, MD^{1*}, Carmelo Gurnari, MD^{4*}, Simona Pagliuca, MD¹, Laila Terkawi^{1*}, **Bhumika J. Patel, MD^{3,5}, Valeria Visconte, PhD¹, Hetty E. Carraway, MD, MBA^{1,6}, Thomas LaFramboise, Ph.D.^{7*}, Seth J. Corey, MD⁸, Torsten Haferlach, MD⁹ and Jaroslaw P. Maciejewski, MD, PhD³**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁷Department of Genetics and Genome Sciences Case Western Reserve University School of Medicine, Cleveland, OH

⁸Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH

⁹MLL Munchner Leukamie Labor GmbH, Munchen, Germany

259 Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, Biological Processes, genomics, Clinically relevant, immune mechanism

Saturday, Dec 5, 2020: 6:15 PM

Simona Pagliuca, MD^{1,2}, Carmelo Gurnari, MD^{2,3*}, Diego Chowell, PhD^{4*}, Chirag Krishna^{5*}, **Bhumika J. Patel, MD⁶, Hassan Awada, MD², Cassandra M Kerr, MS^{2*}, Sunisa Kongkiatkamon, MD^{2,7*}, Ashwin Kishtagari, MBBS², **Thomas Laframboise, PhD^{8*}, Yogenthiran Sauntharajah, MD², Babal K. Jha, PhD^{2*}, Valeria Visconte, PhD², Timothy Chan, MD, PhD^{9*} and Jaroslaw Maciejewski, PhD^{2*}****

¹Université de Paris, Paris, France

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

⁴Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York

⁵Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York

⁶Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁷Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

⁸Genetics and Genome Sciences Department, Case Western Reserve University, Cleveland, OH

⁹Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland

288 Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies

Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Biological Processes, Technology and Procedures, Study Population, Myeloid Malignancies, genomics, Clinically relevant, NGS

Saturday, Dec 5, 2020: 6:00 PM

Hideki Makishima, MD, PhD¹, Yasuhito Nannya, MD, PhD¹, June Takeda, MD^{2*}, Yukihide Momozawa, DVM, Ph.D^{3*}, Ryunosuke Saiki, MD^{4*}, Tetsuichi Yoshizato, MD, PhD⁴, Yoshiko Atsuta, MD, PhD^{5,6*}, Yuka Iijima-Yamashita^{7*}, Kenichi Yoshida, MD, PhD^{1*}, Yuichi Shiraishi, PhD^{8*}, Yasunobu Nagata, MD, PhD^{1*}, Yusuke Shiozawa, MD, PhD^{9*}, Makoto Onizuka, MD, PhD¹⁰, Kenichi Chiba^{11*}, Hiroko Tanaka^{12*}, Nobuyuki Kakiuchi, M.D.^{1*}, Yotaro Ochi, MD^{1*}, Hiroo Ueno, MD, PhD^{2*}, Hidehiro Itonaga, MD, PhD^{13*}, Yoshinobu

Kanda, MD, PhD¹⁴, Masashi Sanada, MD¹⁵, Ayana Kon, MD, PhD^{1*}, Yasushi Miyazaki, MD, PhD¹⁶, Keizo Horibe, MD, PhD^{15*}, Maria Creignou^{17*}, Magnus Tobiasson, MD^{18,19*}, Hisashi Tsurumi, MD, PhD²⁰, Senji Kasahara, MD, PhD²¹, Chantana Polprasert, MD^{22*}, Eva Hellstrom Lindberg, MD, PhD^{23,24}, Akifumi Kondo Takaori, MD, PhD^{25*}, Toru Kiguchi, MD, PhD^{26*}, Mario Cazzola²⁷, Fumihiko Matsuda, MD, PhD^{28*}, Kazuma Ohyashiki, MD, PhD²⁹, **Jaroslav P. Maciejewski, MD, PhD³⁰**, Torsten Haferlach, MD³¹, Yoichiro Kamatani, MD, PhD^{32*}, Michiaki Kubo, MD, PhD^{33*}, Satoru Miyano, PhD^{34*} and Seishi Ogawa, MD, PhD^{4,35}

¹Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

²Department of Pathology and Tumor Biology, Kyoto University, Kyoto, KYO, Japan

³Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

⁴Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

⁵Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

⁶Department of Healthcare Administration, Nagoya University, Nagoya, Japan

⁷Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan

⁸Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center Research Institute, Tokyo, Japan

⁹Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan

¹⁰Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan

¹¹Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan

¹²Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan

¹³Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

¹⁴Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan

¹⁵Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

¹⁶Atomic Bomb Disease Institute, Nagasaki University Hospital, Nagasaki, Japan

¹⁷Karolinska University Hospital, Stockholm, Sweden, Karolinska Institutet, Linköping, SWE

¹⁸Karolinska University Hospital, Stockholm, Sweden

¹⁹Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden

²⁰Hematology, Gifu University Graduate School of Medicine, Gifu, Japan

²¹Hematology, Gifu Municipal Hospital, Gifu, Japan

²²Division of Hematology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

²³Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

²⁴HERM, Dept. of Medicine, Huddinge, Karolinska Institute, and PO Hematology, Karolinska University Hospital, Stockholm, Sweden

²⁵Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

²⁶Department of Hematology, Chugoku Central Hospital, Fukuyama, HIR, Japan

²⁷Department of Molecular Medicine, University of Pavia, Pavia, Italy

²⁸Kyoto University Graduate School of Medicine, Kyoto, JPN

²⁹Department of Advanced Cellular Therapy, Tokyo Medical University, Tokyo, Japan

³⁰Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³¹MLL Munchner Leukamie Labor GmbH, Munchen, Germany

³²Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

³³RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

³⁴The University of Tokyo, Human Genome Centre, Institute of Medical Science, Tokyo, Japan

³⁵Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden

[**299 Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation Results III

Hematology Disease Topics & Pathways: Leukemia, ALL, Adult, Diseases, Young Adult, Lymphoid

Malignancies, Clinically relevant

Saturday, Dec 5, 2020: 5:45 PM

Matthew J. Wieduwilt, MD, PhD¹, Leland Metheny III, MD², Mei-Jie Zhang, PhD^{3*}, Hai-Lin Wang, MPH^{4*}, Noel Estrada-Merly, MS^{5*}, Marcos de Lima, MD⁶, Mark Litzow, MD⁷, Partow Kebriaei, MD⁸, Chris S. Hourigan, MD PhD⁹, Daniel J. Weisdorf, MD¹⁰ and Wael Saber, MD, MS⁴

¹Moore Cancer Center, University of California, San Diego, La Jolla, CA

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁵CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI

⁶Case Western Reserve University, Cleveland, OH

⁷Division of Hematology, Mayo Clinic, Rochester, MN

⁸Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

⁹Myeloid Malignancies Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

¹⁰Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN

317 Germline Gain-of-Function JAK3 Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells

Program: Oral and Poster Abstracts

Type: Oral

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hematologic Malignancies and COVID-19

Hematology Disease Topics & Pathways: autoimmune disorders, Leukemia, Diseases, LGLL, immunodeficiency, Biological Processes, Immune Disorders, Lymphoid Malignancies, genomics, Clinically relevant, Proliferative disorders, hematopoiesis, pathogenesis, signal transduction

Sunday, Dec 6, 2020: 1:45 PM

Harry Lesmana, MD^{1,2}, **Marcela Popescu, MD^{3*}**, **Sara Lewis, MS, LCGC^{4*}**, **Sushree Sangita Sahoo, PhD^{5*}**, **Charnise Goodings-Harris, PhD⁶**, **Mihaela Onciu, MD, FACP⁷**, **John Kim Choi, MD, FACP^{7*}**, **Clifford Takemoto, MD^{1*}**, **Kim E. Nichols, MD⁸** and **Marcin Wlodarski, MD, PhD⁹**

¹Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN

²Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH

³Department of Pediatrics, East Tennessee State University, Johnson City, TN

⁴St. Jude Children's Research Hospital, Memphis, TN

⁵Hematology, St. Jude Children's Research Hospital, Memphis, TN

⁶St. Jude Children's Research Hospital, Memphis, TN

⁷Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN

⁸Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

⁹Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN

331 Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Type: Oral

Session: 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches

Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, Myeloid Malignancies, Clinically relevant

Sunday, Dec 6, 2020: 12:45 PM

Ibrahim Aldoss, MD¹, **Geoffrey L Uy, MD²**, **Norbert Vey, MD³**, **Ashkan Emadi, M.D., Ph.D.⁴**, **Peter H. Sayre, MD, PhD⁵**, **Roland B. Walter, MD, PhD, MS⁶**, **Matthew C Foster, MD⁷**, **Martha L. Arellano, MD⁸**, **John E. Godwin, MD⁹**, **Matthew J. Wieduwilt, MD, PhD¹⁰**, **Michael T. Byrne, DO¹¹**, **Laura C. Michaelis, MD¹²**, **Patrick J. Stiff, MD¹³**, **Matteo Giovanni Carrabba, MD^{14*}**, **Patrice Chevalier, MD, PhD^{15*}**, **Emmanuel Gyan, MD, PhD¹⁶**, **Christian Recher, MD, PhD¹⁷**, **Anjali S Advani, MD¹⁸**, **Martin Wermke^{19*}**, **Harry P. Erba²⁰**, **Fabio Ciceri, MD^{21*}**, **Geert Huls, MD, PhD²²**, **Mojca Jongen-Lavrencic, MD, PhD²³**, **Max S. Topp, MD²⁴**, **Antonio Curti, MD PhD²⁵**, **Farhad Ravandi, MBBS²⁶**, **Michael P. Rettig, PhD²⁷**, **John Muth, MS^{28*}**, **Mary Beth Collins^{29*}**, **Erin Timmeny^{30*}**, **Kuo Guo, MSc^{31*}**, **Jian Zhao, PhD^{31*}**, **Kathy Tran^{28*}**, **Patrick Kaminker, PhD^{32*}**, **Priyanka Patel, PharmD^{29*}**, **Ouiam Bakkacha, MD^{33*}**, **Teia Curtis^{34*}**, **Kenneth Jacobs, MD^{35*}**, **Maya Kostova, PhD^{31*}**, **Jennifer Seiler, PhD, RAC^{29*}**, **Bob Lowenberg, MD, PhD³⁶**, **Sergio Rutella, MD, PhD, FRCPATH³⁷**, **Ezio Bonvini, MD³²**, **Jan K Davidson-Moncada, MD, PhD³⁸** and **John F. DiPersio, MD, PhD²**

¹Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

²Washington University School of Medicine, Saint Louis, MO

³Hematologie clinique, Institut Paoli Calmettes, Marseille, France

⁴University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

⁵University of California, San Francisco, San Francisco, CA

⁶Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁷Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC
⁸Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
⁹Providence Portland Medical Center, Portland, OR
¹⁰Moore Cancer Center, University of California, San Diego, La Jolla, CA
¹¹Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
¹²Division of Hematology/Oncology, Department of Medicine, The Medical College of Wisconsin Inc., Milwaukee, WI
¹³Loyola University Chicago Stritch School of Medicine, Maywood, IL
¹⁴Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
¹⁵Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France
¹⁶CHU de Tours - Hôpital Bretonneau, Tours, France
¹⁷Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
¹⁸Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
¹⁹NCT/UCC Early Clinical Trial Unit, University Hospital Carl Gustav Carus, Dresden, Germany
²⁰Duke University School of Medicine, Durham, NC
²¹Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
²²Department of Hematology, University Medical Center Groningen, Groningen, GZ, Netherlands
²³Erasmus University Medical Center, Rotterdam, Netherlands
²⁴Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
²⁵Hematology/Oncology "L. e A. Seragnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Bologna, Italy
²⁶Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
²⁷Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO
²⁸MacroGenics, Inc., Rockville, MD
²⁹MacroGenics, Rockville
³⁰MacroGenics, Inc., ROCKVILLE, MD
³¹MacroGenics, Rockville, MD
³²MacroGenics, Rockville, MD
³³MacroGenics, Inc., ROCKVILLE, MD
³⁴MacroGenics, Inc., Frederick, MD
³⁵MacroGenics, Inc., Rockville, MD
³⁶Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
³⁷John van Geest Cancer Centre School of Science and Technology, Nottingham Trent University, Nottingham, ENG, United Kingdom
³⁸MacroGenics, Inc., Washington, DC

408 The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes — Basic and Translational Studies

Hematology Disease Topics & Pathways: AML, Anemias, Diseases, aplastic anemia, Bone Marrow Failure, MDS, MPN, Biological Processes, PNH, Myeloid Malignancies, pathogenesis

Sunday, Dec 6, 2020: 3:30 PM

Carmelo Gurnari, MD^{1,2*}, Simona Pagliuca, MD^{2,3}, Bhumika J. Patel, MD⁴, Hassan Awada, MD², Cassandra M Kerr, MS^{2*}, Wenyi Shen, MD^{5*}, Sunisa Kongkiatkamon, MD^{2*}, Laila Terkawi^{2*}, Misam Zawit, MBBS^{2*}, Jibran Durrani, MD^{2*}, Valeria Visconte, PhD², Seth J. Corey, MD⁶, Maria Teresa Voso, MD¹, Hetty E. Carraway, MD, MBA^{2,7} and Jaroslav P. Maciejewski, MD, PhD⁸

¹Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Université de Paris, Paris, France

⁴Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH

⁷Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

438 Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Program: Oral and Poster Abstracts

Type: Oral

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Myeloma

Hematology Disease Topics & Pathways: multiple myeloma, Diseases, Adverse Events, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant

Sunday, Dec 6, 2020: 3:30 PM

Rajshekhar Chakraborty, MD^{1*}, Lisa Rybicki, MS^{2*}, Jason Valent, MD³, Alex V. Mejia Garcia, MD⁴, Beth M. Faiman, PhD, CNP³, Jack Khouri, MD⁴, Nathaniel Rosko, PharmD^{5*}, Christy J. Samaras, DO³, Matt Kalaycio, MD⁶, Faiz Anwer, MD⁴ and Alok A Khorana, MD⁵

¹Department of Medicine, Columbia University Medical Center, New York

²Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Cleveland Clinic, Cleveland, OH

⁶Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

442 Prior History of Venous Thromboembolism Is a Significant Risk Factor for Recurrence of Thrombosis after Cancer Diagnosis

Program: Oral and Poster Abstracts

Type: Oral

Session: 331. Pathophysiology of Thrombosis I

Hematology Disease Topics & Pathways: Adult, Diseases, Bleeding and Clotting, Thromboembolism, Study Population, Clinically relevant

Sunday, Dec 6, 2020: 5:00 PM

Sargam Kapoor, MBBS¹, Aman Opneja, MBBS¹, Jahnavi Gollamudi, MD² and Lalitha V. Nayak, MD³

¹Division of Hematology Oncology, Alaska Native Medical Center, Anchorage, AK

²Department of Pathology and Medicine, Baylor College of Medicine, Houston, TX

³Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

474 Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma

Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies, Clinically relevant

Sunday, Dec 6, 2020: 6:00 PM

Alex F. Herrera, MD¹, Carmelo Carlo-Stella, MD², Graham P. Collins, MD, DPhil³, Kami J. Maddocks, MD⁴, Nancy L. Bartlett, MD^{5*}, Kerry J. Savage, MD MSc⁶, Paolo F Caimi^{7*}, Brian T. Hess, MD⁸, Pier Luigi Zinzani, MD⁹, Hans G Cruz¹⁰, Luqiang Wang^{11*}, Jay Feingold^{12*}, Jens Wuerthner^{10*} and Stephen M. Ansell, MD, PhD¹³

¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA

²Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas University, Milan, Italy

³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

⁴Division of Hematology, Department of Internal Medicine, Ohio State University Hospital, Columbus, OH

⁵Division of Oncology, Washington University School of Medicine in St Louis, St. Louis, MO

⁶Department of Medical Oncology, BC Cancer and University of British Columbia, Vancouver, BC, Canada

⁷University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

⁸Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC

⁹Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy

¹⁰Clinical Development, ADC Therapeutics SA, Epalinges, Switzerland

¹¹ADC Therapeutics America, Inc., Murray Hill, NJ

¹²ADC Therapeutics America, Inc., Murray Hill, NJ

¹³Mayo Clinic, Rochester, MN

478 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: PCNSL Treatment and Prognosis and CNS Prophylaxis in High-Risk Aggressive Lymphomas

Hematology Disease Topics & Pathways: antibodies, Adult, Diseases, Non-Biological, Therapies, Combinations, CNS Lymphoma, chemotherapy, DLBCL, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant

Sunday, Dec 6, 2020: 5:30 PM

Victor M. Orellana-Noia, MD¹, Daniel R Reed, MD², Jeremy M Sen, PharmD, BCOP^{3}, Christian Barlow, MD⁴, Mary-Kate Malecek, MD⁵, Brad S. Kahl, MD⁶, Michael A Spinner, MD⁷, Ranjana Advani, MD⁸, Timothy J Voorhees, MD⁹, Anson Snow, MD¹⁰, Natalie S Grover, MD⁹, Amy Ayers, MPH^{1*}, Jason T. Romancik, MD¹¹, Yuxin Liu, MD^{12*}, Scott F. Huntington, MD, MPH¹², Julio C. Chavez, MD¹³, Hayder Saeed, MD¹⁴, Aleksandr Lazaryan, MD, PhD, MPH¹⁵, Vikram Raghunathan, MD^{16*}, Stephen E. Spurgeon, MD¹⁷, Thomas A Ollila, MD¹⁸, Christopher Del Prete, MD^{18*}, Adam J Olszewski, MD¹⁸, Emily C. Ayers, MD¹⁹, Daniel J. Landsburg, MD²⁰, Benjamin Echalié^{21*}, Jun Lee^{21*}, Manali Kamdar, MD²², **Paolo F Caimi, MD²³**, Timothy Fu, MD^{24*}, Jieqi Liu, MD^{25*}, Kevin A. David, MD²⁶, Hanan Alharthy, MD^{27*}, Jennie Y. Law, MD²⁸, Reem Karmali, MD, MSc²⁹, Harsh Shah, DO³⁰, Deborah M. Stephens, DO³¹, Ajay Major, MD, MBA³², Alexandra E Rojek, MD^{33*}, Sonali M. Smith, MD³⁴, Amulya Yellala, MBBS³⁵, Avyakta Kallam, MD³⁶, Shazia Nakhoda, MD³⁷, Nadia Khan, MD³⁷, Jonathon B. Cohen, MD, MS³⁸ and Craig A. Portell, MD³⁹*

¹Winship Cancer Institute, Emory University, Atlanta, GA

²Division of Hematology/Oncology, Wake Forest University, Winston-Salem, NC

³Department of Pharmacy Services, University of Virginia, Charlottesville, VA

⁴Division of Hematology and Oncology, University of Virginia, Charlottesville, VA

⁵Department of Medicine, Washington University School of Medicine, University City, MO

⁶Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO

⁷Division of Oncology, Department of Medicine, Stanford University, Stanford, CA

⁸Division of Oncology, Department of Medicine, Saul A. Rosenberg Professor of Lymphoma, Stanford Cancer Institute, Stanford, CA

⁹Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

¹⁰University of North Carolina, Chapel Hill, NC

¹¹Department of Hematology and Medical Oncology, Emory University - Winship Cancer Institute, Atlanta, GA

¹²Yale University, New Haven, CT

¹³Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

¹⁴H. Lee Moffitt Cancer Center, Tampa, FL

¹⁵Hematology, Oncology and Transplantation, Moffitt Cancer Center, Tampa, FL

¹⁶Division of Hematology and Oncology, Oregon Health Sciences University, Portland, OR

¹⁷Oregon Health & Science University, Portland, OR

¹⁸Brown University, Providence, RI

¹⁹Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA

²⁰Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

²¹University of Colorado, Aurora, CO

²²Division of Hematology, University of Colorado, Denver, CO

²³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

²⁴Rutgers University, Newark, NJ

²⁵Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ

²⁶Cancer Institute of New Jersey, New Brunswick, NJ

²⁷University of Maryland, Baltimore, MD

²⁸Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

²⁹Division of Hematology Oncology, Northwestern University, Chicago, IL

³⁰University of Utah/ Huntsman Cancer Center, Salt Lake City, UT

³¹University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, Salt Lake City, UT

³²Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

³³Department of Medicine, University of Chicago, Chicago, IL

³⁴Department of Oncology, University of Chicago, Chicago, IL

³⁵Department of Hematology and Oncology, University Of Nebraska Medical Center, Omaha, NE

³⁶University of Nebraska Medical Center, Omaha, NE

³⁷Fox Chase Cancer Center, Philadelphia, PA

³⁸Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

³⁹Division of Hematology/Oncology, University of Virginia, Charlottesville, VA

479 Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials in Polycythemia Vera

Hematology Disease Topics & Pathways: Diseases, Polycythemia vera, Myeloid Malignancies

Sunday, Dec 6, 2020: 5:00 PM

John Mascarenhas, MD¹, Brian Higgins^{2}, Doreen Anders^{3*}, Kate Burbury, MD^{4*}, Tarec Christoffer El-Galaly³, Aaron T. Gerds, MD, MS⁵, Vikas Gupta, MD, FRCP, FRCPath⁶, Bruno Kovic^{7*}, Margherita Maffioli, MD^{8*}, Ruben Mesa, MD⁹, Jeanne M. Palmer, MD¹⁰, Francesco Passamonti, MD^{11*}, Alessandro Rambaldi, MD¹², David M Ross, MBBS, PhD, FRACP, FRCPA^{13*}, Alessandro M. Vannucchi, MD¹⁴ and Abdulraheem Yacoub, MD¹⁵*

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

²Genentech, Inc., South San Francisco, CA

³F. Hoffmann-La Roche, Ltd., Basel, Switzerland

⁴Peter MacCallum Cancer Centre, Melbourne, AUS

⁵Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶Princess Margaret Cancer Centre, Toronto, ON, Canada

⁷F. Hoffmann-La Roche, Ltd., Mississauga, ON, Canada

⁸ASST Sette Laghi, Ospedale di Circolo, Varese, ITA

⁹UT Health San Antonio Cancer Center, San Antonio, TX

¹⁰Mayo Clinic, Phoenix, AZ

¹¹University of Insubria, Varese, Italy

¹²Department of Oncology and Hematology University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

¹³Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia

¹⁴Az. Ospedaliero-Universitaria Careggi, Firenze, Italy

¹⁵The University of Kansas Cancer Center, Leawood, KS

516 Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 331. Pathophysiology of Thrombosis II

Hematology Disease Topics & Pathways: Biological, Diseases, Bleeding and Clotting, Therapies, checkpoint inhibitors, Adverse Events, Thrombosis, immunotherapy, Thromboembolism, Clinically relevant, VTE

Monday, Dec 7, 2020: 11:00 AM

Iris Yeong- Fung Sheng, MD¹, Shilpa Gupta, MD^{1}, Chandana A Reddy, MS^{2*}, Dana E Angelini, MD³, Pauline Funchain, MD^{4*}, Joanna Roopkumar, MBBS, MPH^{4*}, Tamara A. Sussman, MD^{5*}, Joseph Sleiman, MD^{6*}, Timothy D Gilligan, MD^{6*}, Moshe C Ornstein, MD, MA^{1*} and Alok A Khorana, MD⁴*

¹Cleveland Clinic Foundation, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Avon Lake, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁶Cleveland Clinic Foundation, Cleveland

540 Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Personalized Clinical-Decision Tools and treatment of lower risk MDS

Monday, Dec 7, 2020: 11:00 AM

Johannes B Goll, MSc^{1}, Travis L Jensen, BS^{1*}, R. Coleman Lindsley, MD, PhD², Rafael Bejar, MD, PhD³, Jason Walker^{4*}, Robert Fulton, MS^{5*}, Gregory A. Abel, MD, MPH⁶, Tareq Al Baghdadi, MD^{7*}, H. Joachim*

Deeg, MD⁸, Amy E. DeZern, MD⁹, Benjamin L. Ebert, MD, PhD¹⁰, James M. Foran, MD¹¹, Edward J. Gorak, DO, MBA, MS¹², Steven D. Gore, MD¹³, Rami Komrokji, MD¹⁴, Jane Jijun Liu, MD^{15*}, **Jaroslav P. Maciejewski, MD, PhD^{16,17}**, Eric Padron, MD¹⁸, Wael Saber, MD, MS¹⁹, Daniel Starczynowski, PhD²⁰, Myron Wacławski, PhD^{21*}, Steffanie H. Wilson, PhD^{1*}, Donnie Hebert, PhD^{22*}, Harrison Reed, MSc^{1*}, Nancy L. DiFronzo, PhD^{21*}, **Mikael A. Sekeres, MD, MS²³**, Alexandra M. Harrington, MD, MT(ASCP)²⁴, Steven H. Kroft, MD^{25*}, Ling Zhang, MD^{26*} and Matthew J. Walter, MD²⁷

¹The Emmes Company, LLC, Rockville, MD

²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

³Moore's Cancer Center, University of California, San Diego, La Jolla, CA

⁴Washington University School of Medicine, St. Louis, MO

⁵McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO

⁶Dana-Farber Cancer Institute, Boston, MA

⁷IHA Hematology Oncology Consultants, Ypsilanti, MI

⁸Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

¹⁰Division of Hematology, Harvard Medical School, Boston, MA

¹¹Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

¹²Baptist MD Anderson Cancer Center, Jacksonville, FL

¹³National Institutes of Health, National Cancer Institute, Rockville, MD

¹⁴H. Lee Moffitt Cancer Center, Tampa, FL

¹⁵Illinois Cancer Care, P.C., Peoria, IL

¹⁶Cleveland Clinic Main Campus, Department of Hematology/Oncology, Cleveland, OH

¹⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁸Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

¹⁹CIBMTR, Medical College of Wisconsin, Milwaukee, WI

²⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH

²¹National Heart, Lung, and Blood Institute, National Institutes of Health, Division of Blood Diseases & Resources, Bethesda, MD

²²The Emmes Company, LLC, Hamburg, NY

²³Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²⁴Medical College of Wisconsin, Milwaukee, WI

²⁵Department of Pathology, Medical College of Wisconsin, Milwaukee, WI

²⁶Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

²⁷Department of Medicine, Division of Oncology, Washington University In St. Louis, Saint Louis, MO

541 A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Personalized Clinical-Decision Tools and treatment of lower risk MDS

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, CMML, MDS, MPN, Myeloid Malignancies, Clinically relevant

Monday, Dec 7, 2020: 11:15 AM

Nathan Radakovich, BA^{1*}, Manja Meggendorfer, PhD², Luca Malcovati, MD³, **Mikael A. Sekeres⁴**, Jacob Shreve, MD, MS^{5*}, Cameron Beau Hilton, MD⁶, Yazan Rouphail^{7*}, Wencke Walter, PhD^{8*}, Stephan Hutter, PhD^{8*}, **Sudipto Mukherjee, MD, PhD, MPH⁹**, Cassandra M. Kerr, MS^{10*}, **Babal K. Jha, PhD^{11*}**, Anna Galli^{12*}, Sarah Pozzi^{13*}, **Aaron T. Gerds, MD, MS¹⁴**, Cassandra M Kerr, MS^{11*}, Claudia Haferlach, MD¹⁵, **Jaroslav P. Maciejewski, MD, PhD¹⁰**, Torsten Haferlach, MD¹⁶ and **Aziz Nazha, MD¹⁷**

¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

³Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi 2, Pavia, Italy

⁴Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

⁶Department of Internal Medicine, Vanderbilt University, Nashville, TN

⁷Ohio State University, Rocky River, OH

⁸MLL Munich Leukemia Laboratory, Munich, Germany

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹²Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

¹³Centro Cellule Staminali E Terapia Cellulare, Genova, ITA

¹⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁵MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany

¹⁶MLL Munchner Leukamie Labor GmbH, Munchen, Germany

¹⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Quantitative Health Sciences, Avon Lake, OH

552 Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy

Hematology Disease Topics & Pathways: Non-Biological, Combinations, Therapies, Biological Processes, Clinically relevant, multi-systemic interactions

Monday, Dec 7, 2020: 11:00 AM

Raymond L. Comenzo, MD¹, Efstathios Kastritis, MD^{2*}, Giovanni Palladini, MD, PhD³, Monique C. Minnema⁴, Ashutosh D. Wechalekar, MBBS, FRCP, FRCPath, DM⁵, Arnaud Jaccard, MD, PhD^{6*}, Vaishali Sanchorawala, MD⁷, Hans C. Lee, MD⁸, Simon D. Gibbs, FRACP, FRCPA, MBBS^{9*}, Peter Mollee, FRACP, MBBS, MSc, FRCPA¹⁰, Christopher P. Venner, MD¹¹, Jin Lu¹², Stefan Schönland, MD^{13*}, Moshe Gatt, MD¹⁴, Kenshi Suzuki, MD, PhD¹⁵, Kihyun Kim, MD, PhD¹⁶, M. Teresa Cibeira, MD, PhD^{17*}, Meral Beksac, MD¹⁸, Edward Libby, MD¹⁹, Jason Valent, MD²⁰, Vania T. M. Hungria, MD, PhD²¹, Sandy W. Wong, MD²², Michael Rosenzweig, MD²³, Naresh Bumma, MD²⁴, Dominique Chauveau, MD, PhD^{25*}, Meletios A Dimopoulos²⁶, NamPhuong Tran, MD^{27*}, Xiang Qin, MD, PhD^{28*}, Sandra Y. Vasey, MSc^{28*}, Brenda Tromp, MSc²⁹, Brendan M. Weiss, MD^{28*}, Jessica Vermeulen, MD, PhD³⁰ and Giampaolo Merlini, MD³¹

¹Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

²Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece

³Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy

⁴Department of Hematology, UMC Utrecht, Utrecht, Netherlands

⁵University College London, London, United Kingdom

⁶Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France

⁷Amyloidosis Center, Boston University School of Medicine, Boston, MA

⁸Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

⁹The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia

¹⁰Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia

¹¹Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

¹²Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China

¹³Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany

¹⁴Department of Hematology, Hadassah-Hebrew University Medical Center-, Jerusalem, Israel

¹⁵Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan

¹⁶Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

¹⁷Hospital Clinic of Barcelona, Barcelona, Spain

¹⁸Cebeci Yerleskesi Dikimevi, Ankara, Turkey

¹⁹Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

²⁰Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²¹São Germano Clinic, São Paulo, Brazil

²²Tufts Medical Center, San Francisco, CA

²³Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA

²⁴Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

²⁵CHU de Toulouse-Hôpital Rangueil, Toulouse, France

²⁶University of Athens School of Medicine, KIFISIA, Greece

²⁷Janssen Research & Development, LLC, Los Angeles, CA

²⁸Janssen Research & Development, LLC, Spring House, PA

²⁹Janssen Research & Development, LLC, Leiden, Netherlands

³⁰Janssen Research & Development, LLC, Leiden, CB, Netherlands

³¹Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy

564 Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning C

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation Results II

Hematology Disease Topics & Pathways: sickle cell disease, HSCs, Adult, Diseases, Non-Biological, Therapies, chemotherapy, Pediatric, Hemoglobinopathies, Young Adult, Cell Lineage, Study Population, Clinically relevant

Monday, Dec 7, 2020: 8:15 AM

Adetola A. Kassim, MD, MS^{1,2,3}, Josu de la Fuente⁴, Ali Debsan Alahmari, MBBS, MD, MNAMS^{5*}, Michael J. Eckrich, MD, MPH⁶, **Rabi Hanna, MD**⁷, Nathalie Dhedin, MD^{8*}, Biljana N. Horn, MD⁹, Vandy Black, MD, MSc^{10,11}, Roseane V Gouveia^{12*}, Adriana Seber, MD, MS¹³, Belinda Pinto Simões, MD, PhD^{14,15*}, Thalita Cristina de Mello Costa, MD^{16*}, Renato Guerino-Cunha^{17*}, Carmem M. S. Bonfim, MD PhD^{18,19*}, Roberto Luiz da Silva^{20*}, Nelson Hamerschlak, MD, PhD^{21,22}, Juliana Folloni Fernandes, MD^{23*}, Michael Kent, MD, BS²⁴, Satya Prakash Yadav, MBBS, MD^{25,26}, Erfan Nur, MD, PhD^{27,28}, Mohsen Alzahrani^{29,30*}, Ben Carpenter, PhD^{31*}, William Tse, MD^{32,33*}, Maria Isabel^{34*}, Hemalatha G Rangarajan, MD^{35,36,37}, Ibrahim Ahmed, MD³⁸, Adeseye Michael Akinsete, MBBS^{39*}, Courtney D. Fitzhugh, MD⁴⁰, Kathryn A. Culos, PharmD^{41*}, Leena Karnik, FRCPath, MRCP^{42*}, James Connelly, MD^{43*}, Carrie Kitko, MD^{44,45}, Jennifer Andrews, MD, MSc⁴⁶, Karina L Wilkerson, NP, MSN^{47*}, Robert Brodsky^{48,49*}, Tatsuki Koyama^{50*} and Michael R. DeBaun, MD, MPH⁵¹

¹Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Nashville, TN

²Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

³Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

⁴Department of Paediatrics, St. Mary's Hospital/Imperial College London, London, United Kingdom

⁵King Faisal Hospital & Research Ctr., Riyadh, SAU

⁶Pediatric Blood and Marrow Transplantation Program, Texas Transplant Institute at Medical City Dallas, San Antonio, TX

⁷Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸St-Louis Hospital, APHP, Adolescents and Young Adults Hematology Department, Paris, France

⁹UF Shand's Children Hospital, University of Florida, Gainesville, FL

¹⁰University of Florida College of Medicine, Newberry, FL

¹¹Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL

¹²Hospital Sao Camilo Pompeia, Pediatric Oncology and Hematopoietic Cell Transplantation, São Paulo, Brazil

¹³Hospital Samaritano, Sao Paulo, SP, Brazil

¹⁴Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil., Ribeirão Preto, Brazil

¹⁵Center for Cell-Based Therapy, Hemotherapy Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil., Ribeirão Preto, Brazil

¹⁶School of Medicine of Ribeirão Preto, University of São Paulo, São José Do Rio Preto, Brazil

¹⁷Ribeirão Preto Medical School, University of São Paulo, Departments of Medical Imaging and Hematology /Clinical Oncology, São Paulo, Brazil

¹⁸Federal University of Parana, Curitiba, PR, Brazil

¹⁹Hospital Nossa Senhora das Graças, Curitiba, Brazil

²⁰IBCC Oncologia (Instituto Brasileiro de Controle do Câncer), São Paulo, Brazil

²¹Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil

²²Hospital Israelita Albert Einstein, Sao Paulo, Brazil

²³Department of Hematology and Bone Marrow Transplantation, Hospital Israelita Albert Einstein, Hematology unit, São Paulo, Brazil

²⁴Atrium Health/Levine Children's Hospital, Charlotte, NC

²⁵Pediatric Hemato-Oncology & BMT, Medanta The Medicity, Gurgaon, India

²⁶Pediatric Hemato-Oncology & BMT, Fortis Memorial Research Institute, Gurgaon, Haryana, India

²⁷Department of Clinical Hematology, Slotervaart Hospital, Amsterdam, Netherlands

²⁸Department of Clinical Hematology, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, Netherlands

²⁹Saudi Society of Blood & Marrow Transplantation (SSBMT), Riyadh, Saudi Arabia

³⁰Division of Adult Hematology and SCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

³¹University College London Hospital, London, United Kingdom

³²Bone Marrow Transplant, University of Louisville, Louisville, KY

³³University of Louisville, Louisville, KY

³⁴Vall d' Hebron Hospital, Department of Hematology / Oncology, Barcelona, Spain

³⁵Hem/Onc/BMT, Nationwide Children's Hospital, Columbus, OH

³⁶Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Childrens Hospital, Columbus, OH

³⁷Nationwide Childrens Hospital, Columbus, OH

- ³⁸Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Children's Mercy Hospital, Kansas City, MO
³⁹College of Medicine, Division of Pediatric Hematology & Oncology, Lagos University Teaching Hospital, Lagos, Nigeria
⁴⁰Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
⁴¹Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN
⁴²Department of Paediatrics, St. Mary's Hospital, London, United Kingdom
⁴³Department of Pediatrics, Division of Pediatric Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN
⁴⁴Pediatric Hematology/Oncology Division, Vanderbilt-Ingram Cancer Center, Nashville, TN
⁴⁵Vanderbilt University Medical Center, Franklin, TN
⁴⁶Vanderbilt University Medical Center, Nashville, TN
⁴⁷Hematology/Oncology Department Sickle Cell Disease Center of Excellence, Vanderbilt University Medical Center, Nashville, TN
⁴⁸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
⁴⁹Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD
⁵⁰Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN
⁵¹Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University School of Medicine, Nashville, TN

646 Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy in T/NK Cell Lymphoma

Hematology Disease Topics & Pathways: Biological, Follicular Lymphoma, Adult, Lymphoma (any), Diseases, Therapies, checkpoint inhibitors, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, Biological Processes, T-Cell Lymphoma, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, immune mechanism

Monday, Dec 7, 2020: 12:00 PM

Steven M. Horwitz, MD¹, James M. Foran, MD², Michael Maris, MD^{3,4}, Ahmed Sawas, MD⁵, Craig Okada, MD, PhD⁶, Tatyana A. Feldman, MD⁷, Mark D. Minden⁸, Lubomir Sokol, MD, PhD⁹, Matthew Mei, MD¹⁰, Ian W. Flinn, MD, PhD^{11,12}, Diego Villa, MD MPH¹³, Mary-Elizabeth M. Percival, MD^{14,15}, **Deepa Jagadeesh, MD, MPH¹⁶, Kerry J. Savage, MD MSc¹³, Oleg E. Akilov, MD, PhD^{17*}, Catherine Diefenbach, MD¹⁸, Youn H. Kim, MD¹⁹, Gloria H. Y. Lin, PhD^{20*}, Tina Catalano, MSc^{20*}, Penka S. Petrova, PhD^{20*}, Bob Uger, PhD^{20*}, Naomi Molloy, BSc^{20*}, Kathleen Large, RN, MSN^{20*}, Yaping Shou, MD, PhD²⁰ and Stephen M. Ansell, MD, PhD²¹**

¹Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

²Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

³Colorado Blood Cancer Institute, Denver, CO

⁴Sarah Cannon Research Institute, Denver, CO

⁵Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY

⁶Oregon Health and Science University, Portland, OR

⁷Hackensack University Medical Center, NY, NY

⁸Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

⁹Moffitt Cancer Center, Tampa, FL

¹⁰City of Hope National Medical Center, Duarte, CA

¹¹Sarah Cannon Research Institute, Nashville, TN

¹²Tennessee Oncology, Nashville, TN

¹³British Columbia Cancer Agency, Vancouver, BC, Canada

¹⁴Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁵Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

¹⁶Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH

¹⁷University of Pittsburgh Medical Center, Pittsburgh, PA

¹⁸Perlmutter Cancer Center at NYU Langone Health, New York, NY

¹⁹Department of Dermatology, Stanford University School of Medicine, Stanford, CA

²⁰Trillium Therapeutics Inc., Mississauga, ON, Canada

²¹Mayo Clinic, Rochester, MN

655 Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes

Hematology Disease Topics & Pathways: Diseases, CMML, MDS, MPN, Myeloid Malignancies, Clinically relevant

Monday, Dec 7, 2020: 3:00 PM

Nathan Radakovich, BA¹, David A. Sallman, MD², Rena J. Buckstein, MD, FRCPC³, Andrew M. Brunner, MD⁴, Sudipto Mukherjee, MD, PhD, MPH⁵, Rami Komrokji, MD², Najla Al Ali, M.Sc^{6*}, Jacob Shreve, BS, MD, MS⁷, Yazan Rouphail^{8*}, Cassandra M Kerr, MS^{9*}, Yihong Guan, PhD^{9*}, Teodora Kuzmanovic, BA^{10*}, Metis Hasipek, PhD^{10*}, Babal K. Jha, PhD^{9*}, Jaroslaw P. Maciejewski, MD, PhD¹⁰, Mikkael A. Sekeres, MD, MS¹¹ and Aziz Nazha, MD¹²

¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA

²H. Lee Moffitt Cancer Center, Tampa, FL

³Sunnybrook Odette Cancer Center, Toronto, ON, Canada

⁴Dana-Farber Cancer Institute, Boston, MA

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁷Cleveland Clinic, Cleveland, OH

⁸Ohio State University, Rocky River, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Quantitative Health Sciences, Avon Lake, OH

705 The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Front-Line Treatment and Prognostication of Burkitt Lymphoma, Plasmablastic Lymphoma, and DLBCL

Hematology Disease Topics & Pathways: Adult, Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant

Monday, Dec 7, 2020: 4:30 PM

Adam J Olszewski, MD¹, Lasse H. Jakobsen, PhD^{2*}, Graham P. Collins, MD, DPhil³, Kate Cwynarski^{4*}, Veronika Bachanova, MD, PhD⁵, Kristie A. Blum, MD⁶, Kirsten M Boughan, DO⁷, Mark Bower, MD^{8*}, Alessia Dalla Pria, MD^{9*}, Alexey Danilov, MD¹⁰, Kevin A. David, MD¹¹, Catherine Diefenbach, MD¹², Fredrik Ellin, MD, PhD^{13*}, Narendranath Epperla, MD, MS¹⁴, Umar Farooq, MD¹⁵, Tatyana A. Feldman, MD¹⁶, Alina S. Gerrie, MD, MPH¹⁷, Deepa Jagadeesh, MD, MPH¹⁸, Manali Kamdar, MD, MDDS^{19*}, Reem Karmali, MD, MSc²⁰, Shireen Kassam, MBBS, FRCPath, PhD^{21*}, Vaishalee P. Kenkre, MD²², Nadia Khan, MD²³, Andreas Klein, MD²⁴, Izidore S. Lossos, MD²⁵, Matthew A. Lunning, DO, FACP²⁶, Peter Martin, FRCPC, MD, MS²⁷, Nicolas Martinex-Calle^{28*}, Silvia Montoto, MD²⁹, Seema Naik, MD^{30*}, Neil Palmisiano, MD, MS³¹, David Peace, MD³², Elizabeth H Phillips, MBBS, BSc^{33*}, Tycel J. Phillips, MD³⁴, Craig A. Portell, MD³⁵, Nishitha Reddy, MD³⁶, Anna Santarsieri, MBBS^{37*}, Maryam Sarraf Yazdy, MD³⁸, Knut B. Smeland^{39*}, Scott E. Smith, MD, PhD⁴⁰, Stephen D. Smith, MD⁴¹, Suchitra Sundaram, MD⁴², Parameswaran Venugopal, MD⁴³, Adam Zayac, MD⁴⁴, Xiao-Yin Zhang, PhD^{45*}, Catherine Zhu^{46*}, Chan Yoon Cheah, MBBS⁴⁷, Tarec Christoffer El-Galaly⁴⁸ and Andrew M. Evens, DO, MMSc⁴⁹

¹Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI

²Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

⁴Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

⁵Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

⁶Winship Cancer Institute, Emory University, Atlanta, GA

⁷Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁸National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom

⁹Chelsea & Westminster Hospital, London, United Kingdom

¹⁰Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

- ¹¹Cancer Institute of New Jersey, New Brunswick, NJ
¹²New York University School of Medicine, NYU Cancer Institute, New York, NY
¹³Department of Internal Medicine, Kalmar County Hospital, Kalmar, Sweden
¹⁴The Ohio State University James Comprehensive Cancer Center, Columbus, OH
¹⁵Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
¹⁶Hackensack University Medical Center, NY, NY
¹⁷BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada
¹⁸Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH
¹⁹University of Colorado Cancer Center, Aurora, CO
²⁰Division of Hematology Oncology, Northwestern University, Chicago, IL
²¹King's College Hospital, London, United Kingdom
²²Carbone Cancer Center, University of Wisconsin, Madison, WI
²³Fox Chase Cancer Center, Philadelphia, PA
²⁴Division of Hematology and Oncology, Tufts Medical Center, Boston, MA
²⁵Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
²⁶University of Nebraska Medical Center, Omaha, NE
²⁷Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
²⁸Nottingham University Hospitals, Nottingham, GBR
²⁹Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
³⁰Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA
³¹Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA
³²Division of Hematology/Oncology, Department of Medicine, University of Illinois College of Medicine, Chicago, IL
³³Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
³⁴University of Michigan Comprehensive Cancer Center, Dexter, MI
³⁵Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
³⁶Vanderbilt University Medical Center, Nashville, TN
³⁷Department of Haematology, Cambridge University Hospitals NHSFT, Cambridge, United Kingdom
³⁸Georgetown University Hospital, Washington, DC
³⁹Department of Oncology, Oslo University Hospital, Oslo, Norway
⁴⁰Loyola University Medical Center, Maywood, IL
⁴¹University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
⁴²Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁴³Division of Hematology Oncology, Rush University Medical Center, Chicago, IL
⁴⁴Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI
⁴⁵Oxford University Hospitals, Oxford, GBR
⁴⁶University College London Hospitals, London, United Kingdom
⁴⁷Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
⁴⁸Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
⁴⁹Rutgers Cancer Institute of New Jersey, Warren, NJ

706 Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Front-Line Treatment and Prognostication of Burkitt Lymphoma, Plasmablastic Lymphoma, and DLBCL

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant

Monday, Dec 7, 2020: 4:45 PM

Juan Pablo Alderuccio, MD¹, Adam J Olszewski, MD², Andrew M. Evens, DO, MMSc³, Graham P. Collins, MD, DPhil⁴, Alexey Danilov, MD⁵, Mark Bower, MD^{6*}, **Deepa Jagadeesh, MD, MPH⁷**, Catherine Zhu^{8*}, Amy Sperling, BS^{9*}, Seo-Hyun Kim, MD¹⁰, Ryan Vaca, MD¹¹, Catherine Wei^{12*}, Suchitra Sundaram, MD¹³, Nishitha Reddy, MD¹⁴, Alessia Dalla Pria, MD^{15*}, Christopher D'Angelo, MD¹⁶, Umar Farooq, MD¹⁷, David A. Bond, MD, BS¹⁸, Stephanie Berg, DO¹⁹, Michael C. Churnetski^{20*}, Amandeep Godara, MD²¹, Nadia Khan, MD²², Yun Kyong Choi, MD^{23*}, Shireen Kassam, MBBS, FRCPath, PhD^{24*}, Maryam Sarraf Yazdy, MD²⁵, Emma Rabinovich, MD^{26*}, Frank Post^{27*}, Gaurav Varma, MD, MPH^{28*}, Reem Karmali, MD, MSc²⁹, Madelyn Burkart, MD^{30*}, Peter Martin, FRCPC, MD, MS³¹, Albert Ren^{32*}, Ayushi Chauhan, MBBS, MD³³, Catherine Diefenbach, MD²³, Allandria Straker-Edwards, MS^{22*}, Andreas Klein, MD³⁴, Kristie A. Blum,

MD³⁵, Kirsten M Boughan, DO³⁶, Agrima Mian, MBBS, MD^{37*}, Bradley Haverkos, MD, MPH, MS^{38*}, Victor M. Orellana-Noia, MD³⁹, Vaishalee P. Kenkre, MD¹⁶, Adam Zayac, MD⁴⁰, Seth M Maliske, MD¹⁷, Narendranath Epperla, MD, MS⁴¹, **Paolo F Caimi, MD⁴²**, Scott E. Smith, MD, PhD⁴³, Manali Kamdar, MD⁴⁴, Parameswaran Venugopal, MD⁴⁵, Tatyana A. Feldman, MD⁴⁶, Daniel Rector^{47*}, Stephen D. Smith, MD⁴⁸, Andrzej Stadnik, MPH, BS^{49*}, Craig A. Portell, MD⁵⁰, Yong Lin, PhD^{12*}, Seema Naik, MD^{51*}, Silvia Montoto, MD⁵², Izidore S. Lossos, MD¹ and Kate Cwynarski^{53*}

¹Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL

²Brown University, Providence, RI

³Rutgers Cancer Institute of New Jersey, Warren, NJ

⁴Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

⁵Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

⁶National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom

⁷Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH

⁸University College London Hospitals, London, United Kingdom

⁹Fred Hutch Cancer Center, University of Washington, Seattle, UT

¹⁰Rush University Medical Center, Chicago, IL

¹¹Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA

¹²Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

¹³Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹⁴Vanderbilt University Medical Center, Nashville, TN

¹⁵Chelsea & Westminster Hospital, London, United Kingdom

¹⁶Carbone Cancer Center, University of Wisconsin, Madison, WI

¹⁷Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

¹⁸Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

¹⁹Department of Cancer Biology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL

²⁰Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

²¹Tufts Medical Center, Boston, MA

²²Fox Chase Cancer Center, Philadelphia, PA

²³New York University School of Medicine, NYU Cancer Institute, New York, NY

²⁴King's College Hospital, London, United Kingdom

²⁵Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC

²⁶University of Illinois at Chicago, Cleveland Heights, OH

²⁷King's College Hospital NHS Foundation Trust, London, United Kingdom

²⁸Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY

²⁹Division of Hematology Oncology, Northwestern University, Chicago, IL

³⁰Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago

³¹Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY

³²University of Illinois At Chicago, Chicago, IL

³³Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

³⁴Division of Hematology and Oncology, Tufts Medical Center, Boston, MA

³⁵Emory University, Atlanta, GA

³⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³⁷Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

³⁸University of Colorado Cancer Center, Aurora, CO

³⁹Winship Cancer Institute, Emory University, Atlanta, GA

⁴⁰Department of Medicine, Alpert Medical School of Brown University, Providence, RI

⁴¹The Ohio State University James Comprehensive Cancer Center, Columbus, OH

⁴²University Hospitals of Cleveland, Cleveland, OH

⁴³Loyola University Medical Center, Maywood, IL

⁴⁴Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Denver, CO

⁴⁵Division of Hematology Oncology, Rush University Medical Center, Chicago, IL

⁴⁶Hackensack University Medical Center, NY, NY

⁴⁷John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

⁴⁸University of Washington, Seattle, WA

⁴⁹Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR

⁵⁰Division of Hematology/Oncology, University of Virginia, Charlottesville, VA

⁵¹Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA

⁵²Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom

⁵³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

729 Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis

Hematology Disease Topics & Pathways: Biological, antibodies, Therapies, immunotherapy

Monday, Dec 7, 2020: 5:45 PM

Jack Khouri, MD¹, Faiz Anwer, MD², Christy J. Samaras, DO², Alex V. Mejia Garcia, MD¹, Omer N. Koc, MD³, Beth M. Faiman, PhD, CNP², Kimberly Hamilton, CNP^{2}, Saveta Mathur, CNP^{2*}, Cynthia Scott, CNP^{2*}, Kathleen Stefunek, RN^{2*}, Josephine Sgobbo, RN^{2*}, Sherry Fada^{2*}, Brittany Lewis^{2*}, Kelly Shepherd^{2*}, Naqib Ahmad^{2*}, Madeleine Knebusch^{2*}, Susan B. Sobolov, PhD^{4*}, Janet Jobes^{4*}, Eileen Daniel^{4*}, Michael Spector, BS^{4*} and Jason Valent, MD²*

¹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Caelum Biosciences, Bordentown, NJ

POSTER PRESENTATIONS

762 Identification of a Warm Autoimmune Hemolytic Anemia (wAIHA) Population Using Predictive Analytics of a Known Clinically Profiled Cohort

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I

Hematology Disease Topics & Pathways: autoimmune disorders, Adult, Anemias, Diseases, Non-Biological, Therapies, Immune Disorders, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Keith R. McCrae, MD^{1,2}, Jennifer Beachell^{3}, Tricia Gooljarsingh, PhD^{4*}, Mary Lee Tjoa, PhD^{5*}, Graham K Jones, PhD^{6*} and Julieanna K Gubitosa^{7*}*

¹Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

²Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH

³Momenta Pharmaceuticals, Inc, Cambridge, MA

⁴Medical Affairs and Communications, Cambridge, MA

⁵Director of Medical Affairs, Momenta Pharmaceuticals, Boston, MA

⁶Director of Client Engagement, IPM.ai, Cambridge, MA

⁷Director of Integration and Analytics, IPM.ai, Cambridge, MA

787 Thrombin-Induced Endothelial Cell Damage Is Mitigated By Human Anti-Thrombin III in a Microfluidic Device

Program: Oral and Poster Abstracts

Session: 113. Hemoglobinopathies, Excluding Thalassemia—New Genetic Approaches to Sickle Cell Disease: Poster I

Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

William Wulftange^{1}, Erdem Kucukal, PhD^{1*}, Yuncheng Man^{1*}, Ran An, PhD¹, Karamoja Monchamp^{1*}, Olabimpe Olayiwola, MS^{1*}, Jane A. Little, MD², Nigel S. Key, MD² and Umut A. Gurkan, PhD¹*

¹Case Western Reserve University, Cleveland, OH

²University of North Carolina at Chapel Hill, Chapel Hill, NC

815 Nanoparticle-Directed Targeting of Clustered PSGL-1 Mitigates Neutrophil-Derived Thrombosis in Antiphospholipid Antibody Syndrome

Program: Oral and Poster Abstracts

Session: 201. Granulocytes, Monocytes, and Macrophages: Poster I

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

David R Sweet^{1*}, *Asha Thomas, PhD*^{2*}, *Stephanie D Lapping, MS*^{3*}, *Kenneth A Kalikasingh*^{2*}, *Thomas L. Ortel, MD, PhD*⁴, ***Mukesh K Jain, MD***^{1*}, *Andrei Maisseyeu*^{3*} and ***Lalitha V. Nayak, MD***²

¹Cardiovascular Research Institute, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

²Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

³Cardiovascular Research Institute, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland

⁴Department of Medicine, Duke University Medical Center, Durham, NC

835 Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster I

Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting, ITP, Platelet Disorders, Thrombocytopenias, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Morey Blinder, MD^{1*}, *Michael Vredenburg, PhD*^{2*}, *Wei Tian, PhD*^{2*}, *Brian Jamieson, MD, BA*² and ***Keith R. McCrae, MD***³

¹Washington University, Saint Louis, MO

²Dova Pharmaceuticals, Durham, NC

³Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

845 Patients' Reported Perceptions on Satisfaction with Immune Thrombocytopenia Treatments: Results from the ITP World Impact Survey (I-WISH)

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster I

Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Bleeding and Clotting, Non-Biological, Therapies, Combinations, ITP, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

*Waleed Ghanima*¹, *James B. Busse*², *Drew Provan*^{3*}, *Alexandra Kruse*^{4*}, *Caroline Kruse*^{4*}, *Yoshiaki Tomiyama*⁵, *Ming Hou*⁶, *Cristina Santoro*^{7*}, *Serge Laborde*^{8*}, *Mervyn Morgan*^{9*}, *Barbara Lovrencic*^{10*}, *Tom Bailey, MSc*^{11*}, *Jens Haenig*^{12*} and *Nichola Cooper, MD*¹³

¹Department of Medicine, Østfold Hospital Trust, Kalnes, Norway

²Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY

³Barts and The London School of Medicine and Dentistry, London, United Kingdom

⁴Platelet Disorder Support Association, Cleveland, OH

⁵Osaka University Hospital, Osaka, Japan

⁶Department of Hematology, Qilu Hospital of Shandong University, Jinan, China

⁷Hematology, University Hospital Policlinico Umberto I, Rome, Italy

⁸O'Cyto, Saint Loubès, France

⁹ITP Support Association, Bolnhurst, United Kingdom

¹⁰Italian Association for Immune Thrombocytopenic Purpura, Caprino Veronese, Italy

¹¹Adelphi Real World, Bollington, United Kingdom

¹²Novartis Pharma AG, Basel, Switzerland

¹³Hammersmith Hospital, Imperial College London, London, United Kingdom

868 Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Program: Oral and Poster Abstracts

Session: 322. Disorders of Coagulation or Fibrinolysis: Poster I

Hematology Disease Topics & Pathways: Biological, Adult, Bleeding and Clotting, Diseases, Therapies, Pediatric, Study Population, Clinically relevant, VWD

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

*Margaret V. Ragni, MD, MPH*¹, *Frederico Xavier, MD, MS*², *Craig D. Seaman*³, *Suchitra Acharya, MD*⁴, *Catherine E. McGuinn, MD*⁵, *Eric J. Werner, MD*^{6*}, *Courtney Elizabeth Lawrence, MD, MS*^{7*}, *Allison P.*

Wheeler, MD⁸, Ulrike Reiss, MD⁹, Irmel Ayala, MD^{10*}, Erin Cockrell, DO¹¹, Cristina Tarango, MD¹², Amy Dunn¹³, Roshni Kulkarni, MD¹⁴, Sanjay P Ahuja, MD¹⁵, Meera B. Chitlur, MD¹⁶, Steven W. Pipe, MD¹⁷, Lynn M Malec, MD¹⁸, Vilmarie Rodriguez, MD¹⁹, Shelley Crary, MD, MS²⁰, Deborah Brown, MD²¹, Rosa Diaz, MD^{22*}, Maria Velez, MD^{23*}, Cindy A. Leissinger, MD²⁴, Shannon L Carpenter, MD²⁵, Christine M. Knoll, MD²⁶, Michael Wang, MD²⁷, Guy Young, MD²⁸, Courtney D Thornburg, MD²⁹, Joseph L Lasky III, MD^{30*}, Tiffany Lin Lucas, MD³¹, Nina Hwang, MD^{32*}, Deborah Vehec, MSN, RN^{33*}, Dana Ivanco^{34*}, Tamara L. Haller, BS^{35*}, Marnie Bertolet, PhD^{36*} and Maria M Brooks, PhD^{37*}

¹University of Pittsburgh Medicine, Division Hematology/Oncology, Pittsburgh, PA

²Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center and Hemophilia Center of Western PA, Pittsburgh, PA

³University of Pittsburgh, Warrendale, PA

⁴Pediatric Hematology, Oncology and Cellular Therapy, Cohen Children's Medical Center of New York, New Hyde Park, NY

⁵Weill Cornell Medical College, New York, NY

⁶Children's Hospital of The King's Daughters, Norfolk, VA

⁷Division of Pediatric Hematology / Transfusion Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

⁸Dept. of Pediatric Hem./Onc., Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN

⁹Department of Surgery, St. Jude Children's Rsch. Hosp., Memphis, TN

¹⁰Pediatric Cancer and Blood Disorders Center, Johns Hopkins All Children's Outpatient Care Center, St. Petersburg, FL

¹¹St. Joseph's Children's Hospital, Tampa, FL

¹²Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

¹³Nationwide Children's Hospital, Columbus, OH

¹⁴Michigan State University Center for Bleeding and Clotting Disorders, East Lansing, MI

¹⁵University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, OH

¹⁶Hemostasis and Thrombosis Center, Children's Hospital of Michigan, Detroit, MI

¹⁷Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI

¹⁸Blood Research Institute, Versiti, Milwaukee, WI

¹⁹Division of Pediatric Hematology, Mayo Clinic, Rochester, MN

²⁰University of Arkansas for Medical Sciences, Little Rock, AR

²¹Department of Pediatrics- Hematology Division, University of Texas Health Science Center at Houston, Houston, TX

²²Texas Children's Hospital, Houston, TX

²³Children's Hospital New Orleans, Louisiana State University, New Orleans, LA

²⁴Tulane University, New Orleans, LA

²⁵Children's Mercy Hospital, Kansas City, MO

²⁶Arizona Hemophilia and Thrombosis Center, Phoenix Children's Hospital, Phoenix, AZ

²⁷Anschutz Medical Campus, University of Colorado, School of Medicine, Hemophilia and Thrombosis Center, Aurora, CO

²⁸University of California Los Angeles, Children's Hospital Los Angeles, Los Angeles, CA

²⁹Rady Children's Hospital, San Diego, CA

³⁰University of Nevada, Cure 4 the Kids Foundation, Las Vegas, NV

³¹University of California, San Francisco, San Francisco, CA

³²CHOC Children's Hospital, Orange County, Center for Inherited Blood Disorders (CIBD), Orange, CA

³³Hemophilia Center of Western PA, Institute for Transfusion Medicine, Vitalant, Pittsburgh, PA

³⁴Institute for Transfusion Medicine, Hemophilia Center of Western PA, Pittsburgh, PA

³⁵Department of Epidemiology, Epidemiology Data Center, University of Pittsburgh, Pittsburgh, PA

³⁶Epidemiology Data Center, University of Pittsburgh, Pittsburgh, PA

³⁷Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA

874 Improvement of Efficacy Outcomes in Patients Who Switched from Sucrose-Formulated rFVIII to BAY 81-8973 Prophylaxis in the LEOPOLD Clinical Trials

Program: Oral and Poster Abstracts

Session: 322. Disorders of Coagulation or Fibrinolysis: Poster I

Hematology Disease Topics & Pathways: Hemophilia, Adult, Diseases, Bleeding and Clotting, Non-Biological, Therapies, Pediatric, coagulant drugs, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Gili Kenet^{1,2}, Thomas Moulton, MD³, Erika Soltes Rak^{3*}, Brian M. Wicklund, MD, MPH⁴ and Sanjay P Ahuja, MD⁵

¹National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel

²The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel

³Bayer, Whippany, NJ

⁴Children's Mercy-Kansas City, Kansas City, MO

⁵Rainbow Babies & Children's Hospital, Cleveland, OH

887 Efficacy and Safety of Tinzaparin in CAT Patients with Metastatic Disease

Program: Oral and Poster Abstracts

Session: 332. Anticoagulation and Antithrombotic Therapy: Poster I

Hematology Disease Topics & Pathways: anticoagulant drugs, Diseases, Bleeding and Clotting, Non-Biological, Therapies, Thrombosis

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Agnes Y. Lee, MD, MSc¹, Pieter W. Kamphuisen, MD, PhD^{2*}, Rupert Bauersachs, MD, PhD^{3,4*}, Karen Turpin, BScN, MSc^{5*}, Jes Birger Hansen^{6*} and Alok A Khorana, MD⁷

¹Department of Hematology, University of British Columbia, Vancouver, BC, Canada

²University Medical Center Groningen, Groningen, NLD

³Department Vascular Medicine, Darmstadt Hospital, Darmstadt, DEU

⁴Center of Thrombosis and Haemostasis, University of Mainz, Mainz, Germany

⁵Medical Affairs, Leo Pharma Canada, Thornhill, ON, Canada

⁶LEO Pharma A/S, Ballerup, France

⁷Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

929 Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, Biological Processes, Cell Lineage, Study Population, immune mechanism

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Simona Pagliuca, MD^{1,2}, Carmelo Gurnari, MD^{1,3*}, Hassan Awada, MD¹, Cassandra M Kerr, MS^{1*}, Bhumika J. Patel, MD⁴, Laila Terkawi^{1*}, Misam Zawit, MBBS^{1*}, Sunisa Kongkiatkamon, MD^{1*}, Pedro H Prata, MD⁵, Ashwin Kishtagari, MBBS¹, Adam Wahida^{6*}, Thomas Laframboise, PhD^{7*}, Valeria Visconte, PhD¹, Regis Peffault De Latour, MD, PhD^{5,8*} and Jaroslaw P. Maciejewski, MD, PhD⁹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Université de Paris, Paris, France

³Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

⁴Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Transplantation, Hôpital Saint Louis, Paris, France

⁶MLL Munich Leukemia Laboratory, Munich, Germany

⁷Genetics and Genome Sciences Department, Case Western Reserve University, Cleveland, OH

⁸French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

930 Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways: Anemias, Diseases, Bone Marrow Failure, Biological Processes, PNH, genomics, immune mechanism

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Carmelo Gurnari, MD^{1,2*}, Simona Pagliuca, MD^{2,3}, Cassandra M Kerr, MS^{2*}, Hassan Awada, MD², Sunisa Kongkiatkamon, MD^{2*}, Laila Terkawi^{2*}, Neetha Parameswaran, PhD², Misam Zawit, MBBS^{2*}, Adam Wahida^{4*}, Valeria Visconte, PhD² and Jaroslaw P. Maciejewski, MD, PhD⁵

¹Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Université de Paris, Paris, France

⁴MLL Munich Leukemia Laboratory, Munich, Germany

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

934 Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways: Biological, bone marrow, Therapies, Biological Processes, Clinically relevant, hematopoiesis, transplantation, stem cells

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Hillard Lazarus^{1*}, Carolina Escobar, MD^{2*}, Leland Metheny III, MD^{1,3}, Joseph P. McGuirk, DO^{4,5}, Tsila Zuckerman, MD^{6,7}, Mark Litzow, MD⁸, Scott D. Rowley, MD⁹, Racheli Ofir, PhD^{10*}, Liran Shani, MD^{11*} and Jacob M. Rowe, MB, BS¹²

¹Case Western Reserve University, Cleveland, OH

²Texas Oncology-Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, Dallas, TX

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴The University of Kansas Cancer Center, Westwood, KS

⁵Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

⁶Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

⁷The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

⁸Division of Hematology, Mayo Clinic, Rochester, MN

⁹John Theurer Cancer Center, Myeloma and Lymphoma Divisions, NNJCA, Hackensack, NJ

¹⁰Pluristem LTD, HAIFA, Israel

¹¹Pluristem Ltd, HAIFA, Israel

¹²The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

[**942 Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders**](#)

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster I

Hematology Disease Topics & Pathways: AML, Diseases, Technology and Procedures, Myeloid Malignancies, NGS, WGS

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Adam Wahida^{1*}, Stephan Hutter, PhD^{2*}, Manja Meggendorfer, PhD², Claudia Haferlach, MD², Wolfgang Kern, MD², Jaroslaw P. Maciejewski, MD, PhD³ and Torsten Haferlach, MD²

¹Torsten Haferlach Leukaemiediagnostik Stiftung, Munich, Germany

²MLL Munich Leukemia Laboratory, Munich, Germany

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

[**1028 A Multi-Center Open-Labelled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2mutant AML**](#)

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: therapy sequence, Therapies, Combinations

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Swapna Thota, MD¹, Terrence J Bradley, MD², Hetty E. Carraway, MD, MBA³ and Elizabeth A. Griffiths, MD¹

¹Roswell Park Comprehensive Cancer Center, Buffalo, NY

²University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

³Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

[**1029 Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review**](#)

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: AML, Non-Biological, Diseases, Therapies, chemotherapy, MDS, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Muhammad Salman Faisal, MD, MBBS¹, Laila Hashim, MBBS^{2}, Yazan Samhouri, MD³, Syed Maaz Abdullah, MBBS^{4*}, Ahsan Wahab, MD^{5*}, Moazzam Shahzad, MD^{6*}, Hamid Ehsan, MD, MBBS^{7,8*}, Zahoor Ahmed, MD^{9*}, Karun Neupane, MBBS, MD^{10*}, Asim Tameez Ud Din, MD, MBBS^{11*}, **Faiz Anwer, MD¹²** and **Salman Fazal, MD^{13*}***

¹Hematology and Stem Cell Transplant, James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH

²Internal Medicine, Bolan Medical Center, Quetta, Pakistan

³Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA

⁴King Edward Medical University, Lahore, Punjab, Pakistan

⁵Baptist Medical Center South, Montgomery, AL

⁶St Mary's Medical Center, Huntington, WV

⁷Georgetown University, Washington, DC

⁸MedStar Union Memorial Hospital, Baltimore, MD

⁹Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan

¹⁰Manipal College of Medical Sciences, Pokhara, Nepal

¹¹Shifa International hospital, Islamabad, Pakistan

¹²Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹³Allegheny Health Network Cancer Institute, Pittsburgh, PA

1040 A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Biological, AML, Diseases, Therapies, CAR-Ts, MDS, Myeloid Malignancies, Clinically relevant, NK cells

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Carlos Bachier, MD¹, Gautam Borthakur, MD², Chitra Hosing, MD³, William Blum, MD^{4}, Marcello Rotta, MD⁵, Paulius Ojeras^{6*}, Brian Barnett, MD^{6*}, Kanya Rajangam, MD, PhD^{6*}, **Navneet S. Majhail, MD, MS⁷** and Sarah Nikiforow, MD, PhD^{8*}*

¹Sarah Cannon Blood Cancer Network, Sarah Cannon Center for Blood Cancer, Nashville, TN

²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

³University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX

⁴Winship Cancer Institute of Emory University, Atlanta, GA

⁵Sarah Cannon Blood Cancer Network, Colorado Blood Cancer Institute, Denver, CO

⁶Nkarta Therapeutics, South San Francisco, CA

⁷Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

1047 A Phase 1b/2 Study of IMG632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: AML, Biological, antibodies, Adult, Diseases, Therapies, Elderly, Study Population, Myeloid Malignancies, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Naval Daver, MD¹, Kendra L. Sweet, MD, MS^{2}, Pau Montesinos, MD, PhD^{3*}, Eunice S. Wang, MD⁴, Ahmed Aribi, MD^{5*}, Daniel J. DeAngelo, MD, PhD⁶, Harry P Erba, MD PhD⁷, Giovanni Martinelli, MD⁸, Roland P Walter, MD PhD⁹, Jessica K Altman, MD¹⁰, **Anjali S Advani, MD¹¹**, Antonio Curti, MD PhD¹², Callum M Sloss, PhD¹³, Kara E Malcolm, RN^{13*} and Patrick A Zweidler-McKay, MD, PhD¹⁴*

¹The University of Texas MD Anderson Cancer Center, Houston, TX

²H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

³Hospital Universitari i Politècnic La Fe, Valencia, Spain

⁴Roswell Park Comprehensive Cancer Center, BUFFALO, NY

⁵City of Hope National Medical Center, Duarte, CA

⁶Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA

⁷Duke University School of Medicine, Durham, NC

⁸Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy

⁹Department of Medicine, University of Washington, Seattle, WA

¹⁰Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

¹¹Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

¹²Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, Italy

¹³ImmunoGen, Waltham, MA

¹⁴ImmunoGen, Lincoln, MA

1066 Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD^{1*}, Carmelo Gurnari, MD^{2*}, Arda Durmaz^{3*}, Simona Pagliuca, MD⁴, Misam Zawit, MBBS^{4*}, Cassandra M Kerr, MS^{4*} and Valeria Visconte, PhD⁴

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

³Department of Systems biology and Bioinformatics, CWRU, Cleveland

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

1080 Role of Oligoadenylate Synthetases in Myeloid Neoplasia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways: AML, Diseases, MDS, Biological Processes, DNA damage, Technology and Procedures, DNA repair, Cell Lineage, Study Population, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Metis Hasipek, PhD^{1*}, Yihong Guan, PhD^{1*}, Dale Grabowski, BS^{1*}, Xiaorong Gu, PhD^{1*}, Yogenthiran Sauntharajah, MD¹, Robert Silverman, PhD^{2*}, George R Stark, PhD^{2*}, Jaroslaw Maciejewski, PhD^{1*} and Babal K. Jha, PhD^{1*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

1120 One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Adult, Biological, Lymphoma (any), Diseases, CAR-Ts, Therapies, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Michael Wang, MD¹, Javier Munoz, MD², Andre H. Goy, MD³, Frederick L. Locke, MD⁴, Caron A. Jacobson, MD^{5*}, Brian T. Hill, MD⁶, John M. Timmerman, MD⁷, Houston Holmes^{8*}, Samantha Jaglowski, MD, MPH⁹, Ian W. Flinn, MD, PhD¹⁰, Peter A. McSweeney, MD^{11*}, David B. Miklos, MD, PhD¹², John M. Pagel, MD, PhD¹³, Marie José Kersten, MD, PhD¹⁴, Noel Milpied^{15*}, Henry C.H. Fung, MD^{16*}, Max S. Topp, MD¹⁷, Roch Houot, MD, PhD^{18*}, Amer Beitinjaneh, MD, MPH, MSc^{19*}, Weimin Peng, PhD^{20*}, Lianqing Zheng, PhD^{20*}, John M. Rossi, MS^{20*}, Swaminathan Murugappan, MD, PhD^{20*}, Ioana Kloos, MD^{20*} and Patrick M. Reagan, MD²¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX

²Banner MD Anderson Cancer Center, Gilbert, AZ

³John Theurer Cancer Center, Hackensack, NJ
⁴Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
⁵Dana-Farber Cancer Institute, Boston, MA
⁶Cleveland Clinic Foundation, Cleveland, OH
⁷David Geffen School of Medicine at UCLA, Los Angeles, CA
⁸Texas Oncology, Dallas, TX
⁹The Ohio State University, Comprehensive Cancer Center, Columbus, OH
¹⁰Sarah Cannon Research Institute, Nashville, TN
¹¹Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO
¹²Stanford University School of Medicine, Stanford, CA
¹³Swedish Cancer Institute, Seattle, WA
¹⁴Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, on behalf of HOVON/LLPC, Amsterdam, Netherlands
¹⁵Hopital Haut Leveque, Pessac, France
¹⁶Fox Chase Cancer Center, Philadelphia
¹⁷Universitätsklinikum Würzburg, Würzburg, Germany
¹⁸CHU Rennes, Rennes, France
¹⁹University of Miami, Miami, FL
²⁰Kite, a Gilead Company, Santa Monica, CA
²¹University of Rochester School of Medicine, Rochester, NY

1126 Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Lymphoma (any), Therapies, CAR-Ts,
Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Lymphoid Malignancies, Study
Population

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Michael Wang, MD¹, John M. Rossi, MS^{2*}, Javier Munoz, MD³, Andre H. Goy, MD⁴, Frederick L. Locke, MD⁵, Patrick M. Reagan, MD⁶, Caron A. Jacobson, MD⁷, **Brian T. Hill, MD⁸**, Houston Holmes^{9*}, Samantha Jaglowski, MD, MPH¹⁰, Weimin Peng, PhD^{2*}, Lianqing Zheng, PhD^{2*}, Xiang Fang, PhD^{2*}, Allen Xue, PhD^{2*}, Ioana Kloos, MD^{2*} and Adrian Bot, MD, PhD^{2*}

¹The University of Texas MD Anderson Cancer Center, Houston, TX
²Kite, a Gilead Company, Santa Monica, CA
³Banner MD Anderson Cancer Center, Gilbert, AZ
⁴John Theurer Cancer Center, Hackensack, NJ
⁵Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
⁶Wilmot Cancer Institute, University of Rochester Medical Center, Fairport, NY
⁷Dana-Farber Cancer Institute, Boston, MA
⁸Cleveland Clinic Foundation, Cleveland, OH
⁹Texas Oncology, Dallas, TX
¹⁰The Ohio State University, Comprehensive Cancer Center, Columbus, OH

1133 Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Narendranath Epperla, MD, MS¹, Qiuhong Zhao, MS^{2*}, Sayan Mullick Chowdhury, PhD^{3*}, Tamara K. Moyo, MD^{4*}, Lauren Shea, MD^{5*}, Nishitha Reddy, MD, MSCI^{6*}, Julia Sheets, MD^{7*}, David M. Weiner, BA^{8*}, Praveen Ramakrishnan Geethakumari, MD, MS⁹, Malathi Kandarpa, PhD^{10*}, Ximena Jordan Bruno, MD^{11*}, Colin Thomas, MD^{12*}, Michael C. Churnetski^{13*}, Andrew Hsu, MD^{14*}, Joseph Maakaron, MD^{15*}, **Paolo Caimi, MD¹⁶**, Pallawi Torka, MD¹⁷, Celeste Bello, MD¹⁸, Cherie Tan, MD^{19*}, Kevin A. David, MD¹⁹, Kathryn Lindsey, MD^{20*}, Irl Brian Greenwell, MD²¹, Murali Janakiram, MD²², Adam J Olszewski, MD¹⁴, Jonathon B. Cohen, MD, MS²³, Neil Palmisiano, MD, MS²⁴, Elvira Umyarova, MD²⁵, Ryan A. Wilcox, MD²⁶, Farrukh T

Awan, MD⁹, Stefan K. Barta, MD, MRCP, MS²⁷, Natalie S Grover, MD²⁸, Nancy L. Bartlett, MD^{29*}, Yazeed Sawalha, MD², Beth A. Christian, MD³⁰, Alex F. Herrera, MD³¹ and Geoffrey Shouse, MD^{31*}

¹The Ohio State University James Comprehensive Cancer Center, Columbus, OH

²Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

³Hematology, The Ohio State University, Columbus, OH

⁴Atrium Health, Charlotte, NC

⁵Washington University, St. Louis, MO

⁶Vanderbilt University Medical Center, Nashville, TN

⁷University of North Carolina, Chapel Hill, NC

⁸Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

⁹Division of Hematologic Malignancies and Stem Cell Transplantation, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

¹⁰University of Michigan Medical Center, Ann Arbor, MI

¹¹University of Vermont, Burlington, VT

¹²Thomas Jefferson University, Philadelphia, PA

¹³Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

¹⁴Brown University, Providence, RI

¹⁵Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

¹⁶University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁷Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

¹⁸H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁹Cancer Institute of New Jersey, New Brunswick, NJ

²⁰Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC

²¹Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

²²Division of Hematology, Oncology and Transplantation, University of Minnesota, Rochester, MN

²³Winship Cancer Institute, Emory University, Atlanta, GA

²⁴Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA

²⁵The University of Vermont Medical Center, Burlington, VT

²⁶Rogel Cancer Center, University of Michigan, Ann Arbor, MI

²⁷Lymphoma Department, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

²⁸Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

²⁹Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

³⁰Division of Hematology, Department of Internal Medicine, The James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH

³¹City of Hope, Duarte, CA

1155 A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Therapies, Combinations, T-Cell Lymphoma, Lymphoid Malignancies, Study Population

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Swami P. Iyer, MD¹, Auris Huen, MD^{2*}, Bradley Haverkos, MD, MPH, MS^{3*}, Weiyun Z. Ai⁴, Craig Okada, MD, PhD⁵, Timothy M. Kuzel, MD⁶, Mary Jo Lechowicz, MD⁷, Juan Pablo Alderuccio, MD⁸, Ann Mohrbacher, MD⁹, Don A. Stevens, MD¹⁰, Ryan A. Wilcox, MD¹¹, Tatyana A. Feldman, MD¹², Suchitra Sundaram, MD^{13*}, **Deepa Jagadeesh, MD, MPH¹⁴, Nishitha Reddy, MD, MSCI^{15*}, Kasi Viswanath Routhu, PhD^{16*}, Prajak Barde, MD^{16*} and Ajit Mohanchandran Nair, PhD^{16*}**

¹Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX

²The University of Texas MD Anderson Cancer Center, Houston, TX

³University of Colorado Cancer Center, Aurora, CO

⁴Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA

⁵Oregon Health and Science University, Portland, OR

⁶Rush University Medical Center, Chicago, IL

⁷Department of Hematology, Winship Cancer Institute, Atlanta, GA

⁸Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL

⁹Department of Medicine, Division of Hematology, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA

¹⁰Norton Cancer Institute - St Matthews Campus, Louisville, KY

¹¹Rogel Cancer Center, University of Michigan, Ann Arbor, MI

¹²John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹³Roswell Park, Buffalo, NY

¹⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH

¹⁵Vanderbilt University Medical Center, Nashville, TN

¹⁶Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland

1183 Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Paolo F Caimi^{1*}, Weiyun Z. Ai², Juan Pablo Alderuccio, MD³, Kirit M. Ardeshta⁴, Mehdi Hamadani, MD⁵, Brian T. Hess, MD⁶, Brad S. Kahl, MD⁷, John A. Radford, MD, FMedSci^{8*}, Melhem Solh, MD⁹, Anastasios Stathis, MD^{10*}, Pier Luigi Zinzani, MD¹¹, Jay Feingold^{12*}, David Ungar¹³, Yajuan Qin^{13*}, Shui He^{13*} and Carmelo Carlo-Stella, MD¹⁴

¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

²Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA

³Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL

⁴Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

⁵Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

⁶Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC

⁷Department of Medicine, Oncology Division, Washington University, St. Louis, MO

⁸The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

⁹Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

¹⁰Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

¹¹Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy

¹²ADC Therapeutics America, Inc, Murray Hill, NJ

¹³Clinical Development, ADC Therapeutics America, Inc, Murray Hill, NJ

¹⁴Department of Oncology and Hematology, Humanitas Clinical and Research Center - IRCCS, Humanitas University, Rozzano, Italy

1187 Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Therapies, CAR-Ts, Non-Hodgkin Lymphoma, Biological Processes, Lymphoid Malignancies, Study Population, immune mechanism

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Caron Jacobson, MD, MMSc¹, Frederick L. Locke, MD², Armin Ghobadi, MD³, David B. Miklos, MD, PhD⁴, Lazaros J. Lekakis, MD^{5*}, Olalekan O. Oluwole, MBBS, MPH⁶, Yi Lin, MD, PhD⁷, Ira Braunschweig, MD^{8*}, **Brian T. Hill, MD⁹**, John M. Timmerman, MD¹⁰, Abhinav Deol, MD¹¹, Patrick M. Reagan, MD¹², Patrick J. Stiff, MD¹³, Ian W. Flinn, MD, PhD¹⁴, Umar Farooq, MD¹⁵, Andre H. Goy, MD¹⁶, Peter A. McSweeney, MD^{17*}, Javier Munoz, MD¹⁸, Tanya Siddiqi, MD¹⁹, John M. Rossi, MS^{20*}, Adrian Bot, MD, PhD^{20*}, Lianqing Zheng, PhD^{20*}, Remus Vezan, MD, PhD²⁰, Zahid Bashir, MBBS^{20*}, Jenny J. Kim, MD, MS^{20*}, Rong Chu, PhD^{20*} and Sattva S. Neelapu, MD²¹

¹Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

²Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

³Washington University School of Medicine, St Louis, MO

⁴Stanford University School of Medicine, Stanford, CA

⁵Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL

⁶Vanderbilt-Ingram Cancer Center, Nashville, TN

⁷Division of Hematology, Mayo Clinic, Rochester, MN

⁸Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

⁹Cleveland Clinic Foundation, Cleveland, OH

¹⁰UCLA David Geffen School of Medicine, Los Angeles, CA

¹¹Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹²University of Rochester School of Medicine, Rochester, NY

¹³Loyola University Chicago Stritch School of Medicine, Maywood, IL

¹⁴Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

¹⁵University of Iowa, Iowa City, IA

¹⁶John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹⁷Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO

¹⁸Banner MD Anderson Cancer Center, Gilbert, AZ

¹⁹City of Hope National Medical Center, Duarte, CA

²⁰Kite, a Gilead Company, Santa Monica, CA

²¹The University of Texas MD Anderson Cancer Center, Houston, TX

1190 A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Abrerrant Lymphoid Malignancies: The Daciphor Regimen

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways: Diseases, Therapies, Combinations, Non-Hodgkin Lymphoma, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Carlos Galvez, MD¹, Reem Karmali, MD, MSc², Mehdi Hamadani, MD³, Leo I. Gordon, MD², Jane N. Winter, MD⁴, Shuo Ma, MD, PhD², Valerie Nelson, MD, MBA^{2*}, Brett Alan Palmer, BS^{2*}, Timothy S. Fenske, MD³, Nirav N. Shah, MD⁵, **Deepa Jagadeesh, MD, MPH⁶**, Andreas Klein, MD⁷, Irene Helenowski, PhD^{8*}, Borko Jovanovic, PhD^{8*}, Adam M Petrich, MD^{2,9}, Andrew M. Evens, DO, MMSc¹⁰ and Barbara Pro, MD²

¹Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL

²Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

³Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

⁴Division of Hematology and Oncology, Northwestern University, Chicago, IL

⁵Medical College of Wisconsin, Brookfield, WI

⁶Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH

⁷Division of Hematology and Oncology, Tufts Medical Center, Boston, MA

⁸Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

⁹Daiichi-Sankyo, Inc., Basking Ridge, NJ

¹⁰Rutgers Cancer Institute of New Jersey, Warren, NJ

1201 Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A post-Hoc Analysis of the Sadal Pivotal Study

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Michael W. Schuster, MD¹, Miguel A Canales, MD, PhD^{2,3}, Jason Westin, MD⁴, Josée M Zijlstra, MD, PhD^{5*}, George A Follows, MD, PhD^{6*}, Reem Karmali, MD, MSc⁷, Nagesh Kalakonda, MD^{8*}, Andre H. Goy, MD⁹, Rene-Olivier Casasnovas, MD^{10*}, Joost Vermaat, MD, PhD¹¹, Eric Van Den Neste, MD^{12*}, Sylvain Choquet, MD^{13*}, Catherine Thieblemont, MD, PhD¹⁴, Federica Cavallo, MD, PhD^{15*}, Maria de Fatima De La Cruz, MD^{16*}, **Brian T. Hill, MD¹⁷**, Herve Tilly, MD, PhD¹⁸, Shireen Kassam, MBBS, FRCPath, PhD^{19*}, Reda Bouabdallah, MD^{20*}, Ulrich Jaeger, MD²¹, Ronit Gurion, MD^{22*}, **Paolo Caimi, MD²³**, Peter Martin, FRCPC, MD, MS²⁴, Andrew Davies, MD, PhD^{25*}, Sonali M. Smith, MD²⁶, Graham P. Collins, MD, DPhil²⁷, Fritz Offner, MD, PhD²⁸, Gilles Salles, MD, PhD²⁹, Xiwen Ma^{30*}, Kelly Corona^{30*}, Jean-Richard Saint-Martin^{30*}, Anita A. Joshi^{31*}, Kamal Chamoun, MD^{30*}, Hongwei Wang, MD, PhD^{31*}, Jatin J. Shah, MD^{30*}, Sharon Shacham, PhD, MBA^{30*}, Michael G Kauffman, MD, PhD³⁰ and **Marie Maerevoet, MD^{32*}**

¹Stony Brook University, Stony Brook, NY

²La Paz University Hospital, Madrid, Spain

- ³Hematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain
- ⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
- ⁵Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
- ⁶Addenbrooke's Hospital, Cambridge, United Kingdom
- ⁷Division of Hematology Oncology, Northwestern University, Chicago, IL
- ⁸University of Liverpool, Liverpool, United Kingdom
- ⁹Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
- ¹⁰Hématologie Clinique and INSERM 1231, CHU Dijon, Dijon, France
- ¹¹Department of Hematology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
- ¹²Cliniques universitaires Saint-Luc, Brussels, BEL
- ¹³Hospital Pitie Salpetriere, Paris, France
- ¹⁴APHP, Hôpital Saint-Louis, Hématologie-oncologie, Université de Paris, Paris Diderot, Paris, France
- ¹⁵Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Torino, Italy
- ¹⁶Hospital Universitario Virgen del Rocío, Sevilla, Spain
- ¹⁷Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
- ¹⁸Centre Henri Becquerel, Rouen, France
- ¹⁹King's College Hospital, London, United Kingdom
- ²⁰Institut Paoli-Calmettes, Marseille, France
- ²¹Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, AA, Austria
- ²²Robin Medical Center, Petah Tikva, Israel
- ²³University Hospitals Cleveland Medical Center, Cleveland, OH
- ²⁴Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
- ²⁵Cancer Research UK Centre/Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom
- ²⁶Department of Oncology, University of Chicago, Chicago, IL
- ²⁷Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- ²⁸University Hospital Ghent, Gent, Belgium
- ²⁹Centre Hospitalier Lyon-Sud, Lyon, France
- ³⁰Karyopharm Therapeutics, Newton, MA
- ³¹Karyopharm Therapeutics Inc., Newton, MA
- ³²Institut Jules Bordet, Brussels, Belgium

1207 Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States between 2013 and 2020: A Population-Based Study

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster I

Hematology Disease Topics & Pathways:

viral, Follicular Lymphoma, Adult, Diseases, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, DLBCL, B-Cell Lymphoma, T-Cell Lymphoma, Infectious Diseases, Lymphoid Malignancies, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Akram Alkrekshi, MD^{1*}, Ahmad Kassem, MD^{2*}, Changsu Park, MD^{3*} and William Tse, MD³

¹Department of Hematology and Oncology, The MetroHealth System campus of Case Western Reserve University, Westlake, OH

²Department of Hematology and Oncology, The MetroHealth System campus of Case Western Reserve University, Cleveland

³Department of Hematology and Oncology, The MetroHealth System campus of Case Western Reserve University, Cleveland, OH

1210 Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Brian T. Hess, MD¹, Anshu Giri, MD^{2*}, Yeonhee Park, PhD^{1*}, Krina K. Patel, M.D.³, Brian K. Link, MD⁴, Grzegorz S. Nowakowski, MD⁵, Seth M Maliske, MD⁴, Sonia Fortin^{5*}, Julio C. Chavez, MD⁶, Hayder Saeed, MD⁷, **Brian T. Hill, MD⁸, Alex V. Mejia Garcia, MD⁹, Kami J. Maddocks, MD¹⁰, Walter Hanel, MD^{10*}, Nina D. Wagner-Johnston¹¹, Marcus Raymond Messmer, MD^{11*}, Brad S. Kahl, MD¹², Marcus Watkins, PhD^{13*}, Juan Pablo Alderuccio, MD¹⁴, Izidore S. Lossos, MD¹⁴, Sunita Nathan, MD¹⁵, Victor M. Orellana-Noia, MD¹⁶, Craig A. Portell, MD¹⁷, Daniel J. Landsburg, MD¹⁸, Emily C. Ayers, MD¹⁹ and Jorge J. Castillo, MD²⁰**

- ¹Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
²Fox Chase Cancer Center, Philadelphia, PA
³Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
⁵Mayo Clinic, Rochester, MN
⁶Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁷Dept. of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁸Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
⁹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
¹⁰Ohio State University Hospital, Columbus, OH
¹¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD
¹²Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
¹³Barnes-Jewish Hospital, Washington University in St. Louis, St. Louis, MO
¹⁴Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
¹⁵Rush University Medical Center, Chicago, IL
¹⁶Winship Cancer Institute, Emory University, Atlanta, GA
¹⁷Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
¹⁸Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
¹⁹Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA
²⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

1218 Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Non-Hodgkin Lymphoma, chemotherapy, DLBCL, Lymphoid Malignancies, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Mohammad Ahsan Sohail, MD^{1*}, Hong Li^{2*}, Wei Wei, MS^{2*}, Sebastian Cerdena, PharmD^{3*}, Marcus Watkins, PhD^{3*}, Marissa Olson, PharmD^{3*}, Gray Jodon, MD⁴, Jeff Kaiser, PharmD^{4*}, Bradley Haverkos, MD, MPH, MS^{4*}, Mitchell E. Hughes, PharmD^{5*}, Natalie S Grover, MD⁶, Anson Snow, MD⁶, Victor M. Orellana-Noia, MD⁷, Magdalena A Rainey, MS¹, Matthew J Cortese, MD, MPH⁸, Joslyn Rudoni, PharmD^{9*}, Craig A. Portell, MD¹⁰, Timothy J Voorhees, MD⁶, Daniel J. Landsburg, MD⁵, Manali Kamdar, MD, MDDS^{4*}, Brad S. Kahl, MD¹¹ and Brian T. Hill, MD¹²

- ¹Cleveland Clinic, Cleveland, OH
²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
³Barnes-Jewish Hospital, Washington University in St. Louis, St. Louis, MO
⁴University of Colorado Cancer Center, Aurora, CO
⁵Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁶Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
⁷Winship Cancer Institute, Emory University, Atlanta, GA
⁸Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
⁹Department of Pharmacy, Cleveland Clinic, Cleveland, OH
¹⁰Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
¹¹Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
¹²Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

1254 Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster I

Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Therapies, blood banking, MPN, thrombocythemia, Study Population, Myeloid Malignancies, Clinically relevant, pathways

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

John Mascarenhas, MD^{1,2,3,4,5}, Heidi E. Kosiorek, MS^{6,7*}, Lilian Varricchio, PhD^{8*}, Rupali Bhawe, M.D.^{9*}, Andrew T. Kuykendall, MD^{10,11,12,13}, Rami Komrokji, MD¹⁴, Aaron T. Gerds, MD, MS^{15,16,17,18,19,20,21,22,23,24}, Jeanne M. Palmer, MD^{25,26,27}, Amelia R. Gabler^{1,28,29,30,31,32*}, Lonette Sandy^{33*}, Anna Rita Migliaccio, PhD^{34,35,36,37}, Mohamed E Salama, MD^{38,39}, Rona Singer Weinberg, PhD⁴⁰, Maureen O'Connor-McCourt,

PhD^{41*}, Gilles Tremblay, PhD^{42*}, Paul I. Nadler, MD⁴³, Amylou C. Dueck, PhD^{2,44,45,46}, Ruben A. Mesa, MD, FACP⁴⁷ and Ronald Hoffman, MD^{2,48,49,50}

¹Icahn School of Medicine at Mount Sinai, New York, NY

²MPN Research Consortium, New York, NY

³Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

⁴Hematology, Mount Sinai School of Medicine, New York, NY

⁵Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY

⁶Mayo Clinic, Scottsdale, AZ

⁷Department of Biostatistics, Mayo Clinic, Phoenix, AZ

⁸Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

⁹Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC

¹⁰Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹¹Division of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

¹²Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹³Moffitt Cancer Center, University of South Florida, Tampa, FL

¹⁴Moffitt Cancer Center, Tampa, FL

¹⁵Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁶Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

¹⁷Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁸Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

¹⁹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²⁰Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²¹Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

²²Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²³Cleveland Clinic Taussig Cancer Institute, Shaker Heights, OH

²⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²⁵Mayo Clinic, Phoenix, AZ

²⁶Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ

²⁷Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

²⁸Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY

²⁹Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, New York, NY

³⁰Icahn School of Medicine at Mount Sinai, Myeloproliferative Neoplasms Research Consortium, New York, NY

³¹Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

³²Memorial Sloan Kettering Cancer Center, New York, NY

³³Icahn School of Medicine At Mount Sinai, New York City, NY

³⁴Biomedical and Neuromotorial Sciences, Alma Mater Studiorum University, Bologna, Italy

³⁵Department of Biomedical and Neuromotorial Sciences, Mount Sinai School of Medicine, New York, NY

³⁶Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

³⁷Myeloproliferative Neoplasm-Research Consortium, New York, NY

³⁸Mayo Medical Laboratories, Rochester, MN

³⁹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

⁴⁰New York Blood Center, New York, NY

⁴¹Forbush, Montreal, Canada

⁴²Formation Biologics, Montreal, QC, Canada

⁴³Nadler Pharma Associates, LLC, Randolph, NJ

⁴⁴Mayo Clinic Arizona, Phoenix, AZ

⁴⁵Section of Biostatistics, Mayo Clinic, Scottsdale, AZ

⁴⁶Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ

⁴⁷Mays Cancer Center at UT Health San Antonio, San Antonio, TX

⁴⁸Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

⁴⁹Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

⁵⁰Hematology/Oncology, Mount Sinai School of Medicine, New York, NY

1277 Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Anemias, Adult, Diseases, Non-Biological, Therapies, Biological Processes, erythropoiesis, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

David H. Henry, MD¹, John Glaspy, MD, MPH^{2*}, Rosemary Anne Harrup^{3*}, Moshe Mittelman, MD⁴, Amy Zhou, MD⁵, **Hetty E. Carraway, MD, MBA⁶**, Charles Bradley, Ph.D.⁷, Gopal Saha, MD^{7*}, Pamela Bartels^{7*}, Robert Leong^{7*} and Peony Yu, MD^{8*}

¹Pennsylvania Hospital, University of Pennsylvania, Philadelphia, PA

²UCLA School of Medicine, Los Angeles

³Royal Hobart Hospital, Tasmania, Australia

⁴Department of Internal Medicine A, Tel Aviv Sourasky Medical Center/Sackler Faculty of Medicine, Tel Aviv, Israel

⁵Washington University School of Medicine, Saint Louis, MO

⁶Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁷FibroGen Inc., San Francisco

⁸FibroGen, Inc, San Francisco, CA

1294 The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, MDS, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Amer M. Zeidan, MBBS, MHS¹, Jordi Esteve, MD, PhD², Aristoteles Giagounidis³, Hee-Je Kim, M.D., Ph.D.^{4*}, Yasushi Miyazaki, MD, PhD⁵, Uwe Platzbecker, MD⁶, Andre C. Schuh⁷, Mikkael A. Sekeres⁸, Jörg Westermann^{9*}, Zhijian Xiao^{10*}, Kamel Malek^{11*}, Jeffrey Scott^{12*}, Julie Niolat^{13*}, Severine Peyrard^{13*}, Fei Ma^{12*}, Flavia Kiertsman^{12*}, Mario Stegert^{11*}, Sabine Hertle^{11*}, Pierre Fenau, MD, PhD¹⁴ and Valeria Santini¹⁵

¹Yale University and Yale Cancer Center, New Haven, CT

²Hospital Clinic, Barcelona, Spain

³Marien Hospital Düsseldorf, Düsseldorf, Germany

⁴Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

⁵Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan

⁶Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

⁷Princess Margaret Cancer Centre, Toronto, ON, Canada

⁸Cleveland Clinic, Cleveland, OH

⁹Charité-University Medical Center Berlin, Campus Virchow Clinic, Berlin, Germany

¹⁰Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China

¹¹Novartis Pharma AG, Basel, Switzerland

¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ

¹³Novartis Pharma SAS, Rueil-Malmaison, France

¹⁴Hôpital Saint-Louis, Paris, France

¹⁵MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy

1349 Analysis of Racial Differences in the Incidence of a Targetable Biomarker, t(11; 14), in Patients with Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Fang Liu, MD^{1*}, Jeries Kort, MD², Shashirekha Shetty, PhD^{2*}, Ravikumar Kyasaram^{3*}, John Shanahan^{4*} and Timothy E. O'Brien, MD⁵

¹University hospitals, Cleveland, OH

²University Hospitals Cleveland Medical Center, Cleveland, OH

³University hospitals cleveland medical center, cleveland, OH

⁴University Hospital Cleveland Medical Center, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

1355 Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature that Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Hematology Disease Topics & Pathways: multiple myeloma, Diseases, Technology and Procedures, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, genetic profiling

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Ehsan Malek, MD^{1,2}, E. Ricky Chan, PhD^{2,3*}, Daniel Qu^{4*}, Jane Reese^{2,5*}, Robert Fox^{5*}, Byung-Gyu Kim, PhD, DVM^{2,6*}, **Paolo F Caimi, MD^{2,5}**, **Marcos de Lima, MD^{2,5}** and **James J. Driscoll, MD, PhD^{2,5}**

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

²Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

³Institute for Computational Biology, Case Western Reserve University School of Medicine, Cleveland, OH

⁴Case Western Reserve University School of Medicine, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁶Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH

1376 Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, enzyme inhibitors, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Ping Zhou, MD, PhD¹, Hashim Mann, MD², Xun Ma, DMD, MSc, PhD^{1*}, Teresa Fogaren, NP^{3*}, Yifei Zhang, MD³, Denis Toskic, BS^{4*}, Chakra P Chaulagain, MD⁵, Cindy Varga, MD, BSc⁶, Raymond L. Comenzo, MD⁶ and **Amandeep Godara, MD³**

¹John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

²Hematology/Oncology, Tufts Medical Center, Boston, MA

³Tufts Medical Center, Boston, MA

⁴John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Revere, MA

⁵Department of Hematology and Oncology, Maroon Cancer Center, Cleveland Clinic Florida, Weston, FL

⁶Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

1384 Selinexor Efficacy and Safety are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Michael W. Schuster, MD¹, Miguel A Canales, MD, PhD², **Jason Westin, MD³**, Josée M Zijlstra, MD, PhD^{4*}, George A Follows, MD, PhD^{5*}, Reem Karmali, MD, MSc⁶, Nagesh Kalakonda, MD^{7*}, Andre H. Goy, MD⁸, Rene-Olivier Casasnovas, MD^{9*}, Joost Vermaat, MD, PhD¹⁰, Eric Van Den Neste, MD^{11*}, Sylvain Choquet, MD^{12*}, Catherine Thieblemont, MD, PhD^{13,14}, Federica Cavallo, MD, PhD^{15*}, Maria de Fatima De La Cruz, MD^{16*}, **Brian T. Hill, MD¹⁷**, Herve Tilly, MD, PhD¹⁸, Shireen Kassam, MBBS, FRCPath, PhD^{19*}, Reda Bouabdallah, MD^{20*}, Ulrich Jaeger, MD²¹, Ronit Gurion, MD^{22,23*}, **Paolo Caimi, MD²⁴**, Peter Martin, FRCPC, MD, MS²⁵, Andrew Davies, MD, PhD^{26*}, Sonali M. Smith, MD²⁷, Graham P. Collins, MD, DPhil²⁸, Fritz Offner, MD, PhD²⁹, Gilles Salles, MD, PhD³⁰, Xiwen Ma^{31*}, Kelly Corona^{31*}, Jean-Richard Saint-Martin^{31*}, Anita A. Joshi^{32*}, Kamal Chamoun, MD^{31*}, Hongwei Wang, MD, PhD^{32*}, Jatin J. Shah, MD^{31*}, Sharon Shacham, PhD, MBA^{31*}, Michael G Kauffman, MD, PhD³¹ and Marie Maerevoet, MD^{33*}

¹Stony Brook University, Stony Brook, NY

²Hematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain

³Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands

⁵Addenbrooke's Hospital, Cambridge, United Kingdom

⁶Division of Hematology, Northwestern Medical Faculty Foundation, Chicago, IL

⁷University of Liverpool, Liverpool, United Kingdom

- ⁸Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
- ⁹Hématologie Clinique and INSERM 1231, CHU Dijon, Dijon, France
- ¹⁰Department of Hematology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
- ¹¹Cliniques universitaires Saint-Luc, Brussels, BEL
- ¹²Hospital Pitie Salpetriere, Paris, France
- ¹³Department of Hemato-Oncology, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Paris, France
- ¹⁴Diderot University, University de Paris, Paris, France
- ¹⁵Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Torino, Italy
- ¹⁶Hospital Universitario Virgen del Rocío, Sevilla, Spain
- ¹⁷Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
- ¹⁸Centre Henri Becquerel, Rouen, France
- ¹⁹King's College Hospital, London, United Kingdom
- ²⁰Institut Paoli-Calmettes, Marseille, France
- ²¹Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, AA, Austria
- ²²Tel Aviv University, Tel Aviv, Israel
- ²³Rabin Medical Center, Petah Tikva, Israel
- ²⁴University Hospitals Cleveland Medical Center, Cleveland, OH
- ²⁵Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
- ²⁶Cancer Research UK Centre/Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom
- ²⁷Department of Oncology, University of Chicago, Chicago, IL
- ²⁸Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- ²⁹University Hospital Ghent, Gent, Belgium
- ³⁰Centre Hospitalier Lyon-Sud, Lyon, France
- ³¹Karyopharm Therapeutics, Newton, MA
- ³²Karyopharm Therapeutics Inc., Newton, MA
- ³³Institut Jules Bordet, Brussels, Belgium

1421 Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/II HLA Mutations

Program: Oral and Poster Abstracts

Session: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I

Hematology Disease Topics & Pathways: AML, Diseases, MDS, Biological Processes, Myeloid

Malignancies, genomics, immune mechanism

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Simona Pagliuca, MD^{1,2}, Carmelo Gurnari, MD^{2,3*}, Sanghee Hong, MD⁴, Cassandra M Kerr, MS^{2*}, Sunisa Kongkiatkamon, MD^{2,5*}, Hassan Awada, MD², Ashwin Kishtagari, MBBS², Misam Zawit, MBBS^{2*}, Laila Terkawi^{2*}, Valeria Visconte, PhD², Eric D. Hsi, MD⁶, Betty K. Hamilton, MD⁷, Hetty E. Carraway, MD, MBA⁷, Navneet S. Majhail, MD, MS⁷ and Jaroslaw P. Maciejewski, MD, PhD⁸

¹Université de Paris, Paris, France

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

⁴University Hospitals/ Case Western Reserve University, Cleveland, OH

⁵Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

⁶Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

⁷Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1447 Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS)

Program: Oral and Poster Abstracts

Session: 704. Immunotherapies: Poster I

Hematology Disease Topics & Pathways: CRS, Diseases, neurotoxicity, Adverse Events, B-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Akansha Jalota, PhD, MSc, BSc^{1*}, Courtney E. Hershberger, PhD², Manishkumar S. Patel, PhD, MS, BPharm¹, Agrima Mian, MBBS, MD^{3*}, Daniel M. Rotroff, PhD^{2*}, Brian T. Hill, MD³ and Neetu Gupta, PhD, MSc, BSc¹

¹Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH

²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1473 Reduced-Intensity Versus Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials & Cohort Studies

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, MDS, Clinically relevant, Myeloid Malignancies, transplantation

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Arshia Akbar, MD, MBBS^{1*}, Zunairah Shah, MBBS^{2*}, Muhammad Ali Aziz, MD^{3*}, Muhammad Yasir Anwar^{4*}, Saman Bahram^{5*}, Waqas Khan^{6*}, Zahoor Ahmed, MD^{4*}, Qasim Khurshid, MD^{7*}, Abdul Jabbar Dar, MD^{8*}, Anum Javaid, MD^{9*}, Neelam Asghar^{10*}, Harsh Patel^{11*} and **Faiz Anwer, MD¹²**

¹Holy Family Hospital, Rawalpindi, Pakistan

²Department of Internal Medicine, Louis A Weiss Memorial Hospital, Chicago, IL

³King Edward Medical University, Lahore, Pakistan

⁴Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan

⁵Dow university of Health Sciences, Karachi, Pakistan

⁶Army medical College, Rawalpindi, Pakistan

⁷Xinjiang Medical University, Urumqi, China

⁸Shaikh Zayed Medical College, Lahore, Pakistan

⁹Rawalpindi medical university, Rawalpindi, Pakistan

¹⁰Allama Iqbal Medical College, Lahore, Pakistan

¹¹Department of Internal Medicine, Louis A Weiss Memorial Hospital, Chicago

¹²Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1479 Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I

Hematology Disease Topics & Pathways: Biological, bone marrow, Therapies, transplantation, stem cells

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Naveed Ali, MD¹, Ana Carolina Pires de Rezende, MD^{2*}, Folashade Otegbeye, MBChir, MPH³, Mariana Nassif Kerbauy, MD^{4*}, Brenda W. Cooper, MD³, David Mansur, MD^{5*}, Gisele Pereira, PhD^{5*}, Roberto Sakuraba, MD^{2*}, Benjamin K. Tomlinson, MD³, Kirsten M Boughan, DO³, Cinthya Correa Silva, MD^{6*}, Leland Metheny III, MD³, Andreza Feitosa Ribeiro, MD⁷, Molly M Gallogly, MD, PhD³, Ehsan Malek, MD⁸, Eduardo Weltman, MD^{6*}, Marcos de Lima, MD³, Nelson Hamerschlag, MD, PhD⁹ and Paolo F Caimi, MD³

¹Case Western Reserve University, University Heights, OH

²Department of Radiation Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Hospital Albert Einstein / HSCT Program, Hospital Israelita Albert Einstein, São Paulo, BRA

⁵Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH

⁶Oncology and Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil

⁷Hospital Israelita Albert Einstein, São Paulo, Sp, BRA

⁸Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁹Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil

1481 Acute Non-Infectious Complications of Pediatric Hematopoietic Stem Cell Transplantation: An in-Hospital Nationwide Study in the United States from 2001-2019

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I

Hematology Disease Topics & Pathways: Adverse Events, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Maria Alejandra Pereda, MD¹, Sindhoosha Malay, MPH, PharmD^{2*} and Jignesh Dalal, MD³

¹University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

²School of Medicine, Case Western Reserve University, Cleveland, OH

³Rainbow Babies & Children's Hospital, Cleveland, OH

1484 Anti-Thymocyte Globulin (ATG) for Prophylaxis of Severe Graft Vs. Host Disease after Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts

Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I

Hematology Disease Topics & Pathways: Biological, antibodies, Therapies, Adverse Events, Clinically relevant, transplantation, stem cells

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Muhammad Ashar Ali, MD^{1*}, Muhammad Yasir Anwar^{1*}, Sobia Aamir, MD, FCPS^{2*}, Saad Ur Rahman, MBBS^{1*}, Richi Kashyap, MD^{3*}, Sana Irfan Khan, MD^{4*}, Usman Ali Akbar, MBBS^{5*}, Anum Waqar, MBBS^{6*}, Anam Khan^{7*}, Wajeeha Aiman, MD^{5*} and Faiz Anwer, MD⁸

¹King Edward Medical University, Lahore, Pakistan

²Children hospital and Institute of Child Health, Lahore, Pakistan

³Maulana Azad Medical College, New Delhi, India

⁴All India Institute Of Medical Sciences, Delhi, India

⁵Nishtar Medical University, Multan, Pakistan

⁶Fatima Jinnah Medical University, Lahore, Pakistan

⁷Jawaharlal Nehru Medical College, Delhi, India

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland

1500 Safety and Efficacy of Salvage Therapies for Relapse/Refractory AML/MDS after First Allogeneic Hematopoietic Stem Cell Transplant: A Systematic Review

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I

Hematology Disease Topics & Pathways: AML, Biological, Diseases, bone marrow, Non-Biological, Bone Marrow Failure, Therapies, Combinations, MDS, chemotherapy, infusion, Myeloid Malignancies, Clinically relevant, transplantation, stem cells

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Farwah N. Fatima, MBBS^{1*}, Muhammad Ashar Ali, MD^{2*}, Anum Javaid, MD^{3*}, Rimsha Ali^{3*}, Aqsa Mumtaz, MBBS^{2*}, Wajeeha Aiman, MD^{4*}, Nayab Mirza, MD^{2*}, Sana Khan, MBBS^{5*}, Hamza Hashmi, MD⁶ and Faiz Anwer, MD⁷

¹Lahore Medical and Dental College, Lahore, Pakistan

²King Edward Medical University, Lahore, Pakistan

³Rawalpindi Medical University, Rawalpindi, Pakistan

⁴Nishtar Medical University, Multan, Pakistan

⁵Shifa College of Medicine, Islamabad, Pakistan

⁶Department of Hematology/Medical Oncology, Medical University of South Carolina, Charleston, SC

⁷Taussig Cancer Institute, Cleveland Clinic, Cleveland

1504 Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant in the Pediatric Population: A Systematic Review

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I

Hematology Disease Topics & Pathways: Lymphoma (any), Diseases, Combinations, Therapies, Hodgkin Lymphoma, Pediatric, Non-Hodgkin Lymphoma, Adverse Events, B-Cell Lymphoma, DLBCL, T-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Mobeen Zaka Haider, MD, MBBS^{1*}, Zarlakhta Zamani, MBBS^{1*}, Muhammad Taqi, MBBS^{2*}, Hafsa Shahid^{1*}, Zahoor Ahmed, MD^{3*}, Hasan Mahmood Mirza^{4*}, Aneza Irfan, MD^{5*}, Khadija Noor Sami, MD^{6*}, Deepak Kumar, MD^{7*}, Fnu Kiran, MD^{8*}, Mydah Sajid Hashmi, MD^{9*} and Faiz Anwer, MD¹⁰

¹King Edward Medical University, Lahore, Pakistan

²Mayo Hospital, Lahore, Pakistan

³Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan

⁴Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, Boston, MA

⁵University of Missouri Kansas City, Kansas City

⁶Services Institute Of Medical Sciences, Lahore, Pakistan

⁷Jinnah Postgraduate Medical Center, Karachi, Pakistan

⁸Sindh institute of urology and transplantation, Karachi, Pakistan

⁹Army Medical College, Islamabad, Pakistan

¹⁰Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Moreland Hills, OH

1520 Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster I

Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Hemant S. Murthy, MD¹, Kwang Woo Ahn, PhD^{2,3*}, Noel Estrada-Merly, MS^{4*}, Lohith Gowda, MD⁵, Bhagirathbhai Dholaria, MBBS⁶, Susan Bal, MD, MBBS⁷, Hassan B. Alkhateeb, MD^{8*}, Deepa Jagadeesh, MD, MPH⁹, Betul Oran, MD, MS¹⁰, Ryotaro Nakamura, M.D.¹¹, Bart L. Scott, MD¹², Craig S. Sauter, MD¹³, Francine M. Foss, MD¹⁴, Mohamed A kharfan-Dabaja, MD, MBA¹⁵ and Wael Saber, MD, MS¹⁶

¹Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL

²Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI

³Department of Medicine, CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI

⁴CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI

⁵Hematology, Yale University School of Medicine, New Haven, CT

⁶Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical center, Nashville, TN

⁷O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL

⁸Division of Hematology, Mayo Clinic, Rochester, MN

⁹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH

¹⁰Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX

¹¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

¹²Fred Hutchinson Cancer Center, Seattle, WA

¹³Memorial Sloan Kettering Cancer Center, New York, NY

¹⁴Hematology, Yale Cancer Center, New Haven, CT

¹⁵Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

¹⁶CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

1561 Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster I

Hematology Disease Topics & Pathways: Technology and Procedures, Clinically relevant, Quality Improvement

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Ehsan Malek, MD¹, Jeries Kort, MD², Gi-Ming Wang, PhD^{3*}, Paolo F Caimi, MD⁴, Kirsten M Boughan, DO⁴, Stanton L. Gerson, MD⁵, Brenda W. Cooper, MD⁴, Molly M Gallogly, MD, PhD⁴, Benjamin K. Tomlinson, MD⁴, Marcos de Lima, MD⁴, Curtis Tatsuoka, PhD^{3*} and James Driscoll^{6*}

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

²University Hospitals Cleveland Medical Center, Cleveland, OH

³Department of Population and Quantitative Health Sciences, Case Western Reserve University, School of Medicine, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁶Case Western Reserve University, Cleveland, OH

1574 Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster I

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Pediatric, Hemoglobinopathies, Study Population

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Anna M Hood, PhD^{1*}, Heather Strong, PhD^{2*}, Cara Nwankwo, BA^{3*}, Yolanda Johnson, MLS^{4*}, Constance A Mara, PhD^{2*}, Lisa M Shook, DHPE^{5,6*}, William Brinkman, MD, MEd^{7*}, Francis J Real, MD, MEd^{7*}, Melissa Klein, MD, MEd^{7*}, Allison A. King, MD, MPH, PhD⁸, Cecelia Calhoun, MD⁹, Kim Smith-Whitley, MD¹⁰, Susan E Creary, MD^{11,12}, Maria T Britto, PhD^{13*}, Kay Linn Saving, MD^{14,15}, Connie M. Piccone, MD¹⁶, Jean L. Raphael, MD, MPH¹⁷, Emmanuel Volanakis, MD¹⁸, Aimee K Hildenbrand, PhD^{19*}, Steven K Reader, PhD^{20*}, Sohail Rana, MD^{21*}, Lynne D. Neumayr, MD²², Amber M Yates, MD^{23,24}, Sherif M. Badawy, MD^{25,26}, Alexis A. Thompson, MD^{27,28}, Amy Sobota, MD, MPH^{29,30}, Emily Riehm Meier, MD, MSHS³¹, Charles T. Quinn, MD^{6,32} and Lori E. Crosby, PhD³³

¹Great Ormond Street Institute of Child Health, University College London, Cincinnati, OH

²Division of Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, CINCINNATI, OH

³Oklahoma State University, Stillwater, OK

⁴3333 Burnet Ave, MLC 7039, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

⁵College of Medicine/Department of Pediatrics, University of Cincinnati, Cincinnati, OH

⁶Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

⁷Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH

⁸Washington University School of Medicine, St. Louis, MO

⁹Division of Pediatric Hematology/Oncology, Washington University School of Medicine in St Louis, St Louis, MO

¹⁰4th Floor Seashore House, Children's Hosp. of Phila. Division of Hematology, Philadelphia, PA

¹¹Center for Innovation in Pediatric Practice, Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH

¹²Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH

¹³Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

¹⁴Children's Hosp. of Illinois St. Francis Medical Center, Peoria, IL

¹⁵University of Illinois College of Medicine- Peoria, Peoria, IL

¹⁶University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH

¹⁷Center for Child Health Policy and Advocacy, Baylor College of Medicine, Houston, TX

¹⁸Vanderbilt University, Nashville, TN

¹⁹Center for Healthcare Delivery Science, Nemours Children's Health System, Wilmington, DE

²⁰Nemours Children's Health System, Wilmington

²¹Howard University, Washington DC, DC

²²Division of Hematology/Oncology, University of California San Francisco, Oakland, CA

²³Texas Children's Hospital, Houston, TX

²⁴Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX

²⁵Department of Pediatrics, Division of Hematology/Oncology/Stem Cell Transplant, Ann & Robert Lurie Children's Hospital, Chicago, IL

²⁶Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago

²⁷Northwestern University, Chicago, IL

²⁸Division of Hematology, Oncology & Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

²⁹Pediatric Hematology and Oncology, Boston Medical Center, Boston, MA

³⁰Pediatric Hematology/Oncology, Boston Medical Center / Boston University, Boston, MA

³¹Indiana Hemophilia and Thrombosis Center, Indianapolis, IN

³²Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

³³Cincinnati Children's Hospital, Cincinnati

1610 Outcomes of Cardiac Diffuse Large B-Cell Lymphoma in the Rituximab Era

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I

Hematology Disease Topics & Pathways: Adult, Study Population

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Taha Al-Juhaishi, MD¹, Ghaith Abu Zeinah, MD² and Sadeer Al-Kindi, M.D.^{3*}

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

²Richard T. Silver Myeloproliferative Neoplasms Center, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY

³Division of Cardiology, Harrington Heart and Vascular Institute, Case Western Reserve University and University Hospitals, Cleveland, OH

1611 Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, MDS, Myeloid Malignancies, transfusion, Quality Improvement

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Esther Natalie Oliva, MD¹, Uwe Platzbecker, MD², Guillermo Garcia-Manero, MD³, Ghulam J. Mufti, Professor^{4*}, Valeria Santini^{5*}, Mikkael A. Sekeres⁶, Rami S. Komrokji, MD⁷, Jeevan K. Shetty^{8*}, Derek Tang^{8*}, Shien Guo^{9*}, Weiqin Liao^{9*}, George Zhang^{8*}, Xianwei Ha^{8*}, Rodrigo Ito^{8*}, Jennifer Lord-Bessen^{8*}, Jay T. Backstrom^{10*} and Pierre Fenaux, MD, PhD¹¹

¹Grande Ospedale Metropolitano Bianchi Melacino Morelli, Reggio Calabria, Italy

²Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

³The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Department of Haemato-Oncology, King's College London, London, United Kingdom

⁵MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy

⁶Cleveland Clinic Foundation, Cleveland, OH

⁷Moffitt Cancer Center, Tampa, FL

⁸Bristol Myers Squibb, Princeton, NJ

⁹Evidera, Waltham, MA

¹⁰Acceleron Pharma, Cambridge, MA

¹¹Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France

1613 Early Mortality and Overall Survival in Acute Promyelocytic Leukemia: Do Real-World Data Match Results of the Clinical Trials?

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

Hematology Disease Topics & Pathways: AML, Biological, Adult, Diseases, bone marrow, Non-Biological, Therapies, chemotherapy, Pediatric, Young Adult, Study Population, Myeloid Malignancies, Clinically relevant, Quality Improvement, transplantation

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Prajwal Dhakal, MBBS¹, Elizabeth R. Lyden, MS^{2*}, Venkat Rajasurya, MD^{3*}, Krishna Gundabolu, MBBS⁴, Chakra P Chaulagain, MD⁵ and Vijaya R. Bhatt, MD¹

¹Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE

²Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE

³Multicare Health System, Puyallup, WA

⁴Division of Oncology and Hematology, University of Nebraska Medical Center- Fred & Pamela Buffett Cancer Center, Omaha, NE

⁵Department of Hematology and Oncology, Maroon Cancer Center, Cleveland Clinic Florida, Weston, FL

1617 Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect MDS/AML Disease Registry

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

Hematology Disease Topics & Pathways: AML, Diseases, MDS, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Tracy I. George, MD¹, Mehrdad Abedi, MD², Christopher R. Cogle³, Harry P. Erba⁴, Guillermo Garcia-Manero, MD⁵, David L. Grinblatt, MD⁶, Pavel Kiselev^{7}, Rami S. Komrokji, MD⁸, Chrystal U. Louis^{7*}, Jaroslaw P. Maciejewski, MD, PhD⁹, Melissa Nifenecker^{7*}, Daniel A. Pollyea¹⁰, Gail J. Roboz, MD¹¹, Michael R. Savona, MD¹², Bart L. Scott, MD¹³, Mikkael A. Sekeres⁹, David P. Steensma, MD¹⁴, Michael A. Thompson, MD, PhD¹⁵ and Jay L. Patel, MD^{1*}*

¹University of Utah and ARUP Laboratories, Salt Lake City, UT

²University of California, Davis, Comprehensive Cancer Center, Sacramento, CA

³University of Florida, Gainesville, FL

⁴Duke University, Durham, NC

⁵MD Anderson Cancer Center, Houston, TX

⁶NorthShore University HealthSystem, Evanston, IL

⁷Bristol Myers Squibb, Princeton, NJ

⁸Moffitt Cancer Center, Tampa, FL

⁹Cleveland Clinic, Cleveland, OH

¹⁰University of Colorado, Aurora, CO

¹¹Weill Medical College of Cornell University New York-Presbyterian Hospital, New York, NY

¹²Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

¹³Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁴Dana-Farber Cancer Institute, Boston, MA

¹⁵Advocate Aurora Health, Milwaukee, WI

1622 Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster I

Hematology Disease Topics & Pathways: Diseases, thrombocythemia, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Naveen Pemmaraju, MD¹, Aaron T. Gerds, MD, MS², Jingbo Yu, MD, PhD³, Shreekant Parasuraman, BPharm, PhD^{3}, Anne Shah^{4*}, Ann Xi, PharmD^{4*}, Shambhavi Kumar, MS^{4*}, Robyn M. Scherber, MD³ and Srdan Verstovsek, MD, PhD¹*

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Incyte Corporation, Wilmington, DE

⁴Avalere Health, Washington, DC

1629 Bleeding Outcomes of Gastrointestinal Cancer Patients Treated with Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster I

Hematology Disease Topics & Pathways: Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Dana E Angelini, MD¹, Doaa Attia, MD^{2}, Wei Wei, MS^{3*}, Mailey L Wilks, DNP, MSN, APRN^{2*}, Barbara Tripp, APRN, CNS^{2*}, Christopher D'Andrea, PA-C^{2*}, Keith R. McCrae, MD² and Alok A Khorana, MD²*

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Avon Lake, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

1640 Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I

Hematology Disease Topics & Pathways: Non-Biological, Combinations, Therapies, Biological Processes, Clinically relevant, multi-systemic interactions

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Vaishali Sanchorawala, MD¹, Giovanni Palladini, MD, PhD², Monique C. Minnema³, Arnaud Jaccard, MD, PhD^{4}, Hans C. Lee, MD⁵, Simon D. Gibbs, FRACP, FRCPA, MBBS^{6*}, Peter Mollee, FRACP, MBBS, MSc, FRCPA⁷, Christopher P. Venner, MD⁸, Jin Lu⁹, Stefan Schönland, MD^{10*}, Moshe Gatt, MD¹¹, Kenshi Suzuki, MD, PhD¹², Kihyun Kim, MD^{13*}, M. Teresa Cibeira, MD, PhD^{14*}, Meral Beksac, MD^{15*}, Edward Libby, MD¹⁶, Jason Valent, MD¹⁷, Vania T. M. Hungria, MD, PhD¹⁸, Sandy W. Wong, MD¹⁹, Michael Rosenzweig, MD²⁰, Naresh Bumma, MD²¹, Dominique Chauveau, MD, PhD^{22*}, Katharine S. Gries, PhD, PharmD^{23*}, John Fastenau, RPh, MPH, PhD^{23*}, NamPhuong Tran, MD^{24*}, Xiang Qin, MD, PhD^{24*}, Sandra Y. Vasey, MSc^{24*}, Brenda Tromp, MSc²⁵, Brendan M. Weiss, MD^{24*}, Jessica Vermeulen, MD, PhD²⁶, Giampaolo Merlini, MD^{27*}, Raymond L. Comenzo, MD²⁸, Efsthios Kastritis, MD^{29*} and Ashutosh D. Wechalekar, MBBS, FRCP, FRCPath, DM³⁰*

¹Section of Hematology and Oncology, Boston Medical Center and Boston University School of Medicine, Boston, MA

²Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

³University Medical Center Utrecht, Utrecht, Netherlands

⁴CHU de Limoges - Fédération Hépatologie, Limoges, France

⁵Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

⁶Box Hill Hospital, Box Hill, Australia

⁷Princess Alexandra Hospital, Woolloongabba, Australia

⁸Alberta Health Services, Edmonton, AB, Canada

⁹Peking University People's Hospital, Beijing, China

¹⁰Universitätsklinikum Heidelberg Medizinische Klinik V, Heidelberg, Germany

¹¹Hadassah Medical Center, Jerusalem, Israel

¹²Department of Hematology, Japanese Red Cross Central Medical Center, Tokyo, Japan

¹³Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South)

¹⁴Hospital Clinic of Barcelona, Barcelona, Spain

¹⁵Ankara Üniversitesi Tıp Fakültesi Cebeci Hastanesi, Ankara, Turkey

¹⁶Seattle Cancer Care Alliance, Seattle, WA

¹⁷Cleveland Clinic, Cleveland, OH

¹⁸São Germano Clinic, São Paulo, Brazil

¹⁹University of California, San Francisco, San Francisco, CA

²⁰City of Hope, Duarte, CA

²¹The Ohio State University, Columbus, OH

²²CHU Rangueil, Toulouse, France

²³Janssen Research & Development, LLC, Raritan, NJ

²⁴Janssen Research & Development, LLC, Los Angeles, CA

²⁵Janssen Research & Development, LLC, Leiden, Netherlands

²⁶Janssen Research & Development, LLC, Leiden, CB, Netherlands

²⁷Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy

²⁸Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

²⁹Alexandra General Hospital of Athens, Athens, Greece

³⁰University College Hospital, London, United Kingdom

1647 Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I

Hematology Disease Topics & Pathways: Leukemia, Adult, survivorship, Diseases, CLL, Lymphoid

Malignancies, Study Population, Clinically relevant, Quality Improvement

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Anna Eversman^{1*}, Shufen Cao^{1*}, Kirsten M Boughan, DO², Molly M Gallogly, MD, PhD², Ehsan Malek, MD³, Leland Metheny III, MD², Timothy E. O'Brien, MD², Folashade Otegbeye, MBBChir, MPH², Brenda W. Cooper, MD², Pingfu Fu^{1*}, Marcos de Lima, MD² and Paolo F Caimi, MD²

¹Case Western Reserve University, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

1663 Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Program: Oral and Poster Abstracts

Session: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Elderly, MDS, MPN, Study Population, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Gregory A. Abel, MD, MPH¹, Donnie Hebert, PhD^{2*}, Cecilia Lee, DrPH, RN^{3*}, James M. Foran, MD⁴, Steven D. Gore, MD⁵, Wael Saber, MD, MS⁶, Dana Elise Rollison, PhD^{7*}, Eric Padron, MD⁸, Steffanie H. Wilson, PhD^{9*}, Jason Thompson, MS, MBA^{9*}, Myron Wacławiw, PhD^{10*}, Nancy L. DiFronzo, PhD^{10*} and Mikkael A. Sekeres¹¹

¹Dana-Farber Cancer Institute, Boston, MA

²The Emmes Company, LLC, Hamburg, NY

³National Cancer Institute, Rockville, MD

⁴Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

⁵NIH/NCI Cancer Therapy Evaluation Program, Rockville, MD

⁶CIBMTR, Medical College of Wisconsin, Milwaukee, WI

⁷Moffitt Cancer Center and Research Institute, Tampa, FL

⁸Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

⁹The Emmes Company, LLC, Rockville, MD

¹⁰National Heart, Lung, and Blood Institute, National Institutes of Health, Division of Blood Diseases & Resources, Bethesda, MD

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1665 Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Program: Oral and Poster Abstracts

Session: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster I

Hematology Disease Topics & Pathways: Biological, Diseases, CML, Therapies, Myeloid Malignancies, Clinically relevant, TKI

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Sudipto Mukherjee, MD, PhD, MPH¹, Xiting Cao^{2*}, Islam Sadek^{2*}, Rodrigo Maegawa, MD^{2*}, Dominick Latremouille-Viau, MSc^{3*}, Irina Pivneva^{3*}, Annie Guerin^{3*} and B. Douglas Smith, MD⁴

¹Cleveland Clinic, Cleveland, OH

²Novartis Pharmaceuticals Corporation, East Hanover, NJ

³Analysis Group, Inc., Montreal, QC, Canada

⁴Division of Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD

1701 Effect of Nicotinamide, 1-Methylnicotinamide, and N'-Methylnicotinamide on Erythroid Colony Formation and γ -Globin Expression in Cultured Baboon CD34+ Cells

Program: Oral and Poster Abstracts

Session: 112. Thalassemia and Globin Gene Regulation: Poster II

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, thalassemia, Hemoglobinopathies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Donald Lavelle, PhD¹, Vinzon Ibanez, B.S.^{1*}, Kestis Vaitkus^{1*}, Yogenthiran Sauntharajah, MD² and Robert E. Molokie, MD^{3,4}

¹Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Jesse Brown VA Medical Center, Chicago, IL

⁴Department of Medicine, Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL

1711 Contribution of Red Blood Cell Derived Extracellular Vesicles to Sickle Red Blood Cell Adhesion Discerned Using an Endothelialized Microfluidic Assay

Program: Oral and Poster Abstracts

Session: 113. Hemoglobinopathies,

Excluding Thalassemia—Basic and Translational Science: Poster II

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, bioengineering,

Hemoglobinopathies, Technology and Procedures, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Ran An, PhD¹, Yuncheng Man^{1}, Erdem Kucukal, PhD^{1*}, Kevin Cheng^{1*}, William Wulftange^{1*}, Jane A. Little, MD² and Umut A. Gurkan, PhD¹*

¹Case Western Reserve University, Cleveland, OH

²University of North Carolina at Chapel Hill, Chapel Hill, NC

1730 The Grndad Registry: Contemporary Natural History Data and an Analysis of Real-World Patterns of Use and Limitations of Disease Modifying Therapy in Adults with SCD

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, Hemoglobinopathies, Study Population, Clinically relevant, Quality Improvement

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Alexandra Boye-Doe¹, Elizabeth Brown^{2}, Charu Puri-Sharma, MS^{3*}, Anjulika Chawla, MD³, Joshua J Field^{4*}, Lynne D. Neumayr, MD⁵, Susan Padrino, MD^{6*}, Payal Desai, MD⁷, Deepa Manwani, MD⁸, Sophie M. Lanzkron, MD, MHS⁹ and Jane A. Little, MD¹⁰*

¹Department of Medicine, University of North Carolina, Chapel Hill, NC

²Johns Hopkins University, Baltimore, MD

³bluebird bio, Cambridge, MA

⁴Bloodcenter of Wisconsin, Milwaukee, WI

⁵Dept. of Hematology/Oncology, UCSF Benioff Children's Hospital Oakland, Oakland, CA

⁶University Hospital Cleveland Medical Center, Cleveland, OH

⁷The Ohio State University, Columbus, OH

⁸Division of Pediatric Hematology/Oncology, Department of Pediatrics, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY

⁹Department of Medicine, Division of Hematology, Johns Hopkins Medicine, Baltimore, MD

¹⁰University of North Carolina at Chapel Hill, Chapel Hill, NC

1739 Clinical Outcomes of Malignancy-Related Neutropenic Fever Admissions in the United States: A 10-Year National Study

Program: Oral and Poster Abstracts

Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II

Hematology Disease Topics & Pathways: Diseases, white blood cells, Infectious Diseases, Cell Lineage, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Moataz Ellithi, MBBCh¹, Hafez M Abdullah, MD^{1}, Waqas Ullah, MD^{2*}, Radowan Elnair, MD³, Fouad Khalil, MD^{1*} and Faiz Anwer, MD⁴*

¹Department of Internal Medicine, University of South Dakota School of Medicine, Sioux Falls, SD

²Department of Internal Medicine, Abington Hospital - Jefferson Health, Abington, PA

³University of Nebraska Medical Center, Omaha, NE

⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1745 Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster II

Hematology Disease Topics & Pathways: Clinically relevant, Quality Improvement

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Augustine Hong, MD¹, Augusta Eduafo, DO^{2}, Hannah Schmikla, RN^{1*}, George Brown^{3*}, Gayathri Ravi, MD⁴, Marcos de Lima, MD⁵ and Ehsan Malek, MD⁶*

¹University Hospitals Cleveland Medical Center, Cleveland, OH

²Internal Medicine Department, St. John Medical Center, Cleveland, OH

³University Hospitals Cleveland Medical Center, Cleveland

⁴University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

1755 Acute Coronary Syndrome in Patients with Thrombotic Thrombocytopenic Purpura

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster II

Hematology Disease Topics & Pathways: apheresis, Diseases, Bleeding and Clotting, Technology and Procedures, TTP

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Moataz Ellithi, MBBCh¹, Fouad Khalil, MD^{1*}, Smitha N Gowda, MD^{1*}, Waqas Ullah, MD^{2*}, Radowan Elnair, MD³, Hafez M Abdullah, MD^{1*} and Faiz Anwer, MD⁴

¹Department of Internal Medicine, University of South Dakota School of Medicine, Sioux Falls, SD

²Department of Internal Medicine, Abington Hospital - Jefferson Health, Abington, PA

³University of Nebraska Medical Center, Omaha, NE

⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1797 BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study

Program: Oral and Poster Abstracts

Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II

Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Sanjay Ahuja, MD¹, Kathelijnn Fischer^{2*}, Tina Biss^{3*}, Monika Maas Enriquez^{4*}, Maria-Elisa Mancuso^{5*}, MacGregor Steele, MD, FRCPC⁶, Maria Wang^{7*} and Gili Kenet⁸

¹Case Western Reserve University, Cleveland, OH

²Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

³Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

⁴Bayer, Wuppertal, Germany

⁵Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, Italy

⁶Cumming School of Medicine, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada

⁷Bayer, Whippany, NJ

⁸Israel National Hemophilia Center and Thrombosis Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel

1817 Risk of Recurrent Venous Thromboembolism and Bleeding in Patients with Cancer Associated Thrombosis

Program: Oral and Poster Abstracts

Session: 332. Anticoagulation and Antithrombotic Therapy: Poster II

Hematology Disease Topics & Pathways: anticoagulant drugs, Diseases, Non-Biological, Bleeding and Clotting, Therapies, Thrombosis, Thromboembolism, VTE

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Doaa Attia, MD^{1*}, Xuefei Jia, MS^{2*}, Mailey L Wilks, DNP, MSN, APRN^{1*}, Barbara Tripp, APRN, CNS^{1*}, Christopher D'Andrea, PA-C^{1*}, Keith R. McCrae, MD³, Alok A Khorana, MD¹ and Dana E Angelini, MD¹

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

1819 Development and Baseline Characterization of a Thrombosis Risk Alert Tool: A Quality Assessment Project

Program: Oral and Poster Abstracts

Session: 332. Anticoagulation and Antithrombotic Therapy: Poster II

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Claire M Sathe, MD^{1*}, Chester Poon^{2*}, Debra M. M Sarasohn, MD^{3*}, Leah Gilbert^{4*}, Alok A Khorana, MD^{5,6}, Simon Mantha, MD, MPH⁷ and Gerald A. Soff, MD⁸

¹NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY

²Data Solutions Analyst, Memorial Sloan Kettering Cancer Center, New York, NY

³Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

⁴Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶Cleveland Clinic, Cleveland, OH

⁷Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY

⁸Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

1850 TET2 Inhibitory Effects of Eltrombopag Contribute its Hematopoietic Activity

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways: Anemias, Diseases, aplastic anemia, Bone Marrow Failure

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Yihong Guan, PhD^{1*}, Metis Hasipek, PhD^{1*}, Bhumika J. Patel, MD², Dale Grabowski, BS^{3*}, Anand D. Tiwari, PhD^{1*}, Sunisa Kongkiatkamon, MD^{1*}, Cassandra M Kerr, MS^{1*}, Aziz Nazha, MD⁴, Yogenthiran Sauntharajah, MD¹, Mikkael A. Sekeres, MD, MS⁵, Jaroslaw P. Maciejewski, MD, PhD⁵ and Babal K. Jha, PhD^{1*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1853 Targeting of Calbindin 1 (CALB1) Rescues Erythropoiesis in a Human Model of Diamond Blackfan Anemia: Implications for Novel Therapies

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, red blood cells, Cell Lineage

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Nan of Wang, PhD^{1*}, Corinne Marie Lavasseur, BA^{2*}, Hongxia Yan, MS^{3*}, Scott Younger, PhD^{4*}, Bertil Glader, MD, PhD^{5,6}, Kathleen M. Sakamoto, MD, PhD⁷, Lionel Blanc, PhD^{8,9} and Anupama Narla, MD^{7,10,11}

¹Department of Pediatrics - Division of Hematology/Oncology, Stanford University School of Medicine, Palo Alto, CA

²School of Medicine, Case Western Reserve University, Cleveland, OH

³Laboratory of Red Cell Physiology, New York Blood Center, New York, NY

⁴Children's Mercy Kansas City, Children's Mercy Research Institute, Kansas City, MO

⁵Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine, Stanford, CA

⁶Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA

⁷Department of Pediatrics, Stanford University School of Medicine, Stanford, CA

⁸Feinstein Institute for Medical Research, Manhasset, NY

⁹The Feinstein Institutes For Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY

¹⁰Stanford University, Stanford, CA

¹¹Stanford University, Hillsborough, CA

1866 Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Non-Biological, Therapies, chemotherapy, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

June Takeda, MD^{1}, Kenichi Yoshida, MD, PhD², Akinori Yoda, PhD^{3*}, Lee-Yung Shih, MD⁴, Yasuhito Nannya, MD, PhD¹, Yotaro Ochi, MD^{1*}, Ayana Kon, MD, PhD^{1*}, Kenichi Chiba^{5*}, Yuichi Shiraishi, PhD^{6*}, Yusuke Shiozawa, MD, PhD^{7*}, Tetsuichi Yoshizato, MD, PhD³, Cassandra M Kerr, MS^{8*}, Yasunobu Nagata, MD, PhD^{9*}, Toshiyuki Kitano, MD, PhD^{10*}, Akira Hangaishi, MD, PhD^{11*}, Ken Ishiyama, MD, PhD¹², Hisashi Tsurumi, MD, PhD¹³, Yasushi Miyazaki, MD, PhD¹⁴, Nobuhiro Hiramoto, MD^{15*}, Takayuki Ishikawa, MD, PhD¹⁵, Masahiro Marshall Nakagawa, MD, PhD³, Akifumi Takaori-Kondo, MD, PhD¹⁶, Shigeru Chiba, MD, PhD^{17*}, Hideyuki Nakazawa, MD, PhD^{18*}, Ming-Chung Kuo, M.D.^{4*}, Keisuke Kataoka, MD, PhD¹, Ryunosuke Saiki, MD^{3*}, Hiroko Tanaka^{19*}, Kensuke Usuki, MD, PhD¹¹, Shuichi Miyawaki, MD, PhD²⁰, Satoru Miyano, PhD^{6*}, **Jaroslav P. Maciejewski, MD, PhD⁹**, Arnold Ganzer²¹, Michael Heuser, Prof., MD^{22*}, Felicitas Thol²¹, Hideki Makishima, MD, PhD³ and Seishi Ogawa, MD, PhD^{3,23,24}*

¹Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

²Kyoto University, Kyoto, Japan

³Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

⁴Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan

⁵Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan

⁶The University of Tokyo, Human Genome Centre, Institute of Medical Science, Tokyo, Japan

⁷The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan

¹¹Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

¹²Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan

¹³Hematology, Gifu University Graduate School of Medicine, Gifu, Japan

¹⁴Atomic Bomb Disease Institute, Nagasaki University Hospital, Nagasaki, Japan

¹⁵Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan

¹⁶Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

¹⁷Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

¹⁸Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan

¹⁹Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan

²⁰Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, JPN

²¹Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

²²Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

²³Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden

²⁴Institute for the Advanced Study of Human Biology (WPI-ASHBI), Kyoto University, Kyoto, Japan

1918 Routine Laboratory Values Can Predict Therapy-Related Myeloid Neoplasms in Patients with New Cytopenias after Treatment for Breast Cancer

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Giulia Petrone, MD, MBBS¹, Charles Gaulin, MBBS^{2}, Andriy Derkach, PhD^{3*}, Sean M. Devlin, PhD^{3*}, Ashwin Kishtagari, MBBS⁴, Rekha Parameswaran, MD^{5*} and Eytan M. Stein, MD⁶*

¹Internal Medicine, Icahn School of Medicine/Mount Sinai Morningside and West Hospital, New York City, NY

²Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ

³Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY

⁶Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

1923 SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Biological Processes, Technology and Procedures, Myeloid Malignancies, flow cytometry, pathways

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Andrea Massimiliano Tomirotti, PhD^{1*}, Daniela Bellarosa^{2*}, Scott R. Solomon, MD³, Aziz Nazha, MD⁴, Stephen A Strickland, MD, MSCI⁵, Roland P Walter, MD PhD⁶, Farhad Ravandi, MBBS⁷, Krzysztof Brzózka, PhD⁸, Milena Mazan, PhD^{9*}, Simone Baldini, MD^{10*}, Massimiliano Salerno^{11*}, Monica Binaschi, PhD^{12*}, Dirk Laurent, MD^{13*} and Andrea Pellacani, PhD, MD^{14*}

¹Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia, Italy

²Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy

³Leukemia Program, Northside Hospital Cancer Center Institute, Atlanta, GA

⁴Cleveland Clinic, Cleveland

⁵Vanderbilt University Medical Center, Nashville, TN

⁶Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁷MD Anderson Cancer Center, Houston, TX

⁸Ryvu Therapeutics S.A., Cracow, Poland

⁹Ryvu Therapeutics, Cracow, Poland

¹⁰Menarini Ricerche S.p.A., Firenze, Italy

¹¹Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (RM), Italy

¹²Preclinical and Translational Sciences, Menarini Ricerche S.p.A., Pomezia (RM), Italy

¹³Menarini Ricerche/BERLIN-CHEMIE AG, Berlin, Germany

¹⁴Menarini Ricerche S.p.A., Firenze, Florence, Italy

1962 A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy,

Excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: AML, Adult, Diseases, Non-Biological, Therapies, Combinations, chemotherapy, Study Population, Myeloid Malignancies, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Aziz Nazha, MD¹, Sudipto Mukherjee, MD, PhD, MPH², Caitlin Siebenaller, PharmD^{3*}, Madeline Waldron, PharmD, BCOP^{4*}, Eric Parsons, RN^{5*}, Jenna Thomas^{5*}, Hetty E. Carraway, MD, MBA⁶, Dale Grabowski, BS^{7*}, Yihong Guan, PhD^{7*}, Aaron T. Gerds, MD, MS⁸, Bhumika J. Patel, MD⁹, Anjali S Advani, MD¹⁰, Jaroslaw P. Maciejewski, MD, PhD¹¹ and Mikkael A. Sekeres, MD, MS¹²

¹Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Pharmacy, Cleveland Clinic, Cleveland, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹⁰Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹²Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1990 Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD¹, Arda Durmaz^{2*}, Cassandra M. Kerr, MS^{3*}, Jaroslaw P. Maciejewski, MD, PhD³ and Valeria Visconte, PhD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Systems biology and Bioinformatics, CWRU, Cleveland

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2001 TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways: Biological, antibodies, AML, Adult, Diseases, Therapies, Biological Processes, Technology and Procedures, immunotherapy, Study Population, genetic profiling, Clinically relevant, Myeloid Malignancies, immune mechanism, microenvironment

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Catherine Lai, MD, MPH¹, Jayakumar Vadakekolathu, PhD^{2}, Stephen Reeder, BSc^{2*}, Sarah E. Church, PhD^{3*}, Carmen Ballesteros-Merino, PhD^{4*}, Ibrahim Aldoss, M.D.⁵, **Anjali S Advani, MD⁶**, John E. Godwin, MD⁷, Matthew J. Wieduwilt, MD, PhD⁸, Martha L. Arellano, MD⁹, Geoffrey L Uy, MD¹⁰, Farhad Ravandi, MBBS¹¹, Matthew C Foster, MD¹², Emmanuel Gyan, MD, PhD¹³, Patrick J. Stiff, MD¹⁴, Norbert Vey, MD¹⁵, Ashkan Emadi, M.D., Ph.D.¹⁶, Matteo Giovanni Carrabba, MD^{17*}, Roland B. Walter, MD, PhD, MS¹⁸, Peter H. Sayre, MD, PhD¹⁹, Kathy Tran^{20*}, Erin Timmeny^{21*}, Michael P. Rettig, PhD²², Patrick Kaminker, PhD^{20*}, John Muth, MS^{20*}, Kuo Guo, MSc^{23*}, Tung On Yau^{2*}, Peter J.M. Valk, PhD²⁴, Bob Lowenberg, MD, PhD²⁵, Ivana Gojo, MD²⁶, Martin Bornhäuser, MD^{27*}, John F. DiPersio, MD, PhD²⁸, Jan K Davidson-Moncada, MD, PhD²⁰ and Sergio Rutella, MD, PhD, FRCPath^{2,29}*

¹Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

²John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom

³NanoString Technologies, Inc., Seattle, WA

⁴Providence Cancer Center, Earl A. Chiles Research Institute, Portland, OR

⁵Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

⁶Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

⁷Providence Portland Medical Center, Portland, OR

⁸Moore's Cancer Center, University of California, San Diego, La Jolla, CA

⁹Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

¹⁰Washington University School of Medicine, Saint Louis, MO

¹¹Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

¹²Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

¹³Centre Hospitalier Universitaire, Service D'Hématologie Et Thérapie Cellulaire, Tours Cedex, France

¹⁴Loyola University Chicago Stritch School of Medicine, Maywood, IL

¹⁵Hématologie clinique, Institut Paoli Calmettes, Marseille, France

¹⁶University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

¹⁷Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

¹⁸Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁹University of California, San Francisco, San Francisco, CA

²⁰MacroGenics, Inc., Rockville, MD

²¹MacroGenics, Inc., ROCKVILLE, MD

²²Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO

²³MacroGenics, Inc., ROCKVILLE, MD

²⁴Erasmus University Medical Center, Rotterdam, Netherlands

²⁵Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

²⁶Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

²⁷Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany

²⁸Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

²⁹Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham, United Kingdom

2006 Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3) (q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD¹, Cassandra M Kerr, MS^{2}, Heesun J. Rogers, MD, PhD³, **Jaroslav P. Maciejewski, MD, PhD²** and Valeria Visconte, PhD¹*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Hematopathology, Cleveland Clinic, Cleveland

2023 Integrative DNA Methylation and Gene Expression Analysis Reveals Candidate Biomarkers Associated with Dichotomized Response to Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster II

Hematology Disease Topics & Pathways: Diseases, Non-Hodgkin Lymphoma, DLBCL, Biological Processes, Technology and Procedures, epigenetics, Lymphoid Malignancies, genetic profiling, genomics, integrative -omics, RNA sequencing

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Ellen K. Kendall, BA¹, Manishkumar S. Patel, PhD, MS, BPharm¹, Sarah Ondrejka, DO^{2*}, Agrima Mian, MBBS, MD^{3*}, Yazeed Sawalha, MD⁴, Bo Hu, PhD^{5*}, Eric D. Hsi, MD⁶, Brian T. Hill, MD³ and Neetu Gupta, PhD, MSc, BSc¹

¹Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH

²Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH

⁵Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁶Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

2027 Gene Expression and Epigenetic Analysis in Relapsed/Refractory Diffuse Large B Cell Lymphoma Provides Insights into Evolution of Treatment Resistance to R-CHOP

Program: Oral and Poster Abstracts

Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster II

Hematology Disease Topics & Pathways: Adult, Diseases, Therapies, Combinations, biopsy, Elderly, Non-Hodgkin Lymphoma, DLBCL, Biological Processes, Technology and Procedures, immune cells, epigenetics, Cell Lineage, Lymphoid Malignancies, Study Population, genomics, Clinically relevant, RNA sequencing

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Manishkumar S. Patel, PhD, MS, BPharm¹, Ellen K. Kendall, BA¹, Sarah Ondrejka, DO^{2*}, Agrima Mian, MBBS, MD^{3*}, Yazeed Sawalha, MD⁴, Bo Hu, PhD^{5*}, Eric D. Hsi, MD⁶, Brian T. Hill, MD³ and Neetu Gupta, PhD, MSc, BSc¹

¹Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH

²Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH

⁵Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁶Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

2046 Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Giselle K. Perez, PhD^{1*}, Fangxin Hong, PhD², Andrew M. Evens, DO, MMSc³, Thomas M. Habermann, MD⁴, Ranjana Advani, MD⁵, Stephen M. Ansell, MD, PhD⁶, Puneet S. Cheema, MD^{7*}, Philip A. Dy, MD^{8*}, Timothy E. O'Brien, MD⁹, Jane N. Winter, MD¹⁰, Julie E. Chang, MD¹¹, David Cella, PhD^{12*}, Brad S. Kahl, MD¹³ and Lynne I. Wagner, PhD^{14*}

¹Massachusetts General Hospital/Harvard Medical School, Boston, MA

²Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA

³Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

⁴Division of Hematology, Mayo Clinic, Rochester, MN

⁵Division of Oncology, Department of Medicine, Saul A. Rosenberg Professor of Lymphoma, Stanford Cancer Institute, Stanford, CA

⁶Mayo Clinic, Rochester, MN

⁷Saint John's Hospital, Maplewood, MN

⁸Cancer Care Specialists, Effingham, IL

⁹MetroHealth Medical Center, Cleveland, OH

¹⁰Division of Hematology and Oncology, Northwestern University, Chicago, IL

¹¹University of Wisconsin School of Medicine and Public Health, Madison, WI

¹²Northwestern University, Feinberg School of Medicine, Chicago, IL

¹³Washington University School of Medicine in St. Louis, Saint Louis, MO

¹⁴Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC

2049 Results of a Phase I Trial of Lenalidomide, Rituximab (R²) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Non-Biological, Therapies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Brian T. Hill, MD¹, Deepa Jagadeesh, MD, MPH², Alex V. Mejia Garcia, MD³, Robert M. Dean, MD³, Omer N. Koc, MD⁴, Matt Kalaycio, MD³, Kirsten M Boughan, DO^{5,6}, Brenda W. Cooper, MD⁵, Allison M. Winter, MD⁴, Wesam B. Ahmed, MD^{7*}, Brad Pohlman, MD⁴, Christopher D'Andrea, PA-C^{4*}, Kelsey Holkovic, RN^{4*}, Ashley Morrison, RN^{4*}, Paolo Caimi, MD⁵ and Mitchell R Smith, MD, PhD⁸

¹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

²Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH

³Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵University Hospitals Seidman Cancer Center, Cleveland, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁷Florida, Cleveland Clinic, Weston, FL

⁸George Washington University Cancer Center, Washington, DC

2059 A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, Lymphoma (any), Lymphoid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Sudipto Mukherjee, MD, PhD, MPH¹, Rabecka Martin, PhD^{2*}, Brenda Sande^{2*}, Chad Glen, PhD^{3*}, Jeremy Paige, MD, PhD^{3*}, Suresh Yarlagadda, MD, MPH^{3*} and David C Fajgenbaum, MD, MBA, MSc^{4,5}

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²EUSA Pharma, Boston, MA

³HVH Precision Analytics, Wayne, PA

⁴University of Pennsylvania, Philadelphia, PA

⁵Castleman Disease Collaborative Network, Philadelphia, PA

2126 A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II

Hematology Disease Topics & Pathways: Adult, Diseases, Lymphoma (any), drug-drug interaction, Therapies, Combinations, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Matthew J Cortese, MD, MPH¹, Wei Wei, MS^{2*}, Sebastian Cerdena, PharmD^{3*}, Marcus Watkins, PhD^{3*}, Marissa Olson, PharmD^{3*}, Gray Jodon, MD⁴, Jeff Kaiser, PharmD^{4*}, Bradley Haverkos, MD, MPH, MS^{4*}, Mitchell E. Hughes, PharmD^{5*}, Natalie S Grover, MD⁶, Anson Snow, MD⁶, Victor M. Orellana-Noia, MD⁷, Magdalena A Rainey, MS⁸, Mohammad Ahsan Sohail, MD^{8*}, Joslyn Rudoni, PharmD^{9*}, Craig A. Portell, MD⁷, Timothy J Voorhees, MD⁶, Daniel J. Landsburg, MD⁵, Manali Kamdar, MD, MDDS^{4*}, Brad S. Kahl, MD¹⁰ and Brian T. Hill, MD¹¹

¹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, South Euclid, OH

²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Barnes-Jewish Hospital, Washington University in St. Louis, St. Louis, MO

⁴University of Colorado Cancer Center, Aurora, CO

⁵Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁶Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

⁷Division of Hematology/Oncology, University of Virginia, Charlottesville, VA

⁸Cleveland Clinic, Cleveland, OH

⁹Department of Pharmacy, Cleveland Clinic, Cleveland, OH

¹⁰Division of Oncology, Washington University, St Louis, Washington University School of Medicine in St. Louis, Saint Louis, MO

¹¹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

2184 Molecular and Expression Characterization of Monosomy 7 and Del(7q)

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Vera Adema, PhD^{1*}, Cassandra M Kerr, MS^{1*}, Hassan Awada, MD¹, Sunisa Kongkiatkamon, MD^{2*}, Bhumika J. Patel, MD^{1,3}, Mikkael A. Sekeres, MD, MS⁴, Valeria Visconte, PhD¹, John Barnard^{5*}, Jaroslaw P. Maciejewski, MD, PhD^{1,6} and Torsten Haferlach, MD⁷

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland

⁷MLL Munich Leukemia Laboratory, Munich, Germany

2185 Co-Existence of Splicing Factor Mutations in Myeloid Malignancies

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, MDS, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Vera Adema, PhD^{1*}, Hassan Awada, MD^{2*}, Laila Terkawi^{1*}, Sunisa Kongkiatkamon, MD^{1*}, Cassandra M Kerr, MS^{1*} and Valeria Visconte, PhD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2187 Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, CMML, MDS, MPN, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Sunisa Kongkiatkamon, MD^{1,2*}, Yasunobu Nagata, MD, PhD^{3*}, Vera Adema, PhD^{4*}, Hassan Awada, MD², Misam Zawit, MD^{5*}, Laila Terkawi^{2*}, Simona Pagliuca, MD², Carmelo Gurnari, MD^{6*}, Cassandra M Kerr, MS^{2*}, Mikkael A. Sekeres, MD, MS⁷, Hetty E. Carraway, MD, MBA⁸, Yogenthiran Sauntharajah, MD², Bhumika J. Patel, MD⁹, Jaroslaw P. Maciejewski, MD, PhD³ and Valeria Visconte, PhD²

¹Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Houston, TX

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁷Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁸Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

2213 Three Fold Risk of Atrial Fibrillation in Ibrutinib Treated CLL Patients without Increased Risk of Stroke: A SEER-Medicare Database Analysis

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II

Hematology Disease Topics & Pathways: Leukemia, Adult, Diseases, CLL, Adverse Events, Lymphoid Malignancies, Study Population

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Akiva Diamond, MD¹, Wyatt P. Bensken, BS^{2*}, Weichuan Dong, Ph.D.^{2*}, Sarah C. Markt, ScD, MPH^{2*}, Siran M. Koroukian, Ph.D.^{2*} and Paolo Caimi, MD³

¹Dan L Duncan Comprehensive Cancer Center at Baylor St. Luke's Medical Center, Houston, TX

²Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH

³University Hospitals Seidman Cancer Center, Cleveland, OH

2277 Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: Biological, antibodies, CRS, Therapies, Adverse Events, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Jason Valent, MD¹, John Silowsky, RN BSN^{2*}, Michael R. Kurman, MD³, Eileen Daniel^{2*}, Janet Jobes^{2*}, Mark Harnett, MS^{4*}, Margaret Ziola, MD^{2*}, Jessica Roviwong^{2*}, Sherry Fada^{1*}, Michael Spector, BS^{2*} and Susan B. Sobolov, PhD^{2*}

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Caelum Biosciences, Bordentown, NJ

³Michael Kurman Consulting, LLC, Upper Saddle River, NJ

⁴Caelum Biosciences, Stow, MA

2281 Outcomes in AL Amyloidosis: A Single Institution Experience

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: Diseases, Therapies, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Diana Basali, MD^{1*}, Jennifer Tran, DO^{2*}, Wei Wei, MS^{3*}, Sherry Fada^{4*}, Brittany Lewis^{4*} and Jason Valent, MD⁴

¹Department of Internal Medicine, Cleveland Clinic, Pepper Pike, OH

²Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

³Cleveland Clinic, Cleveland, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2313 Maintenance Therapy in Newly Diagnosed and Transplant Ineligible Multiple Myeloma Patients: A Meta-Analysis

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: multiple myeloma, Biological, Diseases, Therapies, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Abdul Rafae, MD^{1*}, Ali Jaan, MD^{2*}, Zahoor Ahmed, MD^{3*}, Karun Neupane, MBBS, MD^{4*}, Sara Ashraf, MD^{5*}, Sundas Ali^{6*}, Sana Irfan Khan, MD^{7*}, Israr Khan^{8*}, Atif Irfan Khan, MD^{7*}, Ahsan Wahab, MD^{9*}, Rabia Ali, MBBS^{6*}, Sara Saeed, MBBS^{10*}, Mustafa Nadeem Malik, MD^{11*} and Faiz Anwer, MD¹²

¹Internal Medicine, McLaren Flint-Michigan State University, Flint, MI

²King Edward Medical University, Lahore, Pakistan

³Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan

⁴Manipal College of Medical Sciences, Pokhara, Nepal

⁵Sharif Medical and Dental College, Lahore, Pakistan

⁶Rawalpindi Medical University, Rawalpindi, Pakistan

⁷All India Institute Of Medical Sciences, Delhi, India

⁸Bolan Medical College, McDonough, GA

⁹Baptist Medical Center South, Montgomery, AL

¹⁰Wah Medical College, Wah, Pakistan

¹¹Internal Medicine, University of Arizona, Tucson, AZ

¹²Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

2314 Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: Combinations, Therapies, Adverse Events, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

David S. Siegel, MD¹, Gary J. Schiller, MD², Christy J. Samaras, DO³, Michael Sebag, MD, PhD, FRCPC⁴, Jesus G. Berdeja, MD⁵, Siddhartha Ganguly, MD^{6*}, Jeffrey V. Matous, MD⁷, Kevin W Song, MD, FRCPC⁸, Christopher S. Seet, MD, PhD², Mirelis Acosta-Rivera^{9*}, Michael Bar^{10*}, Donald P. Quick, MD¹¹, Bertrand M. Anz III, MD^{12*}, Gustavo A. Fonseca, MD¹³, Donna E. Reece, MD¹⁴, Kim Lee^{15*}, Weiyan Chung^{15*}, Amit Agarwal, MD, PhD¹⁵ and Nizar Bahlis, MD¹⁶

¹Hackensack Univ. Med. Ctr., Hackensack, NJ

²David Geffen School of Medicine at University of California, Los Angeles, CA

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Division of Hematology, McGill University Health Centre, Montreal, QC, Canada

⁵Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

⁶The University of Kansas Cancer Center, Fairway, KS

⁷Colorado Blood Cancer Institute, Denver, CO

⁸Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada

⁹Fundación de Investigación, San Juan, Puerto Rico

¹⁰Stamford Hospital, Stamford, CT

¹¹Joe Arrington Cancer Research and Treatment Center, Lubbock, TX

¹²Tennessee Oncology, Chattanooga, TN

¹³Florida Cancer Specialists, St Petersburg, FL

¹⁴Princess Margaret Cancer Centre, Toronto, ON, Canada

¹⁵Bristol Myers Squibb, Princeton, NJ

¹⁶Tom Baker Cancer Center, Calgary, AB, Canada

2373 Efficacy and Safety of Recombinant Thrombomodulin for the Prophylaxis of Vaso-Occlusive Complications in Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute

Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways: anticoagulant drugs, Bleeding and Clotting, Non-Biological, Therapies, Thrombotic Disorders

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Richi Kashyap, MD^{1}, Muhammad Ashar Ali, MD^{2*}, Taaha Muddassir Mirza, MBBS^{3*}, Anum Javaid, MD^{3*}, Aniq Raheem, MBBS^{4*}, Rohail Gul, MBBS^{5*}, Muhammad Tayyeb, MD^{6*}, Muhammad Yasir Anwar^{2*}, Abdul Jabbar Dar, MD^{7*}, Qasim Khurshid, MD^{8*}, Karun Neupane, MBBS, MD^{9*} and **Faiz Anwer, MD¹⁰***

¹Maulana Azad Medical College, New Delhi, India

²King Edward Medical University, Lahore, Pakistan

³Rawalpindi Medical University, Rawalpindi, Pakistan

⁴Shalamar Medical and Dental College, Lahore, Pakistan

⁵Shifa College of Medicine, Islamabad, Pakistan

⁶Department of internal medicine, King Edward Medical University, Lahore, Pakistan

⁷Shaikh Zayed Medical College, Lahore, Pakistan

⁸Xinjiang Medical University, Urumqi, China

⁹Manipal College of Medical Sciences, Pokhara, Nepal

¹⁰Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2377 Risk Factors, Mortality & Cost Analysis of Sinusoidal Obstructive Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways: Diseases, Pediatric, Study Population, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Archana Ramgopal, DO¹, James Zullo^{2*}, Jignesh Dalal, MD³, Meghan McCormick, MD⁴ and Ram Kalpathi, MD⁵

¹UPMC, Department of Pediatrics, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

²UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

³Rainbow Babies & Children's Hospital, Cleveland, OH

⁴Department of Pediatric Hematology/Oncology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

⁵Department of Pediatric Hematology/Oncology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

2382 Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways: Diseases, Non-Biological, neurotoxicity, Therapies, Adverse Events, chemotherapy, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Saad Javed, MD^{1*}, Tariq Iqtidar Sadiq Syed, MD^{2*}, Hejab Fatima, MBBS^{3*}, Syed Hashim Ali Inam, MBBS^{4*}, Tayyab Rehan, MBBS^{5*}, Syed Maaz Abdullah, MBBS^{6*}, Mohammed Musa Najmuddin, MBBS^{3*}, Mobeen Zaka Haider, MD, MBBS^{7*}, Karun Neupane, MBBS, MD^{8*}, Muhammad Khawar Sana, MD^{9*}, Abdul Jabbar Dar, MD^{10*}, Ali Jaan, MD^{11*}, Muhammad Ali Mirza, MD^{12*} and **Faiz Anwer, MD¹³**

¹Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Pakistan

²Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY

³Allama Iqbal Medical College, Lahore, Pakistan

⁴Internal Medicine, Army Medical College, Rawalpindi, Pakistan

⁵Nishtar Medical University, Multan, Pakistan

⁶King Edward Medical University, Lahore, Punjab, Pakistan

⁷King Edward Medical University, Sartell, MN

⁸Manipal College of Medical Sciences, Pokhara, Nepal

⁹Department of Internal Medicine, King Edward Medical University, Lahore, AL, Pakistan

¹⁰Shaikh Zayed Medical College, Lahore, Pakistan

¹¹King Edward Medical University, Lahore, Pakistan

¹²Department of Medicine, Frontier Medical And Dental College, Abbottabad, ON, Pakistan

¹³Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Moreland Hills, OH

2426 Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Hematology Disease Topics & Pathways: Leukemia, Biological, Diseases, Therapies, Lymphoid Malignancies, transplantation, stem cells

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Antonio M. Jimenez, MD, MSc^{1*}, Trent Wang, DO, MPH², **Marcos de Lima, MD³**, Krishna V Komanduri, MD⁴, Partow Kebriaei, MD⁵, Mark Litow, MD⁶, Vijaya Raj Bhatt, MBBS^{7*}, Frédéric Baron, MD, PhD⁸, Ayman Saad, MD, MSc^{9*}, Nandita Khera, MD¹⁰, Joseph Maakaron, MD^{9*}, Hemant S. Murthy, MD¹¹, Edward A Copelan¹², Zachariah Defilipp, MD¹³, Christopher Bredeson, MD, FRCPC, MSc¹⁴, Rodrigo Martino, MD^{15*}, Maxwell Krem^{16*}, Taiga Nishihori, MD¹⁷, Mei-Jie Zhang, PhD^{18,19*}, Daniel J. Weisdorf, MD²⁰, Karen Chen, MS^{21*} and Wael Saber, MD, MS²²

¹Section of Stem Cell Transplantation & Cell Therapy, Sylvester Cancer Center, University of Miami, Miami, FL

²Sylvester Comprehensive Cancer Center, Miami Springs, FL

³University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL

⁵Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

⁶Division of Hematology, Mayo Clinic, Rochester, MN

⁷University of Nebraska Medical Center, Omaha, NE

⁸Hematology Department, CHU and University of Liège, Liège, Belgium

⁹James Cancer Center, Ohio State Medical Center, Columbus, OH

¹⁰Department of Hematology/Oncology, Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, AZ

¹¹Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL

¹²Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

¹³Massachusetts General Hospital / Harvard Medical School, Boston, MA

¹⁴Hematology, The Ottawa Hospital General Campus, Ottawa, ON, Canada

¹⁵Department of Hematology, Hospital Sant Creu i Sant Pau, Barcelona, Spain

¹⁶Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY

¹⁷Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

¹⁸Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

¹⁹Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

²⁰Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN

²¹CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI

²²CIBMTR, Medical College of Wisconsin, Milwaukee, WI

2432 Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, MPN, Technology and Procedures, Myeloid Malignancies, Clinically relevant, transplantation

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Siddharth Jayant Kunte, MD¹, Lisa Rybicki, MS^{2*}, Auro Viswabandya, MD³, Asad Bashey, MD, PhD⁴, Madiha Iqbal, MBBS⁵, Michael R. Grunwald, MD⁶, Bhagirathbhai Dholaria, MBBS⁷, Hany Elmariah, MD, MS⁸, Michael Ozga, MD⁹, Anurag K. Singh, MD¹⁰, Sameem Abedin, MD¹¹, Vikas Gupta, MD, FRCP, FRCPATH¹², Amy E. DeZern, MD¹³, Richard J. Jones, MD¹³, **Aaron T. Gerds, MD, MS¹⁴** and Tania Jain, MD¹⁵

¹Cleveland Clinic, Cleveland, OH

²Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

³Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

⁴Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA

⁵Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL

⁶Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

⁷Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical center, Nashville, TN

⁸Moffitt Cancer Center, Tampa, FL

⁹The Ohio State University Wexner Medical Center, Columbus, OH

¹⁰Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

¹¹Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

¹²Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

¹³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

¹⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁵Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD

2469 A Deep Learning Framework for Sickle Cell Disease Microfluidic Biomarker Assays

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster II

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Niksa Praljak^{1,2*}, Brandon Shipley^{1*}, Ayesha Gonzales^{1*}, Utku Goreke, MSc^{1*}, Shamreen Iram^{1*}, Gundeep Singh^{1*}, Ailis Hill^{1*}, Umut A. Gurkan, PhD¹ and Michael Hinczewski, PhD^{1*}

¹Case Western Reserve University, Cleveland, OH

²Cleveland State University, Cleveland, OH

2485 Thrombocytopenia and Anemia Among Patients with Cerebral Palsy: A Big-Data Analysis

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster II

Hematology Disease Topics & Pathways: Anemias, Adult, Diseases, Pediatric, Biological Processes, Study Population, Clinically relevant, hematopoiesis

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Ioannis Milioglou, MD^{1*}, Sanjay P Ahuja, MD² and Nathan Richard Stehouwer, MD^{3*}

¹University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH

²University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, OH

³University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

2533 Health Care Burden of Monogammopathy of Renal Significance

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster II

Hematology Disease Topics & Pathways: Biological Processes, Clinically relevant, Quality Improvement

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Jeries Kort, MD¹, Paolo F Caimi, MD², Pingfu Fu, PhD^{3*}, Shufen Cao^{3*}, James Driscoll^{3*}, Marcos de Lima, MD² and Ehsan Malek, MD⁴

¹University Hospitals Cleveland Medical Center, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Case Western Reserve University, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

2563 Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II

Hematology Disease Topics & Pathways: Adverse Events, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Amin Firoozmand, MD^{1*}, Naveed Ali, MD², Nausheen Ahmed, MD^{3*}, Pingfu Fu^{4*}, Shufen Cao^{5*}, George Brown^{6*}, Hannah Schmikla, RN^{1*}, James J. Driscoll, MD, PhD⁷, Timothy O'Brien^{6*}, Paolo Caimi, MD^{8,9}, Marcos de Lima, MD^{8,10} and Ehsan Malek, MD^{11,12}

¹University Hospitals Cleveland Medical Center, Cleveland, OH

²Case Western Reserve University, University Heights, OH

³KANSAS UNIVERSITY, KANSAS, KS

⁴university hospitals cleveland medical center, cleveland

⁵Case Western Reserve University, Cleveland, OH

⁶University Hospitals Cleveland Medical Center, cleveland

⁷Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁸Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁹University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁰Adult Hematologic Malignancies & St, Cleveland, OH

¹¹University Hospitals Case Medical Center, Cleveland, OH

¹²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

2567 Age-Based Probability of Ten-Year Overall Survival (OS) of Acute Myeloid Leukemia (AML): A National Cancer Database (NCDB) Analysis

Program: Oral and Poster Abstracts

Session: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster II

Hematology Disease Topics & Pathways: AML, Adult, Diseases, Study Population, Myeloid Malignancies, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Vijaya R. Bhatt, MD¹, Valerie K Shostrom^{2*}, Nabin Khanal, MBBS³, Chakra P Chaulagain, MD⁴, Fiona He, MD⁵ and Krishna Gundabolu, MBBS⁶

¹Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE

²University of Nebraska Medical Center, Omaha, NE

³Franciscan Physician Network Oncology & Hematology Specialists, St Francis hospital, Indianapolis, IN

⁴Department of Hematology and Oncology, Maroon Cancer Center, Cleveland Clinic Florida, Weston, FL

⁵University of Minnesota, Minneapolis, MN

⁶Division of Oncology and Hematology, University of Nebraska Medical Center- Fred & Pamela Buffett Cancer Center, Omaha, NE

2577 Implication of Piga Genotype on Clinical Features of PNH

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III

Hematology Disease Topics & Pathways: Anemias, Diseases, Bone Marrow Failure, Biological Processes, PNH, genomics, pathogenesis

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Carmelo Gurnari, MD^{1,2*}, Simona Pagliuca, MD^{1,3}, Bhumika J. Patel, MD⁴, Hassan Awada, MD¹, Cassandra M Kerr, MS^{1*}, Sunisa Kongkiatkamon, MD^{1*}, Laila Terkawi^{1*}, Misam Zawit, MBBS^{1*}, Valeria Visconte, PhD¹, Adam Wahida^{5*} and Jaroslaw P. Maciejewski, MD, PhD⁶

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

³Université de Paris, Paris, France

⁴Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵MLL Munich Leukemia Laboratory, Munich, Germany

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2593 Efficacy and Safety of Amlodipine in Preventing Myocardial Iron Overload in Patients with Transfusion-Dependent Thalassemia Major: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts

Session: 102. Regulation of Iron Metabolism: Poster III

Hematology Disease Topics & Pathways: Non-Biological, Therapies, pharmacology

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Richi Kashyap, MD^{1*}, Muhammad Ashar Ali, MD^{2*}, Saad Ullah Malik, MD^{3*}, Farhan Khalid, MBBS^{2*}, Ali Jaan, MD^{2*}, Awais Khalid, MBBS^{2*}, Abdul Jabbar Dar, MD^{4*}, Qasim Khurshid, MD^{5*}, Karun Neupane, MBBS, MD^{6*}, Mobeen Zaka Haider, MD, MBBS^{2*}, Syed Maaz Abdullah, MBBS^{2*} and **Faiz Anwer, MD⁷**

¹Maulana Azad Medical College, New Delhi, India

²King Edward Medical University, Lahore, Pakistan

³Department of Internal Medicine, Joan C. Edward School of Medicine, Huntington

⁴Shaikh Zayed Medical College, Lahore, Pakistan

⁵Xinjiang medical university, Urumqi, China

⁶Manipal College of Medical Sciences, Pokhara, Nepal

⁷Taussig Cancer Institute, Cleveland Clinic, Cleveland

2603 Combinatorial Administration of Pharmacological Inhibitors Targeting DNMT1 and KDM1A Produces Synergistic and Additive Increases in F Reticulocytes and γ -Globin Expression in Normal Baboons

Program: Oral and Poster Abstracts

Session: 112. Thalassemia and Globin Gene Regulation: Poster III

Hematology Disease Topics & Pathways: Non-Biological, Therapies, Combinations, pharmacology

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Vinzon Ibanez, B.S.^{1,2*}, Kestis Vaitkus^{2*}, Robert E. Molokie, MD^{3,4}, Yogenthiran Saunthararajah, MD^{5,6} and Donald Lavelle, PhD^{2,7}

¹Department of Medicine, University of Illinois Chicago, Chicago, IL

²Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL

³Jesse Brown VA Medical Center, Chicago, IL

⁴Department of Medicine, Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL

⁵Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL

2610 Assessment of Red Blood Cell-Mediated Microvascular Occlusion in Sickle Cell Disease By a Novel Electrical Impedance-Based Microfluidic Device

Program: Oral and Poster Abstracts

Session: 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III

Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures, Study Population, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Yuncheng Man^{1*}, Debnath Maji, PhD^{1*}, Ran An, PhD¹, Sanjay P Ahuja, MD², Jane A. Little, MD³, Pedram Mohseni, PhD^{1*}, Michael A Suster, PhD^{1*} and Umut A. Gurkan, PhD¹

¹Case Western Reserve University, Cleveland, OH

²University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, OH

³University of North Carolina at Chapel Hill, Chapel Hill, NC

2756 Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways: Technology and Procedures, NGS, WGS

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Adam Wahida^{1*}, Stephan Hutter, PhD^{2*}, Manja Meggendorfer, PhD², Cassandra M. Kerr, MS^{3*}, Carmelo Gurnari, MD^{3*}, Elisabeth Weiss, PhD^{2*}, Claudia Haferlach, MD², Wolfgang Kern, MD², Jaroslav P. Maciejewski, MD, PhD⁴ and Torsten Haferlach, MD²

¹Torsten Haferlach Leukaemiediagnostik Stiftung, Munich, Germany

²MLL Munich Leukemia Laboratory, Munich, Germany

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2776 Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles

Program: Oral and Poster Abstracts

Session: 603. Oncogenes and Tumor Suppressors: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, MDS, MPN, Biological Processes, Myeloid Malignancies, genomics, pathogenesis

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Carmelo Gurnari, MD^{1,2*}, Vera Adema, PhD^{2*}, Hassan Awada, MD², Simona Pagliuca, MD^{2,3}, Cassandra M Kerr, MS^{2*}, Sunisa Kongkiatkamon, MD^{2*}, **Thomas Laframboise, PhD^{4*}**, Valeria Visconte, PhD², Maria Teresa Voso, MD¹, **Mikael A. Sekeres, MD, MS^{2,5}**, **Hetty E. Carraway, MD, MBA^{2,6}**, Torsten Haferlach, MD⁷ and **Jaroslav P. Maciejewski, MD, PhD⁸**

¹Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Université de Paris, Paris, France

⁴Genetics and Genome Sciences Department, Case Western Reserve University, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁷MLL Munich Leukemia Laboratory, Munich, Germany

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2778 Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine that are Non-Myelosuppressive

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III

Hematology Disease Topics & Pathways: AML, therapy sequence, CML, Diseases, Non-Biological, Therapies, Combinations, CMML, MDS, chemotherapy, MPN, Myeloid Malignancies, Clinically relevant, pharmacology

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Xiaorong Gu, PhD^{1*}, Rita Tohme, PhD^{2*}, Mendel Goldfinger, MD^{3*}, **Benjamin K. Tomlinson, MD^{4,5}**, Nneha Sakre, PhD^{6*}, Shannon Hanmer^{6*}, **Babal K. Jha, PhD^{1*}**, **Jaroslav P. Maciejewski, MD, PhD⁷**, Amit Verma, MBBS³ and **Yogenthiran Saunthararajah, MD¹**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

³Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Case Western Reserve University, Cleveland, OH

⁶Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2780 Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III

Hematology Disease Topics & Pathways: AML, Biological, Diseases, Therapies, MDS, enzyme inhibitors, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Simona Pagliuca, MD^{1,2}, Yihong Guan, PhD^{2*}, Anand D. Tiwari, PhD^{2*}, Dale Grabowski, BS^{2*}, Carmelo Gurnari, MD^{2,3*}, Cassandra M Kerr, MS^{2*}, Sunisa Kongkiatkamon, MD^{2,4*}, Metis Hasipek, PhD^{2*}, Laila Terkawi^{2*}, Misam Zawit, MBBS^{2*}, Hassan Awada, MD², Valeria Visconte, PhD², **Yogenthiran Saunthararajah, MD²**, **James G Phillips, PhD^{2*}**, **Jaroslav P. Maciejewski, MD, PhD⁵** and **Babal K. Jha, PhD^{2*}**

¹Université de Paris, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

⁴Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2817 Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways: AML, antibodies, Biological, CRS, Adult, Diseases, Therapies, Adverse Events, Biological Processes, Study Population, Myeloid Malignancies, Clinically relevant, TKI
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Geoffrey L Uy, MD¹, Michael P. Rettig, PhD², Stephanie Christ, MS^{3}, Ibrahim Aldoss, MD⁴, Michael T. Byrne, DO⁵, Harry P. Erba, MD, PhD⁶, Martha L. Arellano, MD⁷, Matthew C Foster, MD⁸, John E. Godwin, MD⁹, Farhad Ravandi, MBBS¹⁰, Peter H. Sayre, MD, PhD¹¹, **Anjali S Advani, MD¹²**, Matthew J. Wieduwilt, MD, PhD¹³, Ashkan Emadi, M.D., Ph.D.¹⁴, Laura C. Michaelis, MD¹⁵, Patrick J. Stiff, MD¹⁶, Martin Wermke^{17*}, Norbert Vey, MD¹⁸, Patrice Chevalier, MD, PhD^{19*}, Emmanuel Gyan, MD, PhD²⁰, Christian Recher, MD, PhD²¹, Fabio Ciceri, MD^{22*}, Matteo Giovanni Carrabba, MD^{23*}, Antonio Curti, MD PhD²⁴, Geert Huls, MD, PhD²⁵, Max S. Topp, MD²⁶, Mojca Jongen-Lavrencic, MD, PhD²⁷, John Muth, MS^{28*}, Teia Curtis^{29*}, Mary Beth Collins^{30*}, Erin Timmeny^{31*}, Kuo Guo, MSc^{32*}, Jian Zhao, PhD^{32*}, Kathy Tran^{28*}, Patrick Kaminker, PhD^{33*}, Priyanka Patel, PharmD^{30*}, Ouiam Bakkacha, MD^{34*}, Kenneth Jacobs, MD^{35*}, Maya Kostova, PhD^{32*}, Jennifer Seiler, PhD, RAC^{30*}, Bob Lowenberg, MD, PhD³⁶, Sergio Rutella, MD, PhD, FRCPath³⁷, Roland B. Walter, MD, PhD, MS³⁸, Ezio Bonvini, MD³³, Jan K Davidson-Moncada, MD, PhD³⁹ and John F. DiPersio, MD, PhD¹*

¹Washington University School of Medicine, Saint Louis, MO

²Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO

³Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

⁴Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

⁵Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

⁶University of Alabama at Birmingham, Birmingham, AL

⁷Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

⁸Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

⁹Providence Portland Medical Center, Portland, OR

¹⁰Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

¹¹University of California, San Francisco, San Francisco, CA

¹²Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

¹³Moore Cancer Center, University of California, San Diego, La Jolla, CA

¹⁴University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

¹⁵Division of Hematology/Oncology, Department of Medicine, The Medical College of Wisconsin Inc., Milwaukee, WI

¹⁶Loyola University Chicago Stritch School of Medicine, Maywood, IL

¹⁷NCT/UCC Early Clinical Trial Unit, University Hospital Carl Gustav Carus, Dresden, Germany

¹⁸Hematologie clinique, Institut Paoli Calmettes, Marseille, France

¹⁹Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France

²⁰CHU de Tours - Hôpital Bretonneau, Tours, France

²¹Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

²²Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

²³Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

²⁴Hematology/Oncology "L. e A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Bologna, Italy

²⁵Department of Hematology, University Medical Center Groningen, Groningen, GZ, Netherlands

²⁶Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany

²⁷Erasmus University Medical Center, Rotterdam, Netherlands

²⁸MacroGenics, Inc., Rockville, MD

²⁹MacroGenics, Inc., Frederick, MD

³⁰MacroGenics, Rockville

³¹MacroGenics, Inc., ROCKVILLE, MD

³²MacroGenics, Rockville, MD

³³MacroGenics, Rockville, MD

³⁴MacroGenics, Inc, ROCKVILLE, MD

³⁵MacroGenics, Inc, Rockville, MD

³⁶Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

³⁷John van Geest Cancer Centre School of Science and Technology, Nottingham Trent University, Nottingham, ENG, United Kingdom

³⁸Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

³⁹MacroGenics, Inc., Washington, DC

2840 Targeting NLRP3 Inflammasome-Induced Therapy Resistance in ALL

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: Leukemia, ALL, Non-Biological, Diseases, Therapies, chemical interactions, chemotherapy, Lymphoid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Zhongbo Hu, MD, PhD¹, Michael Sporn, MD^{2*} and John Letterio, MD^{3*}

¹Rainbow Babies and Children's Hospital, Cleveland, OH

²Dartmouth Medical School, Hanover, NH

³Department of Pediatrics, Case Western Reserve University, Cleveland, OH

2870 Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, Non-Biological, Therapies, chemical interactions, MDS, Biological Processes, DNA damage, DNA repair, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Lina Benajiba, MD, PhD^{1*}, Hetty E. Carraway, MD, MBA², Nada Hamad, MB.BS, FRACP, FRCPA^{3,4*}, Eytan M. Stein, MD⁵, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA^{6*}, Amy Burroughs^{7*}, Scott Harris^{7*}, Hayley Lane^{7*}, Dorothy D. Nguyen, MD^{7*}, Monic Stuart, MD, MPH⁷, Jesse Vargas, PhD⁸, Alexandre Puissant, PhD^{1*}, Kimberly Stegmaier, MD⁹ and Courtney D. DiNardo, MD, MSc¹⁰

¹APHP, INSERM U944, Institute of Hematology - St Louis Hospital, PARIS, France

²Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

³Department of Haematology, St. Vincent's Hospital, Sydney, NSW, Australia

⁴University of New South Wales, Sydney, Australia

⁵Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

⁶Department of Molecular Oncology and Cancer Immunology, Epworth HealthCare, East Melbourne, VIC, Australia

⁷Cleave Therapeutics, Inc., San Francisco, CA

⁸Cleave Therapeutics, Inc., San Diego, CA

⁹Dana-Farber Cancer Institute, Boston, MA

¹⁰Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2874 A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, MDS, Myeloid Malignancies, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Ahmed Aribi, MD^{1,2*}, Anjali S Advani, MD³, William Donnellan, MD⁴, Amir T. Fathi, M.D.⁵, Marcello Rotta, MD⁶, Benjamin K. Tomlinson, MD⁷, Pankit Vachani, MD^{8*}, Jay Yang, MD⁹, Phoenix Ho, MD¹⁰ and Guillermo Garcia-Manero, MD¹¹

¹Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

²City of Hope National Medical Center, Duarte, CA

³Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

⁴Tennessee Oncology / Sarah Cannon Research Institute, Nashville, TN

⁵Massachusetts General Hospital, Harvard Medical School, Cambridge, MA

⁶Sarah Cannon Blood Cancer Network, Colorado Blood Cancer Institute, Denver, CO

⁷Case Western Reserve University, Cleveland, OH

⁸University of Alabama-Birmingham, Birmingham, AL

⁹Karmanos Cancer Institute, Detroit, MI

¹⁰Seattle Genetics, Bothell, WA

¹¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2878 Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123xCD3 Bispecific DART Molecule, in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster III

Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, Biological Processes, Technology and Procedures, immunotherapy, Myeloid Malignancies, genetic profiling, Clinically relevant, immune mechanism, microenvironment

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Jayakumar Vadakekolathu, PhD^{1*}, Tung On Yau^{1*}, Sarah E. Church, PhD^{2*}, Michael P. Rettig, PhD³, Ibrahim Aldoss, M.D.⁴, Geoffrey L Uy, MD⁵, Norbert Vey, MD⁶, Ashkan Emadi, M.D., Ph.D.⁷, Peter H. Sayre, MD, PhD⁸, Roland B. Walter, MD, PhD, MS⁹, Matthew C Foster, MD¹⁰, Martha L. Arellano, MD¹¹, John E. Godwin, MD¹², Matthew J. Wieduwilt, MD, PhD¹³, Michael T. Byrne, DO¹⁴, Laura C. Michaelis, MD¹⁵, Patrick J. Stiff, MD¹⁶, Matteo Giovanni Carrabba, MD^{17*}, Patrice Chevalier, MD, PhD^{18*}, Emmanuel Gyan, MD, PhD¹⁹, Christian Recher, MD, PhD²⁰, **Anjali S Advani, MD²¹**, Martin Wermke^{22*}, Harry P. Erba²³, Fabio Ciceri, MD^{24*}, Geert Huls, MD, PhD²⁵, Mojca Jongen-Lavrencic, MD, PhD²⁶, Farhad Ravandi, MBBS²⁷, Antonio Curti, MD PhD²⁸, Max S. Topp, MD²⁹, John Muth, MS^{30*}, Patrick Kaminker, PhD^{30*}, Bob Lowenberg, MD, PhD³¹, Ivana Gojo, MD³², Leo Luznik, MD³², John F. DiPersio, MD, PhD⁵, Jan K Davidson-Moncada, MD, PhD³⁰ and **Sergio Rutella, MD, PhD, FRCPath^{1,33}**

¹John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom

²NanoString Technologies, Inc., Everett, WA

³Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO

⁴University of Southern California, Duarte, CA

⁵BMT and Leukemia Program, Department of Medicine, Washington University School of Medicine, Saint Louis, MO

⁶Hematologie clinique, Institut Paoli Calmettes, Marseille, France

⁷University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

⁸University of California, San Francisco, San Francisco, CA

⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁰Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

¹¹Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

¹²Providence Portland Medical Center, Portland, OR

¹³Moore's Cancer Center, University of California, San Diego, La Jolla, CA

¹⁴Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

¹⁵Division of Hematology/Oncology, Department of Medicine, The Medical College of Wisconsin Inc., Milwaukee, WI

¹⁶Loyola University Chicago Stritch School of Medicine, Maywood, IL

¹⁷Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

¹⁸Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France

¹⁹CHU de Tours - Hôpital Bretonneau, Tours, France

²⁰Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

²¹Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

²²NCT/UCC Early Clinical Trial Unit, University Hospital Carl Gustav Carus, Dresden, Germany

²³Duke University School of Medicine, Durham, NC

²⁴Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

²⁵Department of Hematology, University Medical Center Groningen, Groningen, GZ, Netherlands

²⁶Erasmus University Medical Center, Rotterdam, Netherlands

²⁷Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

²⁸Hematology/Oncology "L. e A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Bologna, Italy

²⁹Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany

³⁰MacroGenics, Inc., Rockville, MD

³¹Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

³²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

³³Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham, United Kingdom

2879 The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD¹, Arda Durmaz^{2*}, Carmelo Gurnari, MD^{3*}, Misam Zawit, MBBS^{1*}, Sunisa Kongkiatkamon, MD^{1*}, Simona Pagliuca, MD¹, Cassandra M. Kerr, MS^{4*}, Hetty E. Carraway, MD, MBA⁵, Aziz Nazha, MD⁶, Mikkael A. Sekeres, MD, MS⁷, Jaroslaw P. Maciejewski, MD, PhD⁴ and Valeria Visconte, PhD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Systems biology and Bioinformatics, CWRU, Cleveland

³Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

2884 Molecular Dissection of Normal Karyotype Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster III

Hematology Disease Topics & Pathways: Technology and Procedures, cytogenetics, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Jacob Shreve, BS, MD, MS¹, Manja Meggendorfer, PhD², Sudipto Mukherjee, MD, PhD, MPH³, Wencke Walter, PhD^{4*}, Stephan Hutter, PhD^{4*}, Ahed Makhoul, MD^{5*}, Nathan Radakovich, BA⁶, Hassan Awada, MD⁷, Yihong Guan, PhD^{7*}, Teodora Kuzmanovic, BA^{8*}, Jaroslaw P. Maciejewski, MD, PhD⁸, Claudia Haferlach, MD⁹, Mikkael A. Sekeres, MD, MS¹⁰, Torsten Haferlach, MD¹¹ and Aziz Nazha, MD¹²

¹Cleveland Clinic, Granger, IN

²MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴MLL Munich Leukemia Laboratory, Munich, Germany

⁵Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁶Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹¹MLL Munchner Leukamie Labor GmbH, Munchen, Germany

¹²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Quantitative Health Sciences, Avon Lake, OH

2934 Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Follicular Lymphoma, Biological, Adult, Diseases, Marginal Zone

Lymphoma, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, Lymphoid

Malignancies, Study Population, Clinically relevant, TKI, microenvironment, pathways

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Pier Luigi Zinzani, MD¹, Felipe Samaniego, MD², Wojciech Jurczak, MD, PhD³, Nilanjan Ghosh, MD, PhD⁴, Enrico Derenzini, MD, PhD^{5*}, James A Reeves, MD^{6*}, Wanda Knopinska-Posluszny, MD, PhD^{7*}, Chan Yoon Cheah, MBBS⁸, Tycel J. Phillips, MD⁹, Ewa Lech-Marañda, MD, PhD^{10*}, Bruce D. Cheson, MD¹¹, Paolo F Caimi, MD¹², Sebastian Grosicki, MD, PhD¹³, Lori A. Leslie, MD¹⁴, Julio C. Chavez, MD¹⁵, Gustavo A. Fonseca, MD¹⁶, Sunil Babu^{17*}, Daniel J. Hodson, MD, PhD¹⁸, Spencer H. Shao, MD¹⁹, John M. Burke, MD²⁰, Jeff P Sharman, MD²¹, Jennie Y. Law, MD²², John M. Pagel, MD PhD²³, Owen A. O'Connor, MD, PhD²⁴, Hari P. Miskin, MSc^{25*}, Peter Sportelli, BS²⁵, Michael S. Weiss^{25*} and Nathan H Fowler, MD²

- ¹Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy
- ²Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
- ³Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland
- ⁴Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC
- ⁵Hematology Division, European Institute of Oncology IRCCS, MILANO, Italy
- ⁶Florida Cancer Specialists South / Sarah Cannon Research Institute, Fort Myers, FL
- ⁷Gdynia Oncology Center, Gdynia, Poland
- ⁸Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
- ⁹University of Michigan Comprehensive Cancer Center, Dexter, MI
- ¹⁰Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
- ¹¹Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC
- ¹²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
- ¹³Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland
- ¹⁴John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
- ¹⁵H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
- ¹⁶Florida Cancer Specialists, St Petersburg, FL
- ¹⁷Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN
- ¹⁸Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
- ¹⁹Compass Oncology / US Oncology Research, Portland, OR
- ²⁰US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO
- ²¹Willamette Valley Cancer Institute and US Oncology Research, Eugene, OR
- ²²Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
- ²³Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
- ²⁴Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY
- ²⁵TG Therapeutics, Inc., New York, NY

2953 Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Diseases, Non-Biological, Mantle Cell Lymphoma, Therapies, Non-Hodgkin Lymphoma, Lymphoid Malignancies, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Yazeed Sawalha, MD¹, Subir Goyal, PhD^{2*}, Jeffrey M. Switchenko, PhD, MS^{3*}, Jason T. Romancik, MD⁴, Manali Kamdar, MD⁵, Irl Brian Greenwell, MD⁶, Brian T. Hess, MD⁷, Krista Isaac, DO, MS⁸, Craig A. Portell, MD⁹, Alex V. Mejia Garcia, MD¹⁰, Scott R. Goldsmith, MD¹¹, Natalie S Grover, MD¹², Peter A. Riedell, MD¹³, Reem Karmali, MD, MSc¹⁴, Madelyn Burkart, MD^{15*}, Michael J Buege, PharmD¹⁶, Othman S. Akhtar, MD¹⁷, Pallawi Torka, MD^{18*}, Anita Kumar, MD¹⁹, **Brian T. Hill, MD²⁰**, Brad S. Kahl, MD²¹ and Jonathon B. Cohen, MD, MS²²

- ¹Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
- ²Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA
- ³Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA
- ⁴Department of Hematology and Medical Oncology, Emory University - Winship Cancer Institute, Atlanta, GA
- ⁵Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Denver, CO
- ⁶Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
- ⁷Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC
- ⁸Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
- ⁹Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
- ¹⁰Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
- ¹¹Division of Oncology, Washington University, Rock Hill, MO
- ¹²Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
- ¹³Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
- ¹⁴Division of Hematology Oncology, Northwestern University, Chicago, IL
- ¹⁵Northwestern University; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, IL
- ¹⁶Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY
- ¹⁷Department of Medicine, State University of New York at Buffalo, Buffalo, NY
- ¹⁸Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
- ¹⁹Department of Medicine, Lymphoma Service, Memorial Sloan Kettering, Short Hills, NJ
- ²⁰Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
- ²¹Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO
- ²²Winship Cancer Institute, Emory University, Atlanta, GA

2976 Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Biological, Diseases, Non-Biological, Therapies, chemotherapy, T-Cell Lymphoma, immunotherapy, Lymphoid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Deepa Jagadeesh, MD, MPH¹, Robert B. Sims, MD² and Steven M. Horwitz, MD³

¹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH

²Seattle Genetics, Inc., Bothell, WA

³Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

2981 Pharmacokinetic and Pharmacodynamic Correlates from the Phase I Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Joseph Boni^{1*}, Karin Havenith^{2*}, Mehdi Hamadani, MD³, **Paolo F Caimi, MD⁴**, Katie Anderson^{2*}, Tim Kopotsha^{2*}, Hans G Cruz⁵ and Jens Wuerthner^{5*}

¹Clinical Development, ADC Therapeutics America, Inc., Murray Hill, NJ

²Clinical Research, ADC Therapeutics (UK) Ltd, London, United Kingdom

³Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

⁴University Hospitals of Cleveland, Cleveland, OH

⁵Clinical Development, ADC Therapeutics SA, Epalinges, Switzerland

2992 Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) – Updated Data from the Phase 2 ACE-536-MF-001 Study

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MPN, erythropoiesis, Myeloid Malignancies, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Aaron T. Gerds, MD, MS¹, Alessandro M. Vannucchi, MD², Francesco Passamonti^{3*}, Marina Kremianskaya⁴, Jason Gotlib, MD MS^{5*}, Jeanne M. Palmer, MD⁶, Kelly McCaul^{7*}, Vincent Ribrag, MD⁸, Adam J. Mead, MD, PhD⁹, Claire Harrison, DM, FRCP, FRCPath¹⁰, Ruben Mesa, MD¹¹, Jean-Jacques Kiladjian¹², Giovanni Barosi¹³, Torsten G. Geike^{14*}, Jeevan K. Shetty^{15*}, Joseph Pariseau^{14*}, Gabriel Miranda^{14*}, Martin Schwickart^{14*}, Ana Carolina Giuseppe^{14*}, Jennie Zhang^{14*}, Jay T. Backstrom^{16*} and Srdan Verstovsek, MD, PhD¹⁷

¹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Florence, Italy

³Department of Medicine and Surgery, University of Insubria, Varese, Italy

⁴Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY

⁵Stanford Cancer Institute, Stanford, CA

⁶Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

⁷Avera Cancer Institute, Sioux Falls, SD

⁸Institut Gustave Roussy, Villejuif, France

⁹Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

¹⁰Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom

¹¹Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX

¹²Hôpital Saint-Louis et Université Paris Diderot, Paris, France

¹³IRCCS Policlinico San Matteo Foundation, Pavia, Italy

¹⁴Bristol Myers Squibb, Princeton, NJ

¹⁵Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

¹⁶Acceleron Pharma, Cambridge, MA

¹⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3080 Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

Hematology Disease Topics & Pathways:

Diseases, Polycythemia vera, Technology and Procedures, Myeloid Malignancies, NGS

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Francesco Passamonti^{1*}, Kate Burbury, MBBS, FRACP, FRCPA, DPhil^{2*}, Tarek Christoffer El-Galaly³, **Aaron T. Gerds, MD, MS⁴**, Vikas Gupta, MD, FRCP, FRCPath⁵, Brian Higgins^{6*}, Ling-Yuh Huw, PhD^{6*}, Margherita Maffioli, MD^{7*}, Ruben Mesa, MD⁸, Jeanne M. Palmer, MD⁹, Alessandro Rambaldi, MD¹⁰, David M Ross, MBBS, PhD, FRACP, FRCPA^{11*}, Alessandro M. Vannucchi, MD¹², Abdulraheem Yacoub, MD¹³ and John Mascarenhas, MD¹⁴

¹Università Degli Studi Dell'Insubria, Varese, VA, Italy

²Peter MacCallum Cancer Centre, Melbourne, Australia

³F. Hoffmann-La Roche, Ltd., Basel, Switzerland

⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Princess Margaret Cancer Centre, Toronto, ON, Canada

⁶Genentech, Inc., South San Francisco, CA

⁷ASST Sette Laghi, Ospedale di Circolo, Varese, ITA

⁸UT Health San Antonio Cancer Center, San Antonio, TX

⁹Mayo Clinic, Phoenix, AZ

¹⁰Department of Oncology and Hematology University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

¹¹Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia

¹²Azienda Ospedaliero Universitaria Careggi, Firenze, Italy

¹³The University of Kansas Cancer Center, Leawood, KS

¹⁴Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

3100 Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and are Associated with Increased Circulating Burden of Microbial DNA

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, Bone Marrow Failure, CMML, MDS, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Sunisa Kongkiatkamon, MD^{1,2*}, Samuel Li, BA^{3*}, Tatiana Dombrowski^{4*}, Laila Terkawi^{2*}, Cassandra M Kerr, MS^{5*}, Vera Adema, PhD^{2*}, Yasunobu Nagata, MD, PhD^{6*}, Wencke Walter, PhD^{7*}, Hassan Awada, MD^{5*}, Bartłomiej Przychodzen^{8*}, Stephan Hutter, PhD^{7*}, Carmelo Gurnari, MD^{8*}, Simona Pagliuca, MD², Manja Meggendorfer, PhD⁹, Claudia Haferlach, MD¹⁰, Valeria Visconte, PhD², Torsten Haferlach, MD¹¹, **Jaroslav P. Maciejewski, MD, PhD⁵** and **Thomas LaFramboise, Ph.D.^{4*}**

¹Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁴Department of Genetics and Genome Sciences Case Western Reserve University School of Medicine, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Cleveland, Ohio

⁷MLL Munich Leukemia Laboratory, Munich, Germany

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁹MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

¹⁰MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany

¹¹MLL Munchner Leukamie Labor GmbH, Munchen, Germany

3106 The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD¹, **Cassandra M. Kerr, MS^{2*}**, **Vera Adema, PhD^{2*}**, **Carmelo Gurnari, MD^{3*}**, **Simona Pagliuca, MD¹**, **Heesun J. Rogers, MD, PhD⁴**, **Hetty E. Carraway, MD, MBA⁵**, **Mikael A. Sekeres, MD, MS⁶**, **Jaroslav P. Maciejewski, MD, PhD²** and **Valeria Visconte, PhD¹**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland, OH

⁴Department of Hematopathology, Cleveland Clinic, Cleveland

⁵Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3111 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the MEDALIST Study

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, MDS, MPN, Clinically relevant, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Rami S. Komrokij, MD¹, **Uwe Platzbecker, MD²**, **Pierre Fenaux, MD, PhD³**, **Guillermo Garcia-Manero, MD⁴**, **Ghulam J. Mufti, Professor^{5*}**, **Valeria Santini^{6*}**, **Maria Diez-Campelo, PhD, MD^{7*}**, **Carlo Finelli^{8*}**, **Joseph G. Jurcic, MD⁹**, **Peter L. Greenberg¹⁰**, **Mikael A. Sekeres¹¹**, **Amer M. Zeidan, MBBS, MHS¹²**, **Amy E. DeZern, MD¹³**, **Michael R. Savona, MD¹⁴**, **Jeevan K. Shetty^{15*}**, **Rodrigo Ito^{16*}**, **George Zhang^{16*}**, **Xianwei Ha^{16*}**, **Daniel Sinsimer^{16*}**, **Jay T. Backstrom^{17*}** and **Amit Verma, MBBS¹⁸**

¹Moffitt Cancer Center, Tampa, FL

²Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

³Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris, France

⁴Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

⁵Department of Haemato-Oncology, King's College London, London, United Kingdom

⁶MDS Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, FI, Italy

⁷Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain

⁸Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy

⁹Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

¹⁰Stanford University Cancer Institute, Stanford, CA

¹¹Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹²Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

¹³The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

¹⁴Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

¹⁵Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

¹⁶Bristol Myers Squibb, Princeton, NJ

¹⁷Acceleron Pharma, Cambridge, MA

¹⁸Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

3137 A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: Biological, Therapies, Combinations, Clinically relevant, TKI

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Paul M. Barr, MD¹, **Shuo Ma, MD, PhD²**, **Clive S. Zent, MD¹**, **Andrea M. Baran, MS^{1*}**, **Andrew Bui^{1*}**, **Philip J Meacham, PhD^{1*}**, **Ashley Morrison, RN^{3*}**, **Kelsey Holkovic, RN^{3*}**, **Jane L. Liesveld, MD¹**, **Deborah A Mulford, MD^{1*}**, **Peter Sportelli, BS⁴**, **Hari P. Miskin, MSc^{4*}**, **Michael S. Weiss^{4*}**, **Jonathan W. Friedberg, MD, MSc¹** and **Brian T. Hill, MD³**

¹Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

²Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

³Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴TG Therapeutics, Inc., New York, NY

3149 The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: Leukemia, Adult, CLL, Non-Biological, Diseases, Therapies, Study Population, Lymphoid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Max J. Gordon, MD¹, Andy Kaempfer, MS^{2*}, Andrea Sitlinger, MD³, Tareq Salous^{4*}, Hamood Alqahtani, MBBS^{5*}, Michael C. Churnetski^{6*}, Paul Wisniewski, BS^{7*}, Xavier Issac Rivera, BS^{8*}, Krish Patel, MD⁷, Daniel O. Persky, MD⁹, Jonathon B. Cohen, MD, MS¹⁰, Michael Y. Choi, MD¹¹, **Brian T. Hill, MD¹², Mazyar Shadman, MD¹³, Deborah M. Stephens, DO¹⁴, Danielle M. Brander, MD¹⁵, Byung Park, PhD^{16*} and Alexey Danilov, MD¹⁷**

¹MD Anderson Cancer Center, Houston, TX

²Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR

³Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC

⁴Cleveland Clinic, Cleveland, OH

⁵Moore's Cancer Center at UC San Diego, San Diego, CA

⁶Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

⁷Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

⁸University of Arizona, Tucson, AZ

⁹Division of Hematology/Oncology, University of Arizona, Tucson, AZ

¹⁰Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

¹¹University of California-San Diego, San Diego, CA

¹²Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹³Uw/Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁴University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, Salt Lake City, UT

¹⁵Duke University, Durham, NC

¹⁶Oregon Health and Science University, Portland, OR

¹⁷Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

3191 A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells by Targeting Protein Disulfide Isomerase

Program: Oral and Poster Abstracts

Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III

Hematology Disease Topics & Pathways: apoptosis, Diseases, Biological Processes, Technology and Procedures, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Metis Hasipek, PhD^{1*}, Dale Grabowski, BS^{1*}, Yihong Guan, PhD^{1*}, Anand D. Tiwari, PhD^{1*}, Xiaorong Gu, PhD^{1*}, Jason Valent, MD², **Jaroslav Maciejewski, PhD^{1*}, Frederic Joel Reu³, **James G Phillips, PhD^{1*}** and **Babal K. Jha, PhD^{1*}****

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC, Tampa, FL

3281 Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Program: Oral and Poster Abstracts

Session: 711. Cell Collection and Processing: Poster III

Hematology Disease Topics & Pathways: HSCs, Diseases, Plasma Cell Disorders, Cell Lineage, Lymphoid Malignancies, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Anne K Hubben, MD¹, Lisa Rybicki, MS^{2*}, Kristin Ricci, MD^{2*}, Navneet S. Majhail, MD, MS³, Matt Kalaycio, MD², Betty K. Hamilton, MD³, Brian T. Hill, MD², Allison M. Winter, MD⁴, Brad Pohlman, MD⁴, Deepa Jagadeesh, MD, MPH², Faiz Anwer, MD⁴, Robert M. Dean, MD², Ronald Sobecks, MD², Chakra P Chaulagain, MD⁵, Hien D. Liu, MD⁶ and Jack Khouri, MD⁴

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Oncology, Maroon Cancer Center, Cleveland Clinic Florida, Weston, FL

⁶Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

3305 Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster III

Hematology Disease Topics & Pathways: Biological, Non-Biological, Therapies, chemotherapy, transplantation, stem cells

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Sagar S. Patel, MD¹, Kwang Woo Ahn, PhD^{2,3*}, Manoj Khanal, BS, MS^{2*}, Caitrin Fretham, MPH^{4*}, Celalettin Ustun, MD⁵, Betty K. Hamilton, MD⁶, Navneet S. Majhail, MD, MS⁶, Shin Mineishi, MD⁷, Bipin N. Savani, MD⁸, Mohamed Sorrow, MD, MSc^{9,10*}, Edward A. Stadtmauer, MD, FACP¹¹, Brent Logan, PhD^{2,3*}, Marcelo C. Pasquini, MD, MS^{12,13} and Saurabh Chhabra, MD, MS^{14,15}

¹Blood and Marrow Transplant Program, University of Utah Health, Salt Lake City, UT

²Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

³Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI

⁴National Marrow Donor Program/Be The Match, Minneapolis, MN

⁵Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL

⁶Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁷Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA

⁸Department of Medicine, Division of Hematology-Oncology, Vanderbilt University, Brentwood, TN

⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁰Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA

¹¹University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

¹²CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

¹³Froedtert & The Medical College Cancer Ctr., Milwaukee, WI

¹⁴Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI

¹⁵Medical College of Wisconsin, Milwaukee, WI

3345 Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster III

Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Guru Subramanian Guru Murthy, MD^{1*}, Soyoung Kim^{2,3*}, Zhen-Huan Hu, MPH^{4*}, Noel Estrada-Merly, MS^{5*}, Ryotaro Nakamura, M.D.⁶, Betul Oran, MD, MS⁷, Bart L. Scott, MD⁸, Ronald Sobecks, MD⁹ and Wael Saber, MD, MS¹⁰

¹Medical College of Wisconsin, Milwaukee, WI

²Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

³Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

⁴CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁵CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI

⁶Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

⁷Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX

⁸Fred Hutchinson Cancer Research Center, Seattle, WA

⁹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹⁰CIBMTR, Medical College of Wisconsin, Milwaukee, WI

3361 Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster III

Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Sanghee Hong, MD¹, Lisa Rybicki, MS^{2*}, Linda McLellan, LISW^{2*}, Jane Dabney, LISW-S^{2*}, Aaron T. Gerds, MD, MS², Seth J Rotz, MD^{2*}, Matt Kalaycio, MD², Rabi Hanna, MD², Betty K. Hamilton, MD³, Navneet S. Majhail, MD, MS³ and Ronald Sobecks, MD⁴

¹University Hospitals/ Case Western Reserve University, Cleveland, OH

²Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁴Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

3470 Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster III

Hematology Disease Topics & Pathways: Diseases, Hodgkin Lymphoma, Pediatric, Young Adult, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Sharon M. Castellino, MD, MSc^{1,2,3}, Angela Punnett, MD^{4*}, Susan K Parsons, MD, MRP⁵, Nicholas P. DeGroote, MPH^{2*}, Sally Muehle^{6*}, Hongli Li, MS^{7*}, Michael E. Roth, MD^{8*}, Alex F. Herrera, MD⁹, Jonathan W. Friedberg, MD, MSc¹⁰, Nita L. Seibel, MD¹¹ and Kara M. Kelly, MD¹²

¹Aflac Cancer and Blood Disorders Center, Emory University School of Medicine / Children's Healthcare of Atlanta, Atlanta, GA

²Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA

³Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

⁴Hospital for Sick Children, Toronto, ON, Canada

⁵Tufts Medical Center, Tufts University School of Medicine, Boston, MA

⁶University Hospital- Rainbow Babies and Children's, Cleveland, OH

⁷SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

⁸MD Anderson Cancer Center, Houston, TX

⁹City of Hope, Duarte, CA

¹⁰Division of Hematology/Oncology, University of Rochester, Rochester, NY

¹¹Cancer Therapy Evaluation Prgm., NCI, Bethesda, MD

¹²Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

3381 Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster III

Hematology Disease Topics & Pathways: Diseases, CMML, MDS, MPN, Myeloid Malignancies, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Nathan Radakovich, BA¹, Luca Malcovati, MD², Manja Meggendorfer, PhD³, Mikkael A. Sekeres, MD, MS⁴, Jacob Shreve, BS, MD, MS⁵, Cameron Beau Hilton, MD⁶, Yazan Rouphail^{7*}, Wencke Walter, PhD^{8*}, Stephan Hutter, PhD^{8*}, Anna Galli^{9*}, Sarah Pozzi^{10*}, Aaron T. Gerds, MD, MS¹¹, Sudipto Mukherjee, MD, PhD, MPH¹², Cassandra M Kerr, MS^{13*}, Babal K. Jha, PhD^{13*}, Claudia Haferlach, MD¹⁴, Jaroslaw P. Maciejewski, MD, PhD¹⁵, Torsten Haferlach, MD¹⁶ and Aziz Nazha, MD¹⁷

- ¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA
²Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi 2, Pavia, Italy
³MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany
⁴Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁵Cleveland Clinic, Cleveland, OH
⁶Department of Internal Medicine, Vanderbilt University, Nashville, TN
⁷Ohio State University, Rocky River, OH
⁸MLL Munich Leukemia Laboratory, Munich, Germany
⁹Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
¹⁰Centro Cellule Staminali E Terapia Cellulare, Genova, ITA
¹¹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
¹²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
¹³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
¹⁴MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany
¹⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
¹⁶MLL Munchner Leukamie Labor GmbH, Munchen, Germany
¹⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Quantitative Health Sciences, Avon Lake, OH

3383 Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, Technology and Procedures, Clinically relevant, genetic profiling, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Yazan Rouphail^{1*}, Nathan Radakovich, BA², Jacob Shreve, BS, MD, MS³, Sudipto Mukherjee, MD, PhD, MPH⁴, Babal K. Jha, PhD^{5*}, Jaroslaw P. Maciejewski, MD, PhD⁶, Mikkael A. Sekeres, MD, MS⁷ and Aziz Nazha, MD⁸

- ¹Ohio State University, Rocky River, OH
²Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA
³Cleveland Clinic, Cleveland, OH
⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁷Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Quantitative Health Sciences, Avon Lake, OH

3405 Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting, Therapies, ITP, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Adam Cuker, MD^{1*}, Jenny M. Despotovic, DO^{2*}, Rachael F. Grace, MD^{3,4}, Caroline Kruse^{5*}, Michele P. Lambert, MD, MSTR^{6,7}, Howard Liebman, MD^{8*}, Roger M. Lyons, MD⁹, Keith R. McCrae, MD¹⁰, Vinod A. Pullarkat, MD¹¹, Jeffrey Wasser, MD^{12*}, David Beenhouwer, MD^{13*}, Sarah N Gibbs, MPH^{13*}, Irina Yermilov, MD, MPH, MS^{13*} and Michael S Broder, MD, MSHS^{13*}

- ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA
²Baylor College of Medicine, Houston, TX
³Harvard Medical School, Boston, MA
⁴Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
⁵Platelet Disorder Support Association, Cleveland, OH
⁶Children's Hospital of Philadelphia, Philadelphia, PA
⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
⁸University of Southern California, Los Angeles, CA
⁹Texas Oncology/US Oncology Research, San Antonio, TX
¹⁰Cleveland Clinic, Cleveland, OH
¹¹City of Hope, Duarte, CA

¹²University of Connecticut, Farmington, CT

¹³Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA

3441 Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Hematology Disease Topics & Pathways: Coronaviruses, SARS-CoV-2/COVID-19, Leukemia, Diseases, Lymphoma (any), Bone Marrow Failure, Lymphoid Malignancies, Myeloid Malignancies, Quality Improvement

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Kimberly C Jenkins, MSNM^{1*}, Emily C Zabor, DrPH^{2*}, Lindsey A. R. Mooney, BS^{1*}, Aaron T. Gerds, MD, MS³, Kerry O'Hop, BS^{4*}, Makenzie Guy, BA^{4*}, Megan Kilbane, MBA^{1*}, Nathan A Pennell, MD, PhD^{4*} and Mikkael A. Sekeres, MD, MS⁵

¹Hematology and Medical Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3442 Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Hematology Disease Topics & Pathways: Biological, therapy sequence, Diseases, Therapies, Combinations, MPN, Myeloid Malignancies, TKI

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Jonathan K. Kish, PhD, MPH^{1*}, Arianna Kee^{2*}, Pranav Abraham^{2*}, Ronda Copher, PhD^{2*}, Talia Miller^{1*} and Aaron T. Gerds, MD, MS³

¹Cardinal Health, Dublin, OH

²Bristol Myers Squibb, Princeton, NJ

³Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3458 Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways: Diseases, Polycythemia vera, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Naveen Pemmaraju, MD¹, Aaron T. Gerds, MD, MS², Shreekant Parasuraman, BPharm, PhD^{3*}, Jingbo Yu, MD, PhD³, Anne Shah^{4*}, Ann Xi, PharmD^{4*}, Shambhavi Kumar, MS^{4*}, Robyn M. Scherber, MD³ and Srdan Verstovsek, MD, PhD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Incyte Corporation, Wilmington, DE

⁴Avalere Health, Washington, DC